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Abstract
Early clinical progression of ischaemic stroke is common and is associated with increased 
risk of death and dependency. It was hypothesised that activation of the coagulation system 
may be an important contributor in early cases of deterioration. A study was designed with 
the aim of characterising alterations in circulating haemostatic markers in patients with 
progressing stroke. A number of validation projects were also undertaken around this main 
study. Consecutive acute ischaemic stroke admissions were recruited to the haemostasis in 
progressing ischaemic stroke study and had haemostatic markers measured within 24 hours 
of symptom recognition. Fifty four (25%) of the 219 patients recruited met criteria for 
progressing stroke. Prothrombin fragments 1+2 (Fl+2)(median 1.28 v. 1.06 nmol/1, 
p=0.01), thrombin-antithrombin complex (TAT)(5.28 v. 4.07 pg/1, p<0.01), D-dimer (443 
V.  194 ng/ml, p<0.001) and von Willebrand factor (216 v. 198 iu/dl, p<0.05) levels were 
higher in these patients than stable/ improving patients. In logistic regression analysis, with 
all important clinical and laboratory variables included, only natural log D-dimer (odds 
ratio 1.88, p=0.0001) and mean arterial blood pressure (odds ratio 1.26 per 10 mmHg 
change, p=0.01) remained independent predictors of progressing stroke. In conclusion, 
there is evidence of excess thrombin generation and fibrin turnover in patients with 
progressing ischaemic stroke. Further research is required to determine whether such 
patients benefit from aeute interventions aimed at modifying haemostatie function.
Atrial fibrillation (AF) is associated with cognitive impairment and dementia. It was 
hypothesised that haemostatic function is altered in subjects with AF who develop 
dementia, and that long-term warfarin anticoagulation is protective against cognitive 
decline. Recruitment was from an observational cohort study of AF, Cognitive function 
was assessed using both a telephone interview and an informant questionnaire. In 218 
subjects assessed D-dimer, F I+2 and TAT levels were higher in AF subjects with dementia 
compared to those without (geometric means 97.1 v. 62.0 ng/ml, p=0.008; 0.74 v. 0.53 
nmol/1, p=0.006; and medians 1.78 v. 1.44 pg/1, p=0.003 respectively). Dementia was less 
common in those treated with warfarin; 18% v. 32%, p=0.023. In conclusion, the results 
were consistent with increased thrombin generation and fibrin turnover in subjects with AF 
and dementia compared to those without dementia.
The work contained in this thesis was carried out in the Academic Section of Geriatric 
Medicine at the Royal Infirmary, Glasgow. I was supported by a Clinical Research 
Fellowship funded jointly by NHS Education for Scotland and the Chief Scientist Office of 
the Scottish Executive Health Department. A grant supporting some of the projects 
contained herein was obtained from the Chief Scientist Office of the Scottish Executive 
Health Department (Reference CZG/1/72 -  Haemostasis in Progressive Ischaemic Stroke). 
I carried out all work personally, unless indicated. The projects included, and some which 
are not, led to collaboration with a number of colleagues. The writing and illustration of 
this thesis is all my own work.
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Summary
The main aim of this thesis was to examine haemostatic function in subjects with 
progressing ischaemic stroke. This exercise was, however, supported by a number of 
exploratory and validation projects. Further opportunity arose to examine haemostatic 
markers in a community cohort with atrial fibrillation (AF), some of whom had developed 
dementia. A study design was, therefore, developed in an attempt to assess the relationship 
between haemostatic markers and dementia in AF, and to examine whether warfarin is 
protective against cognitive decline. The following is a summary of the research presented 
in this thesis:
Chapter one contains an introduction to the concept of progressing stroke. It identifies the 
various definitions of progressing stroke and examines the pros and cons of these 
definitions. A systematic review of the literature is used to examine potential clinical, 
laboratory and neuroimaging associations of progressing stroke. In a meta analysis, 
progressing stroke was found to be associated with death [odds ratio of 3.6 (95% 
confidence interval 2.39, 5,41)], poor outcome (death or dependency) [odds ratio 8.22 
(95% confidence interval 4.53, 14.92)] and the need for institutional care [odds ratio 3.57 
(95% confidence interval 2.15, 5.94)]. The reasons for a decision to mount the research 
portfolio contained in this thesis are then laid out.
Chapter two contains a review of reports of abnormalities of circulating haemostatic 
markers in subjects with ischaemic stroke. As in chapter one, efforts are made to conform 
to the MOOSE consensus guidelines on reporting meta analyses of observational studies \  
The methods of the search strategy are recorded explicitly. Only studies that recruited 
subjects acutely (<72 hrs) were included. The review includes papers examining:
1. Differences in haemostatic markers between subjects with stroke and non­
stroke controls.
2. Differences in haemostatic markers in different stroke subtypes
3. Haemostatic markers as predictors of outcome.
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The chapter includes information on the specific markers of haemostatic function that have 
been used in projects reported later in this thesis. The data presented are used to justify the 
need for the study reported in chapter seven.
Chapter three reports a validation study. In the retrospective and prospective progressing 
stroke studies it was not feasible for one examiner to assess each patient, personally, at the 
time of arrival in the Accident and Emergency department (although this was done as often 
as was practical). A study was designed to assess the validity and reliability of estimating 
Scandinavian Stroke Scale (SSS) scores, a measure of stroke neurological impairment, 
retrospectively from routine hospital admission notes. Fifty acute stroke admissions were 
examined and had their SSS scored by an experienced clinician shortly after the 
examination performed by the emergency admissions team. Two independent examiners (a 
research nurse and the author) later estimated retrospective SSS scores using information 
documented in the medical hospital admission notes. Agreement between the retrospective 
and face-to-face total SSS scores was good. Weighted kappa statistics for agreement 
between domains of the face-to-face and retrospective SSS were found to be as follows: 
consciousness 0.73, eye movements 0.60, arm motor power 0.83, hand motor power 0.71, 
leg motor power 0.81, orientation 0.81, speech 0.80, and facial palsy 0.53. Interobserver 
reliability for the different components of the retrospective SSS was excellent apart from 
eye movements (kappa 0.58). With respect to assessment of the European Progressing 
Stroke Study (EPSS) group definition of progressing stroke using retrospective case note 
information for the baseline assessment, agreement was excellent. The Kappa statistic for 
agreement between the face-to-face and the author’s own retrospective assessment of 
progressing stroke was 0.88. It was concluded that, where necessary, retrospective 
assessment of baseline SSS can be made using information in routine hospital admission 
records.
In chapter four the results of a retrospective database study aie reported. The aim of this 
study was to examine potential clinical predictors of progressing stroke. A case control 
design was employed to counter the influence of some non-modifiable baseline factors. 
From a database of 873 consecutive acute stroke admissions 218 cases of progressing 
stroke were matched to 218 non-progressing control patients on the basis of age and stroke 
type (Oxfordshire Community Stroke Project (OCSP) classification and haemorrhage/ 
infarct status). In multivariate analysis warfarin use prior to admission was associated with 
a reduced risk of progressing stroke (odds ratio 0.17, p<0.01). Elevated systolic blood
20
pressure on admission (odds ratio 1.08 for each lOmmHg rise, p=0.04) was also found to 
be associated with progressing stroke. A visible causative lesion on CT scanning was more 
common in the progressing stroke group (odds ratio 2.46, p=0.01). It had been thought 
that abnormal physiological variables, particularly pyrexia in the first 3 days after 
admission, would be independently associated with progressing stroke. The matched 
analysis, however, did not support this hypothesis in multivariate analysis. The information 
provided by this retrospective analysis was helpful when considering later analyses in the 
haemostatic function in progressing ischaemic stroke prospective study reported in chapter 
seven. The association between prior warfarin anticoagulation and reduced incidence of 
progressing stroke raises some interesting questions, although the limitations of this 
retrospective study have to be recognised.
Chapter five describes a case control study, examining outcome in primary intracerebral 
haemorrhage (PICH). The hypothesis here was that PICH patients would represent a 
heterogeneous group with markedly different outcomes from subjects with ischaemic 
stroke. The experiment employed a nested analysis, matching haemorrhages to infarcts on 
a 1:2 basis for age, pre-stroke disability, early neurological impairment (as measured using 
the SSS) and OCSP classification. Six hundred and seventy nine subjects were included in 
the analysis. Fifty three (8%) had PICH; this group had more severe initial neurological 
impairment (day 3 SSS 28 v. 45 points, p<0.001) and a higher prevalence of total anterior 
circulation syndromes (55% v. 21%, p<0.001) compared to ischaemic stroke patients. 
Outcomes were poorer in the PICH group with 36% inpatient mortality and 68% of 
survivors having a day 30 Rankin scale of 3 - 5 (compared to 13% and 52% respectively in 
the ischaemic stroke group). Following matching for baseline clinical characteristics the 
PICH group tended to have higher inpatient mortality than ischaemic stroke patients, 
although this was no longer statistically significant (perhaps partly because of reduced 
statistical power). Dependency levels at day 30 and need for institutionalisation in those 
who survived to hospital discharge were similar in PICH and matched infarct groups. From 
this study it was concluded that severity of clinical stroke is a major contributor to poor 
outcomes in PICH, but that it may not be the only important factor. A decision was made 
to exclude these subjects from the haemostatic function in progressing stroke study.
Chapter six reports the results of a study aimed at further validating the EPSS definition of 
progressing stroke. Three definitions of progressing stroke were used; the EPSS definition 
one based on the European Cooperative Acute Stroke Study (ECASS) definition  ^and
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one based on the Jprgensen definition of progressing stroke Each definition, for the 
purposes of this analysis, was based on change from baseline to day 3. Univariate and 
multivariate techniques were used to compare the predictive validity of these definitions, 
allowing the conclusion that the EPSS definition performed at least as well, and perhaps a 
little better, than the other two definitions of progressing stroke, in terms of predicting poor 
outcome.
Chapter seven contains the central project of this thesis. It had been hypothesised that 
activation of the coagulation system was an important contributor in some cases of early 
neurological deterioration after ischaemic stroke. Consecutive acute ischaemic stroke 
admissions were recruited allowing examination of differences in clinical features and 
circulating haemostatic factors in patients with and without progressing stroke (based on 
the EPSS definition). Haemostatic markers [coagulation factors VII, VIII and IX, 
prothrombin fragments 1+2 (FI+2), thrombin-antithrombin complexes (TAT), D-dimer, 
fibrinogen, von Willebrand Factor (vWF) and tissue plasminogen activator] were measured 
within 24 hours of symptom recognition.
Fifty four (25%) of 219 patients met criteria for progressing stroke. F l+2 (median 1.28 v. 
1.06 nmol/1, p=0.01), TAT (5.28 v. 4.07 pg/1, p<0.01), D-dimer (443 v. 194 ng/ml, 
p<0.001) and vWF (216 v. 198 iu/dl, p<0.05) levels were higher in these patients than 
stable/ improving patients. Logistic regression analysis was performed, including these 
variables together with age, gender, OCSP classification, admission SSS score, mean 
arterial blood pressure, fibrinogen and C-reactive protein. Only natural log D-dimer (odds 
ratio 1.88, 95% confidence interval 1.39, 2.56, p<0.0001) and mean arterial blood pressure 
(odds ratio 1.26 per 10 mmHg change, 95% confidence interval 1.05, 1.51, p=0.01) 
remained independent predictors of progressing stroke in this model. D-dimer also proved 
to be associated with poor outcome (odds ratio 1.40 for 30-day death or dependency), 
although this result was of borderline statistical significance (p=0.07). Sensitivities and 
specificities for prediction of progressing stroke by D-dimer were calculated, and reported, 
at a number of pragmatic cut-off levels. Chapter seven also reports a validation of repeated 
measures of haemostatic function. This exercise was underpowered; the reasons for this are 
discussed. Î
Chapter eight reports a validation of the Telephone Interview for Cognitive Status (TICS) 
and a modified 13-item version (TICSm); both are telephone screening tools for cognitive
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impairment and dementia. The R-CAMCOG (a modification of the cognitive part of the 
Cambridge Examination for Mental Disorders of the Elderly, developed for use in post­
stroke subjects) was used for a face-to-face “gold standard” diagnosis of dementia. Sixty 
four patients were assessed and the Pearson correlation coefficients between the R- 
CAMCOG and the TICS and TICSm were found to be high at 0.833 and 0.855 (both 
p<0.001) respectively. Twenty four (38%) patients met R-CAMCOG criteria for post­
stroke dementia. The area under the ROC curve for both the TICS and TICSm was 0.94 for 
this diagnosis. The reasons for choosing the TICSm (which at a cut-off of 20 or lower 
produced a sensitivity of 92% and a specificity of 80% for dementia diagnosis) for use in 
chapter nine are explained.
Chapter nine tests the hypotheses that haemostatic function is altered in subjects with AF 
who develop dementia, and that long-term warfarin anticoagulation is protective against 
this cognitive decline. Recruitment of subjects was from an observational cohort study of 
AF, the CARSAF study Baseline assessment included measurement of plasma 
fibrinogen, fibrin D-dimer, F 1+2, TAT, vWF, tissue plasminogen activator antigen and C- 
reactive protein. Cognitive function was assessed after a median of three years follow up 
using the TICSm and the short form of the Informant Questionnaire on Cognitive Decline 
in the Elderly (IQCODE).
Of the 218 subjects assessed, 49 (22%) met TICSm/ IQCODE combined criteria for 
dementia. In those on warfarin (145 subjects, 66%) the median duration of treatment was 
6.5 yrs. D-dimer, F I+2 and TAT levels were higher in AF subjects with dementia 
compared to those without (geometric means 97.1 v. 62.0 ng/ml, p=0.008; 0.74 v. 0.53 
nmol/1, p=0.006; and median 1.78 v. 1.44 pg/1, p=0.003 respectively). These associations 
became of borderline statistical significance following adjustment for age. No other 
haemostatic vai’iable was independently associated with dementia. Dementia was less 
common in those treated with warfarin; 18% v. 32%, p=0.023. It was concluded that there 
was some evidence of increased thrombin generation and fibrin turnover in subjects with 
AF and dementia compared to those without dementia. The data also gave some support to 
the concept that long-term warfarin might protect against development of dementia in 
patients with AF. The study did, however, have a number of important sources of potential 
bias. These weaknesses are discussed in detail.
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Following these chapters conclusions are drawn from the work to date and future 
directions for further exploration of these concepts are set out. A number of appendices are 
included as is a list of publications and presentations leading from the work contained in 
the thesis. The thesis concludes with a bibliography.
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Chapter 1
. . .“Progressing Stroke: What does it mean?”
Progressing stroke is one of a number of phrases that has come to be used in the literature 
to describe clinical deterioration early after acute stroke. Other expressions include “stroke 
progression”, “shoke-in-progression”, “worsening stroke”, “neurological deterioration” 
and “deteriorating stroke”. A number of factors may lead to deterioration after acute 
ischaemic stroke. In the early phase, up to 72 hours after stroke onset, factors such as 
increasing cerebral oedema and transtentorial herniation, clot propagation and recurrent 
cardioembolism are possibly to blame. Haemorrhagic transformation of an infarct may 
also occur. During this phase, but particularly in the time from 48 hours onward, the 
harmful effects of associated medical complications may begin to play a role. These 
complications may include infection (chest, urinary, other), pulmonary embolism and 
seizures
Discussion of the concept of progressing stroke has been recorded in the literature for more 
than 50 years Within the last 30 years, however, a number of neurological scales, some 
specific to stroke, have been developed for use in clinical research. These scales measure 
levels of stroke neurological impairment objectively, allowing the development of 
definitions of progressing stroke based on changes in neurological scores. These 
definitions do have some validity as they have been shown to independently predict poor 
outcome in stroke
Many studies have investigated potential predictors of progressing stroke. This research is 
driven, in part, by frustration at failure to prevent deterioration after hospital admission. It 
is hoped that, by intervening to modify these predictors, progressing stroke might be 
prevented and, therefore, outcomes improved. Predictors of progressing stroke can be 
divided into those which are potentially modifiable (such as hyperglycaemia) and those 
which are not (including age). The following summary concentrates on papers whose main 
aim was to investigate predictors of progressing stroke and which used validated 
neurological impairment scales to define deterioration. Most studies have concentrated on 
patients with acute ischaemic stroke and, indeed, Birschel at al. found that primary 
intracerebral haemorrhage alters the likelihood of progressing stroke This chapter
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examines the varying definitions of progressing stroke, potential predictors of progressing 
stroke and the impact of progressing stroke on mortality and functional outcome in 
ischaemic stroke.
Searching the literature for papers surrounding the study of progressing stroke proved 
difficult. No specific search terms are available for this entity. The search strategy used is 
shown in table 1.1. A more detailed description of the methods of this search is presented 
later in this chapter.
Definitions of progressing stroke:
One of the difficulties with defining progressing stroke is in deciding which criteria to use. 
These may differ with regard to the methods used to define neurological deterioration and 
also the time period over which progressing stroke is said to occur. Depending on which 
criteria are used a different group of subjects may be selected. Some eaiiy studies in 
progressing stroke either did not describe how progression was defined or based their 
findings on neuiological examination without the use of more objective scoring systems 
The development of formal neurological scales has allowed more objective definitions of 
progressing stroke to be developed. Scales used to define progressing stroke in the 
“predictors” studies have included the Scandinavian Stroke Scale (SSS) ^  Canadian 
Neurological Scale (CNS) National Institutes of Health Stroke Scale (NIHSS) 
Hemisphere Stroke Scale and European Stroke Scale ’I
Even when using these specific sti'oke scales different methods have been developed for 
defining progressing stroke. In studies examining predictors of progressing stroke the most 
commonly used scales are the SSS and the CNS. Table 1.2 demonstrates some examples of 
the varying definitions of progressing stroke using the SSS in predictor papers. The 
following review concentrates on studies that examined early deterioration and, therefore, 
if a study included early and late deterioration, only the definition for early deterioration is 
reported. The CNS has generally used a definition of a worsening of one or more points to 
indicate progressing stroke. The time period over which this deterioration should occur 
does vary between studies; mostly defined at 48 hours but occasionally at 4 days or 7 days 
Studies using the NIHSS have used deterioration over 48 hours for their definition 
and either a > 3 point or > 4 point change in total score. Other groups have used a 
definition of > 4  point gain in NIHSS score over 7 days or over 24 hours or 7-10 days 19
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A potential disadvantage of a definition that is based on changes in total stroke scale score 
is that these scales aie not necessarily ordinal. Some areas might be seen as more important 
with respect to short-term prognosis, such as deterioration in conscious level, while other 
areas, such as sensation or facial palsy, might not be seen as quite so crucial. It is possible 
to improve in some areas while deteriorating in others. For some scales there may be 
domains that aie more liable to interobserver variability (and therefore potentially prone to 
false negative or false positive diagnosis of progressing stroke) such as the face and eye 
movement components of the NIHSS and SSS It is possible that definitions based on 
change in only certain important domains of stroke scales, such as those used by Davalos, 
J0rgensen and Birschel, are more valid and reliable methods of establishing the diagnosis 
of progressing stroke Recently attempts have been made to develop an internationally 
agreed definition of progressing stroke If accepted this should standardise research in 
this field.
Potential predictors of progressing stroke:
As discussed earlier much of the literature regarding progressing stroke has concentrated 
on establishing possible predictors in the hope that some of these predictors might be 
modified leading to an improvement in outcome. The following pages summarise much of
factor for progressing stroke. Results have varied but many papers investigating
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the available evidence on predictors of progressing stroke. These predictors can be 
categorised in a number of ways. One method is to divide them into clinical features, 
laboratory investigations and neuroimaging findings (see table 1.3).
Each potential feature is discussed individually below, although many studies have 
examined multiple risk factors. Because of the wide variation in the methodology used and 
the subjects recruited it is not feasible to perform meta analysis to draw firm conclusions 
from the various studies and, instead, the following is a summary of some of the important 
findings
Clinical features
"  Age:
Age is an important predictor of outcome after acute stroke and a non-modifiable risk
progressing stroke suggest that increasing age does increase the likelihood of 
neurological deterioration following acute stroke, especially after the first 24 hours 
Once other important baseline factors are taken into account in multivariate 
analysis, however, age sometimes, but not always loses its independence as a 
predictor of progressing stroke.
■ Admission delay:
Admission delay is potentially modifiable. Efforts to extend the role of thrombolysis, 
with rt-PA, for acute stroke in the UK will require major public education and changes 
to the ways that emergency services respond These efforts have potential benefits 
even for the majority of acute stroke admissions who will not receive such treatment 
Most studies concentrating on progressing stroke have recorded delays from symptom 
onset to admission. Unfortunately, issues such as stroke severity and social isolation 
(themselves significant prognostic factors) may also impact on delay to hospital 
admission. It can be argued that the longer the delay between symptoms and admission 
the smaller the chance of progression as, at least potentially, any neurological 
deterioration may have occurred before presentation Studies have used a wide 
variety of time windows for inclusion (from 5 hours to 7 days) and the split between 
positive and negative results makes it difficult to comment on whether admission delay 
is genuinely a risk factor for progressing stroke.
■ Stroke type:
Pathological stroke subtype may influence the probability of progressing stroke. 
Steinke et al., in a highly selected group of subjects with severe motor deficit, found 
that 59% of subjects with progressing motor deficits had subcortical infarctions 
whereas 39% of subjects in the stable group had subcortical infarctions Stroke 
classification was based on the TOAST criteria Only 10% of admissions (92 out of 
941) met study inclusion criteria and outcomes were not statistically significantly 
different between the progressing and stable stroke groups. They concluded that 
lacunar stroke is the major cause of progressive motor deficits; however, it is ai'guable 
that their results cannot be extrapolated to a wider group of general stroke admissions. 
Details of deterioration in non-motor domains (e.g. consciousness) were not reported 
by this study.
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Other papers have consistently found that a lacunar stroke classification is less 
common in patients with deterioration. Christensen et al. found, in 896 admissions with 
acute stroke, that 15% of patients in the deteriorating group had lacunar infarction 
compai'ed to 28% in the stable group (P^O.OOl) This was a much more 
representative group of patients. The frequency of cardioembolic stroke was higher in 
the deteriorating group compared to the stable stroke group (32% v. 22%, P<0.05). It is 
not completely clear in the paper how strokes were classified with respect to lacunar/ 
cardioembolic nature. De Graba et al. classified stroke on the basis of CT findings and 
demonstrated a lower rate of lacunar infarction in the progressing stroke group (5% v. 
22%, p<0.001) Yamamoto et ai. studied over 3000 patients in a retrospective 
analysis of data from the Lausanne Stroke Registry A classification similar to the 
TOAST criteria was used; however, neurological progression was defined by study 
neurologists without the use of a specific neurological impairment scale. In the non- 
cardioembolic group (1968 subjects) 38% of the neurologically worsening group and 
46% of the stable stroke group were felt to have stroke caused by small vessel disease
(p < 0.001).
The data regarding stroke subtype, as documented above, does not appear to support 
the conclusion that progressing stroke is predominantly a problem relating to 
subcoitical infarction and, in general stroke admissions, cortical stroke is more likely to 
be associated with early worsening of neurological impairment and death. Can this 
disparity be explained? It is possible that this represents an artifact produced by 
variation in the time taken from stroke onset to hospital presentation. It is said that 
lacunai- infarction may, in many instances, have a slow mode of onset This might 
then mean that if a patient presents early to hospital services with lacunar stroke they 
may not yet have reached maximal stroke impairment. This could make it more likely 
that the patient presenting early, during the development process of stroke signs, will 
be recorded as having progressing stroke when reassessed two or three days later 
(something that may not have occurred if they had presented to hospital services a few 
hours later). A subject with cortical infarction who has already quickly reached 
maximal stroke impairment may be less likely to progress than an early presenting 
lacunar- infarction. This issue is presented graphically in figure 1.1.
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■ Level o f  Neurological Impairment:
It is recognised that admission neurological impairment, as measured using the CNS, 
NIHSS, SSS or other similar objective rating scale, is an important predictor of 
outcome following stroke What is the role of measured admission neurological 
impairment in predicting progressing stroke? The fact that this summary has 
concentrated on studies that measured neurological deterioration using standardised 
tools means that admission neurological status is consistently reported. Christensen et 
al. found that SSS (but none of the other variables discussed here) was an important 
predictor of progressing stroke It is interesting that this study, which is considerably 
larger than most others, was negative for so many of the other potential predictors 
previously reported. The progressing sti'oke rate was relatively low and it has been 
postulated that their definition of progressing stroke may not be as specific for poor 
outcome as others These differences, however, seem unlikely to provide the full 
explanation. Other groups have agreed with Christensen's finding that initial stroke 
severity is an important and independent predictor of deterioration
■ Temperature:
Pyrexia after stroke is associated with poor outcome, both in terms of mortality and 
morbidity. This was clearly demonstrated in a meta analysis of 3790 patients 
Potential causative mechanisms for eai'ly post-stroke pyrexia may include neurogenic 
fever, massive tissue necrosis, thrombus formation or superimposed (or preceding) 
infection. It is postulated that pyrexia may lead to poor outcome through its deleterious 
effects on the peri-ischaemic (potentially salvageable) penumbra. High body 
temperature may increase the levels of harmful neurotransmitters, encourage free 
radical release or increase blood-brain barrier permeability. These potential 
mechanisms mean that there could be a role for post-stroke pyrexia in relation to 
progressing stroke as well as in longer term poor outcomes. The role for pyrexia in 
progressing stroke was investigated by Davalos et al In their series of 128 subjects, 
admitted within 24 hours of first hemispheric cerebral infarction, they found an 
increase in relative risk for progressing stroke of 9.2 for every 1®C increase in 
admission body temperature. A later retrospective analysis of data from the larger 
ECASS thrombolysis study (620 patients randomised to receive tissue plasminogen 
activator or placebo) was negative with regard to both body temperature on admission 
and at twenty four hours It should be remembered that this was a highly select group 
of stroke admissions and, therefore, not necessarily a representative sample In
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animal models active reduction of body temperature has shown some protective 
benefits, and studies of interventions that reduce body temperature in humans are now 
being reported. Interventions have included simple methods such as the use of 
paracetamol to more complex interventions such as active cooling These 
studies have not yet provided enough information from which to draw firm conclusions 
on the best management of post-stroke hyperthermia.
■ Hyperglycaemia/ history o f  diabetes:
Diabetes is a recognised risk factor for ischaemic stroke and can predict future death 
from stroke Stroke outcome is poorer in subjects with diabetes This 
observation also stands in subjects who are hyperglycaemia when admitted to hospital, 
even without a known history of diabetes. Some of these subjects will have 
undiagnosed diabetes and some may be hyperglycaemia without diabetes, perhaps with 
impaired glucose tolerance or “stress” hyperglycaemia. Transitory hyperglycaemia in 
the absence of diabetes is common following acute stroke and is associated with 
increased mortality and poor functional outcome Acute hyperglycaemia appears to 
increase brain lactate production and facilitates conversion of “penumbral” tissue into 
infarction
Some studies have been performed examining the effect of diabetes on risk of 
progressing stroke, Jprgensen et al. studied 1006 consecutive admissions with acute 
stroke (including those with haemorrhagic stroke) of whom 868 were included in 
further analysis Within this group 281 subjects (32%) developed progressing stroke. 
Unusually, within this study, two different definitions of progressing stroke were used. 
Patients were included if they were admitted within 1 week of stroke onset. In those 
admitted within 12 hours of sh'oke onset “progression” was defined by point 
deterioration in domains of the SSS at 36 hours. In those admitted after 12 hours from 
stroke onset “progression” was defined by the same point changes over the first week. 
These time related definitions and the inclusion of patients admitted up to one week 
after stroke onset set this study apart from most others. The more traditional subset, 
with regard to progressing stroke, was the early progression group and they found, 
within this early admission group (n=392), an odds ratio of 1.9 (95% confidence 
interval 1.1, 3.3) for progression in subjects with known diabetes or diabetes diagnosed 
during hospital stay. This was independent of other important factors including age, 
admission SSS and admission blood glucose. Mean blood sugar concentrations were
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similar in the progressing and non-progressing groups. What the study does not tell us 
is whether diabetes is a useful predictor of progressing stroke, as no figures were given 
for those subjects with previously known diabetes (i.e. not diagnosed following 
hospital admission).
A smaller study in subjects with lacunar infarction drew similar conclusions to those 
of Jprgensen. This study had rigid inclusion criteria and is, therefore, not necessarily 
representative of general stroke admissions. Only motor deficits were included in the 
definition of progressing stroke. In the final subset of 92 patients, a known history of 
diabetes gave an odds ratio of 3.8 (95% confidence interval 1.2,11.7) for progression 
of motor deficits. Mean blood glucose levels in the total progressing group were 
significantly higher than in the stable group (8.4 v. 6.5 mmol/1 respectively on day 1 
and 8.3 v. 6.1 mmol/1 respectively on day 2, both p<0.001). Davalos et al., in subjects 
enrolled in the ECASS trial, found that a past medical history of diabetes predicted 
deterioration between admission and 24 hours (odds ratio 1.79, 95% confidence 
interval 1.03, 3.09) but not between 24 hours and 1 week Several other authors have 
demonstrated non-significant (but potentially important) trends towards increased risk 
of progressing sh oke in diabetic subjects All of these studies have been small
and, therefore, possibly underpowered in this respect.
With respect to admission hyperglycaemia, Toni et al. examined its influence on 
progressing stroke over the first four days after admission, as part of an observational 
study of 152 patients admitted within 5 hours of acute stroke Neurological 
deterioration was defined by change in CNS score over the first 4 days, although a later 
publication looked at earlier assessment There was a non-significant trend towards 
an increased likelihood of a history of diabetes in the progressing stroke group (23% v. 
17%, p=0.4), a factor not included in their regression model. They found, in their 
model, a significant, but not overly impressive, odds ratio of 1.01 for progressing 
stroke for each mmol rise in admission blood sugar. The National Institute of 
Neurological Disorders and Stroke (NINDS) rt-PA trial confirmed this odds ratio of
1.01 for clinical deterioration (over 1 week but not 24 hours) in multivariate analysis 
This finding of higher admission serum glucose levels in those who deteriorate is 
common when using univariate analysis Frequently hyperglycaemia as a predictor 
disappear s in multivariate analysis, particularly if history of diabetes is also included in 
the statistical model.
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What can be done, therefore, to intervene with regard to diabetes and hyperglycaemia 
in stroke? Is it possible to prevent progressing stroke? Evidence suggests choice of 
therapy for tight diabetic control in type II diabetes may reduce the incidence of stroke 
Once stroke has occurred many units have protocols for managing hyperglycaemia 
following acute stroke. So far there is little evidence to support the use of these 
protocols. Information from the ongoing Glucose Insulin in Stroke (GIST) trial, a 
randomised trial of 24 hours of normal saline or a Glucose/ Insulin/ Potassium infusion 
in moderate hyperglycaemia, may help to clarify the situation
■ Atrial Fibrillation:
Atrial fibrillation (AF) affects 5% of community dwelling subjects aged 65 years or ■
over and is present in nearly 20% of acute stroke admissions It is a potential cause 
of cai'dioembolic stroke, and is associated with greater severity of neurological 
impairment along with higher mortality following stroke If AF is present this does
not necessai'ily mean that this is the cause of stroke. AF may be a secondary 
phenomenon following acute brain injury. AF may also be coincidental, as many 
subjects will have more than one potential explanatory mechanism to explain their 
stroke.
With regard to the effect of AF on the risk of progressing stroke the literature is mixed.
De Graba et al. found an excess of AF in the progressing stroke group (38% v. 11%, 
p=0.001) in a series of 127 consecutive stroke admissions to a neuroscience intensive 
care unit This finding remained significant in multivariate analysis. Steinke et al. 
found a non-significant trend towards lower prevalence of AF in subjects with 
progressing stroke As has been discussed, this study had a number of weaknesses 
which should be born in mind when considering predictors of progressing stroke. It, 
therefore, adds little helpful information regarding the role of AF in progressing stroke.
Other authors have found no significant differences in AF rates between progressing 
and stable strokes 3.4, i4,32,6t, 62
■ Hypoxaemia:
It has been suggested that measured oxygen saturation (using pulse oximetry), along 
with other physiological variables over the first 3 days following stroke, is associated 
with neurological improvement Increased use of oxygen therapy is one of the many
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potential reasons why stroke units are effective This is an area that has received little 
attention in the literature surrounding progressing stroke, particularly as hypoxaemia is 
potentially modifiable. De Graba et al. reported “lowest oxygen saturation over the first 
48 hours after admission” They found no association between the occurrence of 
neurological progression and minimum O2 saturation. A quasi-randomised study of 
routine oxygen supplementation (100% at 3 litres through nasal cannulae) 
demonstrated trends for increased mortality and poorer functional outcomes in the 
group allocated to oxygen . There is, therefore, no evidence at present to support the 
routine use of oxygen in patients admitted with acute stroke.
■ Blood Pressure:
Raised blood pressure in the acute stage of stroke might have a number of possible 
underlying mechanisms. These include acute stress of hospitalization, increased 
sympathetic nervous system activity, activation of the renin-angiotensin system and 
response to raised intracranial pressure (and, therefore, might reflect, to a laige extent, istroke severity). Post-stroke hypertension could be harmful; increasing cerebral |
oedema and risk of haemorrhagic transformation. Conversely it also has potentially 
protective effects. Cerebral autoregulation is lost after acute stroke meaning that 
increased blood pressure might mean increased cerebral perfusion (and actively 
lowering blood pressure might, potentially, reduce cerebral perfusion).
There has been some controversy over the role of blood pressure in predicting 
neurological outcomes following acute stroke. It has been suggested that raised blood 
pressure shortly after stroke is associated with poor outcome in terms of increased 
mortality and morbidity Leonardi-Bee et al. suggested a U shaped curve to this 
relationship in more than 17,000 subjects recruited to the 1ST study Randomisation 
to this study, however, was performed at a median of 20 hours after symptom onset.
Admission blood pressure has been reported in several progressing stroke studies with 
mixed results. Jprgensen et al. investigated the effect of blood pressure on progressing 
stroke They discovered that systolic blood pressure on admission was inversely 
related to risk of early deterioration (within 36 hours). They found a relative risk for 
progression of 0.66 for every 20 mmHg increase in systolic blood pressure, in an 
analysis corrected for other potentially important factors. A smaller study revealed the 
opposite result in multivariate analysis Other studies have found higher blood
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pressure in deteriorating patients, but that this is not significant after correction for 
other baseline variables It has recently been suggested that a larger fall in blood 
pressure in the 24 hours following stroke is associated with progression (rather than 
basal levels themselves) There remains significant uncertainty with regard to the 
association between blood pressure and progressing stroke. Varying definitions of 
progressing stroke may have been a confounding factor in this and, unfortunately, 
many of the studies were too small or had such restrictive inclusion criteria that 
drawing definitive conclusions is not possible.
■ Headache:
Headache is present in between 10 and 39% of patients during the acute phase of 
cerebral infarction Many mechanisms have been suggested including roles for 
excitatory amino acids and inflammation (see later in this chapter). Leira et al., in a 
subgroup of patients which has been extensively reported on, found that headache was 
an independent factor (odds ratio 16, 95% confidence interval 5, 47, P<0.0001) 
associated with early neurological deterioration
Laboratory Investigations
■ Fibrinogen:
Fibrinogen is produced by the liver and circulates in plasma. It plays a role in normal 
haemostatic mechanisms being cleaved to fibrin monomers, which are subsequently 
cross-linked as part of the process of forming an insoluble fibrin clot. It is also a major 
determinant of blood viscosity. Fibrinogen is considered a major cardiovascular risk 
factor; in epidemiological studies raised levels have been associated with stroke and 
ischaemic heart disease Fibrinogen levels have also been associated with higher 
risk of recurrent stroke Fibrinogen levels have been shown to be elevated in acute 
stroke Fibrinogen is an acute phase reactant and, therefore, may be raised in 
stroke as a marker of extent of tissue damage, infection or reaction to inflammation.
Davalos and colleagues investigated the role of early measurement of fibrinogen levels 
in predicting progressing stroke in 128 subjects They found an odds ratio of 1.05 
(95% confidence interval 1.01,1.09) for each lOmg/dl increase in fibrinogen 
concentration. No other acute phase reactants were included in the analysis. Other
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factors included in multivariate analysis seemed appropriate. Other analyses by the |
same author have not been as convincing In a small study Steinke et al. found a
■
trend towards higher fibrinogen levels in subjects with progressing stroke A
significant number of patients in the “progressing” group had fibrinogen levels outside 
of the “normal range”. Only patients with severe motor deficits were included in this 
study and multivariate analysis was not performed. Other reports have shown similar 
fibrinogen levels in progressing and non-progressing stroke groups Fibrinogen 
levels were measured in the NINDS TPA trial but not found, on multivariate 
analysis, to predict clinical deterioration either at 24 hours or 7-10 days
■ D-dimer, Thrombin-Antithrombin Complexes and other Haemostatic Factors:
As mentioned previously fibrinogen plays an important role in haemostasis. Little work 
has been carried out examining the role of the coagulation and fibrinolytic systems in 
relation to progressing stroke. Chapter two reports a review of the literature 
surrounding haemostatic markers in acute stroke. Two papers were partly responsible 
for the decision to mount the study of haemostatic function in progressing stroke 
reported in chapter seven (see below).
Uchiyama et al. investigated a series of subjects with cerebral infarction 
Unfortunately it is not clear how the patients were recruited; in particular no clear 
information is supplied on whether these were consecutive admissions, what inclusion/ 
exclusion criteria were used and at which stage blood samples were withdrawn. No 
basic demographics or information on risk factors or stroke severity were reported. No 
cieai- description was given as to how progressing stroke was defined. In a subgroup 
(n~84) of patients defined as having atherothrombotic stroke they found a higher 
prevalence of raised D-dimer levels (44% v. 19%) and thrombin-antithrombin 
complexes (52% v. 22%) in subjects with “worsening” stroke compared to stable or 
improving patients. Despite many weaknesses the study is interesting and deserved to 
be repeated using stricter methodology and reporting. Presumably most subjects 
included were Japanese and this raises interesting questions about racial differences in 
measures of haemostatic markers
Prior to this study a Taiwanese group investigated a variety of haemostatic factors in 
subjects with progressing and non-progressing stroke A relatively large time 
window for recruitment was used (35 hours) with a mean time to first blood sampling
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of 33 hours. The decision regaining diagnosis of progressing stroke was apparently not 
based on objective criteria. It is not clear whether consecutive admissions were 
included but if this was the case the progressing stroke rate was relatively high (44%). 
No firm conclusions were drawn about the predictive value of haemostatic function in 
progressing stroke; however, the sample size was probably inadequate (n -  32).
Both of the above studies have important weaknesses. The haemostatic system appears 
to be a neglected research ar ea, particularly as it is a candidate area for intervention to 
prevent earty deterioration in ischaemic stroke subjects. Further study is, therefore, 
warranted.
In a post-hoc analysis of the NINDS rt-PA trial baseline fibrin degradation products 
were found to be associated with an increased risk of late clinical deterioration (7-10 
days) but not early deterioration ( 24 hours) Many of the patients studied will have 
received therapy that potentially has significant impact on haemostatic function. 
Another randomised controlled trial, by de Boer et al., of heparin in thrombotic sti'oke 
found a trend towards higher fragment E (a specific fibrin degradation product) levels 
in subjects with motor progression Subjects with “cardiac embolism” were 
excluded, not all patients had CT brain performed and motor progression was measured 
using the MRC power scale. The study was statistically underpowered (only 12 
subjects in the progressing stroke group).
With regal'd to platelet activation, Cha et al. examined platelet expression of P-selectin 
in a series of 45 ischaemic strokes, 9 (20%) of whom had progressive signs over 7 days 
They found increased levels of P-selectin in subjects with progressing stroke at 72 
hours but not at baseline. This is a small study and is, therefore, unable to correct for 
potentially important differences in age and baseline stroke severity. The study by de 
Boer et ai., mentioned above, also measured B thromboglobulin levels (a marker of 
platelet activation) in subjects with progressing stroke and found no evidence of 
elevated basal levels.
■ C-Reactive Protein:
C-reactive protein (CRP), an acute phase reactant, has been shown to be a predictor of 
future TIA or ischaemic stroke in large population studies Levels may be
elevated after acute stroke and do seem to have an influence on outcome within the
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first year of acute ischaemic stroke when measured within 24 hours of stroke onset  ^
Little evidence has been forthcoming regarding the role of CRP in predicting 
progressing stroke. One study found no significant difference between admission CRP 
and risk of progressing stroke The group of patients investigated was not 
representative of general stroke admissions (less than 10% of admissions met study 
inclusion criteria).
■ Glutamate:
Glutamate is an excitatory amino acid that plays a role in the pathogenesis of stroke. 
Indeed some studies of neuroprotectives have tried to block the toxic effect of 
glutamate in its relation to cell death.
Most of the published research here has come from a single group. This group has 
produced multiple publications from stored samples on overlapping groups of stroke 
patients and it is, therefore, difficult, at times, to separate which papers represent which 
patient group. In 1997 Davalos et al. published results of an analysis of serum and 
cerebrospinal fluid (CSF) glutamate levels in acute ischaemic stroke admissions 
They found that serum levels of glutamate higher than 200pmol/L were associated with 
increased risk of progressing stroke. These results were supported by a later study 
examining only lacunar infai'ctions No multivariate analysis was performed in this 
later study.
Although interesting, trials of neuroprotectives, including those testing the glutamate 
release inhibitor lubeluzole, have so far been disappointing
■ Nitric Oxide:
Inducible nitric oxide (NO) is felt to be involved in the evolution of cerebral ischaemic 
injury Not suiprisingly, then, niti'ic oxide concentrations have been examined in the 
context of progressing stroke in further analysis of CSF samples obtained by the 
Davalos group They found that CSF NO concentrations were higher in ischaemic 
stroke subjects than control subjects and that levels were higher in those with early 
neurological deterioration than those with stable stroke. One possible explanation for 
these findings is that NO is related to production of neurotoxic free radicals in the 
ischaemic penumbra.
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■ Ferritin:
Ferritin is an acute phase reactant as well as a marker of body iron stores. It has been 
suggested that iron-dependent free radicals are related to greater damage in cerebral 
ischaemia. There is limited evidence that serum ferritin is associated with eai'ly 
prognosis following stroke (a study including both cerebral haemorrhages and 
infarctions) Davalos et ai. examined ferritin and total iron concentrations in serum 
and CSF in a subgroup of 100 subjects admitted with ischaemic stroke who had had 
CSF stored They found that serum ferritin levels were significantly associated with 
progressing stroke, although one potential criticism of this study is that other 
recognised predictors of progressing stroke should have been included in their 
regression model. Christensen et al. studied 162 acute stroke admissions and found no 
evidence of an association between ferritin levels and progressing stroke This 
apparently contradictory information, along with the limited number of studies, means 
that no firm conclusions can be drawn.
"  Cytokine /  Inflammatory Molecules:
Cytokines, such as interleukin 6 (IL-6), are key regulators of the acute-phase response 
EL-6 expression is induced in neurones in cerebral ischaemia. Vila et al. found that 
IL-6 concentrations in plasma and CSF were associated with early neurological 
deterioration in 231 acute stroke patients with available samples Tumour necrosis 
factor concentrations were also raised in progressing stroke subjects, although not 
when corrected for other variables. Another analysis published on the same cohort 
suggested an inverse relationship between plasma IL-10 levels and progressing stroke 
Oddly, little mention was made of the authors’ previous work on IL-6 levels, and 
these were not included in multivariate analysis. Christensen et al. found no suggestion 
of differences in plasma cytokine levels in progressing and non-progressing stroke 
patients There was a longer delay to blood sampling in the 162 subjects recruited to 
this part of their study.
In the situation of lacunar stroke Castellanos et al. found that plasma IL-6, tumour 
necrosis factor and intercellular adhesion molecule-1 levels were higher in subjects 
with progressing lacunar stroke than stable patients
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Neuroimaging findings
■ Computed Tomography:
A number of studies have examined the association between computed tomography 
(CT) scan findings and progressing stroke. Toni et al. found that subjects with a 
progressing course were more likely to have early focal hypodensity and mass effect on 
CT performed at the time of admission Later CT scans (approximately 1 week after 
admission) showed larger lesions with more mass effect and a higher incidence of 
haemorrhagic transformation in the progressing stroke group. It is worth noting that 
intravenous heparin use was high in this study cohort and that in particular 
subcutaneous heparin was more commonly used in the progressing stroke group (49% 
V, 31%, p <0.05). Other studies have shown that early CT scan signs and larger 
infarction volumes are associated with progressing stroke
■ Magnetic Resonance Imaging:
Admission magnetic resonance imaging (MRI) for acute stroke patients is not available 
in most units. There has been some research done in the field of MRI and progressing 
stroke. In a highly selected (< 5% of stroke admissions) group of 30 subjects with 
intracranial vessel occlusion, Aienillas et al. examined subjects using diffusion and 
perfusion weighted MRI MRI scans were performed within 6 hours of stroke onset, 
however, a significant number of subjects received tlnombolysis (23%), which is likely 
to alter the risk of progressing stroke. They found that abnormalities seen on diffusion 
weighted imaging were an independent predictor of ear ly neurological deterioration. A 
cut-off point of DWI > 89 cm^ had a sensitivity of 86% and a specificity of 96% for 
predicting progressing stroke in this selected group. In a larger study of progressing 
stroke a subgroup of patients with lacunar infarct were investigated with MRI (21 with 
progressing stroke and 64 stable patients) nearly two weeks after stroke onset 
Infarction volumes were larger in the progressing stroke group.
■ Transcranial Doppler:
Reseai'ch has shown that transcranial doppler (TCD) examination changes are 
associated with neurological progression/ improvement, although this is a labour 
intensive technique. A small highly selected study (see comments in the above MRI 
section) suggested that duration of aiterial occlusion, as demonstrated on serial TCD, 
was significantly associated with neurological progression Toni et al. found that
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TCD evidence of middle cerebral artery asymmetry or “no-flow” within 6 hours of 
stroke does have predictive value for progressing stroke/ improving stroke At 
present many stroke units do not have easy access to TCD imaging.
Progressing stroke and outcome; a meta analysis
Research into progressing stroke is important because of the potential role of progressing 
stroke in predicting poor prognosis. Previously a review of the literature suggested that 
progressing stroke was associated with increased mortality and institutionalisation 
Outcome assessments were only analysed for 4 studies Several studies have been
published since and so it now seemed an appropriate time to take the opportunity to review 
the available evidence.
■ Hypothesis Statement:
Progressing stroke is associated with poor outcome in terms of mortality, functional 
recovery, and discharge destination.
Selection Criteria:
Study designs used - case series comparing outcomes in progressing stroke
- those using recognised objective stroke neurological 
impairment scales or well described newly developed ones
- progressing stroke described over a defined, relatively 
short, time course e.g 72 hours
Exclusions studies which only included haemorrhagic stroke 
non-English language papers
Outcomes mortality during follow up period 
“Poor outcome” (combination of mortality and 
dependency/ poor functional status) (see table 1.4) 
need for institutional care i
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■ Search Strategy:
This search was designed and run in OVED Medline by the author (at 
http://gateway.ovid.com/athens/) using the strategy described in table 1.1. As of 
January Week 1 2004 this search produced 6498 hits. All titles and relevant 
abstracts were read by the author and selected papers requested from the library. 
Further hand seai'ches of journals [Cerebrovascular Diseases (1999 -  present) and 
Stroke (last lOyears)] along with the reference lists of all relevant selected articles 
were made. Abstract only publications were not included. The author also included 
two of his own studies; one in published in Gerontology and one accepted for 
publication by Stroke,
■ Analysis:
Odds ratios were calculated using a random effects model in Revman 4.2 (update 
softwai'e, Oxford).
" Results:
A description of the studies used in this meta analysis is shown in table 1.5. Five of 
the papers included have used selection criteria that might bias outcome results.
The author’s own case control analysis included stable stroke patients matched to 
progressing stroke patients on the basis of age and stroke type Studies by 
Steinke et al. (92 subjects recruited from 941 admitted), Serena et al. and 
Nakumura et al. (unclear what percentage of total stroke admissions recruited) only 
included subjects with severe motor deficit or lacunar stroke Arenillas et al.
only included subjects with proven MCA occlusion or intracranial carotid artery 
occlusion (38 out of 610 admitted) The outcome measures from these studies, 
where available, have been included in this meta analysis for sake of completeness. 
Two post hoc analyses of subjects recruited to thrombolysis studies are also 
included These studies had strict entry criteria, but recruited all types of 
ischaemic stroke and have, therefore, been included with the other general 
ischaemic stroke studies in this meta analysis. For the analysis by Grotta et al. 
details of outcome in the deteriorating and stable groups was only provided as an 
odds ratio. Conservative estimates have been calculated using these odds ratios.
In the meta analysis outcome information for odds ratio of death included 
information from 14 studies (nearly 5000 patients). An odds ratio, for death in the
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progressing stroke group, of 3.6 (95% confidence interval 2.39, 5.41) was found 
(see figure 1.2). For “poor outcome” (a combination of death or poor functional 
outcome -  see figure 1.3) information was available for over 2000 patients. The 
odds ratio for poor outcome in the progressing stroke group was 8.22 (95% 
confidence interval 4.53, 14.92). For the 937 patients in whom there was reliable 
information on transfer to nursing home care there was an odds ratio of 3.57 (95% 
confidence interval 2.15, 5.94) in the progressing stroke group (see figure 1.4).
With only the unselected ischaemic stroke studies included in the analysis the odds 
ratios for death and poor outcome increased to 4.24 and 9.19 respectively. Some 
possible bias still remains. Many studies have included death within the 
deterioration time period as progressing stroke. These subjects clearly will have a 
poor outcome as this has already occurred before the second neurological 
assessment. These studies assumed that patients had already deteriorated 
neurologically before death.
It is important to remember that this meta analysis does not include any adjustment 
for baseline imbalance, particularly in stroke severity. The findings of this meta 
analysis, however, do support those of the previous review Although the precise 
definition of progressing stroke varies, depending on the criteria used, there is little 
doubt that patients who suffer neurological deterioration after hospital admission do 
have higher mortality rates and poorer functional outcomes. Information in this area 
has expanded significantly over the last few years but is still a long way from being 
complete. The main emphasis of the work leading to submission of this thesis was 
to expand the knowledge base surrounding progressing stroke. It was clear that 
there was a particular’ lack of reliable information on the association between 
haemostatic function and progressing stroke - an area that might potentially be 
modifiable. In addition the ability to improve the risk assessment of acute stroke 
admissions would be useful.
Reviewing the literature relating to haemostatic function and stroke along with the 
literature suiTounding AF and cognitive function led to an interest in whether 
haemostatic function in AF might be a predictor of cognitive decline (at least, in 
part, as a possible marker of increased risk of silent stroke). An experiment 
examining this hypothesis (along with some relevant validation work) is also 
included in the thesis.
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Stroke onset
Neurological impaimient 
at 72 hours
Figure 1.1: Illustration of possible artifactual reason for some studies finding an increased 
incidence of progressing stroke in subjects with lacunar stroke, depending on the delay to 
hospital presentation. Dotted line represents lacunar infarction. Unbroken line represents 
cortical infarction. Illustration design suggested by Professor P Langhorne.
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1. Cerebrovascular disorders/
2. exp Brain ischemia/
3. Carotid aitery diseases/ or Carotid artery thrombosis/
4. exp Cerebrovascular accident/
5. exp Hypoxia-ischemia, brain/
6. Cerebral aiterial diseases/ or Intracranial arterial diseases/
7. exp "Intracranial embolism and thrombosis"/
8. (strokes or apoplex$ or cerebral vasc$ or cerebrovascS or cva or transient isch?emic 
attacks or tia$).tw.
9. (brain or cerebrS or cerebellS or vertebrobasilS or hemispherS or intracranS or 
intracerebral or infratentorial or supratentorial or middle cerebrS or mcaS or anterior 
circulation).tw.
10. (isch?emiS or infarctS or thromboS or emboliS or occlusS or hypoxiS).tw.
11.9 and 10
12. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 11
13. (Worsening or ProgressiS or EvolS or DeteriorS).tw.
14. 12 and 13
15. (Stroke Deterioration or Deteriorating Stroke or Stroke Progression or ProgresS 
Stroke or Stroke in Progression or Worsening Stroke or Stroke Worsening or Stroke in 
Evolution or Evolving Stroke or Neurological Deterioration or Neurological Worsening 
or Neurological Progression or Progressive Neurology or Evolving Neurology).tw.
16. 14 or 15
17. subarachnoid hemorrhage/
18. 16 not 17
19. limit 18 to (human and english language and yr=1985-2004)
Table 1.1: Ovid search strategy for progressing stroke literature review.
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Scandinavian Stroke Scale
Change in SSS Duration Authors
Two point fall in total score For > 6 hours in first 72 Christensen 02
For > 4 hours in first 48 Boysen 01
Three point fall in speech or two 
point change in consciousness or 
hand/ai'm/leg motor power
24 hours Davalos 99 ^
Three point fall in speech or two 
point change in hand/arm/leg motor 
power
36 hours 
72 hours
J0rgensen 94 
Barber 04
Three point fall in speech or two 
point change in conscious level or eye 
movement or arm or leg motor power 
(or death)
- progression could not be said to 
happen if conscious level improved
72 hours Birschel 04 on behalf 
of the European 
Progressing Stroke 
Study ^
Barber (in press)
(gaze domain omitted)
Table 1.2 : Examples of definitions of progressing stroke based on changes in total 
Scandinavian Stroke Scale (SSS) score or change in individual domains of the SSS.
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Clinical Features Laboratory Investigations Neuroimaging findings
Age
Admission delay Fibrinogen
Stroke type Haemostatic markers Computed tomography
Neurological impairment C-reactive protein
Temperature Glutamate Magnetic resonance
Hyperglycaemia / diabetes Nitric oxide imaging
Atrial fibrillation Ferritin
Hypoxia Cytokines Transcranial doppler
Blood pressure
Headache
Table 1.3: Potential predictors of progressing stroke classified as clinical, laboratory and 
neuroimaging features.
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Mortality
In hospital mortality J0rgensen 94, Steinke 02, Birschel 04, Britton 85,
Barber (in press)
One month mortality Davalos 99, Toni 95, Barber 04, Tei 00
3, 14, 15, 123
Three month mortality Davalos 90, Arenillas 02, Christensen 02, Grotta 01
19, 32, 68
Six Month Mortality Davalos 97
“Poor Outcome”
Discharge BI < 60 Nakamura 99
Dead or BI < 60 at 30 days Toni 95 Toni 98
Death or mRS > 2 at 1 month Barber 04 Barber (in press)
mRS > 2 at 3 months Serena 01
Death or mRS > 1 at 1 month Davalos 99 ^
Death or 20-point BI < 15 at 3 Birschel 04 ^
months
Death or BI < 95 at 6 months Davalos 97
Table 1,4: Meta analysis of progressing stroke and outcome; list of outcome measures 
used. BX indicate Baithel Index; mRS, modified Rankin Scale.
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Chapter 2
11
‘A Review of Studies of Haemostatic Function in Acute Stroke”
■'1
In the following chapter I review those studies examining abnormalities of haemostatic 
function after acute stroke. Although not a meta analysis attempts have been made, where 
possible, to report findings in a way similai* to the methodology suggested in the MOOSE
statement
A stylised illustration of the coagulation system is shown in figures 4.1 and 4.2. 
Haemostatic markers reported in this chapter are shown and those used in my own studies, 
reported later in this thesis, are highlighted in yellow.
Hypothesis statement:
Haemostatic factors are abnormal in acute ischaemic stroke and are associated with 
prognosis.
Selection Criteria:
" Study designs used case series examining haemostatic markers in 
acute ischaemic stroke compared to non-stroke controls 
studies examining haemostatic markers in ischaemic stroke 
subtypes
studies examining haemostatic markers and outcome 
(death, dependency, recurrent stroke or vascular event)
Haemostatic markers - coagulation factors (II, V, VII, VIII, IX, X, XI, XII, XIII)
- thrombin generation (FI+2 and TAT)
- fibrin generation (fibrinopeptide a)
- fibrin degradation products (FDPs, D-dimer, fragment E)
- fibrinolysis (t-PA, PAI-1, plasminogen, PIC)
- fibrinogen
- natural anticoagulants (ATIII, Proteins C and S)
- von Willebrand factor
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■ Exclusions - studies recruiting less than 25 subjects
- samples taken more than 72 hours from stroke onset
- non-English language papers
Search Strategy:
This seai'ch was designed and run in OVID Medline by the author (at 
http://gateway.ovid.com/athens/) using the strategy described in table 2.1. As of Januaiy 
Week 1 2004 this search produced 8436 hits. All titles and relevant abstracts were read by 
the author and selected papers requested from the library. Reference lists of all papers 
meeting inclusion criteria were hand searched to find further relevant studies. Further hand 
searches of journals [Cerebrovasculai’ Diseases (1999 -  present) and Stroke (last lOyears)] 
were made. Abstract only publications and unpublished studies were not included. No 
authors were contacted, however, Professor GDO Lowe kindly provided a reference to a 
paper not listed in Medline
Findings:
Coagulation factors:
■ Factor VII:
As part of the extrinsic (contact) coagulation pathway factor VII is activated by tissue 
factor and then plays a part in activation of factor X (itself involved in thrombin 
generation).
Takano et al. examined factor VII activity, measured within 48 hours of stroke onset, in 
63 consecutive subjects admitted with acute ischaemic stroke Subjects were 
classified using angiographic criteria as embolic, lacunar or atherothrombotic. 
Unclassified subjects were excluded. They found that factor VII activity was 
significantly higher in subjects with thrombotic stroke (n = 36) than subjects with 
cerebral embolism (n = 27) or age-matched controls (n -  30). One weakness is that all 
members of the control group were male whereas only 73% of the stroke group were 
male. Factor VII activity is higher in females than males in middle and older age
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He et al. used more rigorous methodology and came to a similar conclusion; factor VII 
activity is higher in acute ischaemic stroke than controls
Ferlito et al. also found raised factor VII levels in subjects with ischaemic stroke (n = 
45) or transient ischaemic attack (TIA) (n = 25) compared to controls This study, 
however, had a number of flaws. The control group was 20 years younger than the 
stroke cases. Almost all the controls were male (88%) whereas all the cases were 
female. Strokes were not reported distinct from TIAs and strokes classified as embolic 
were excluded. The statistical methods appear inappropriate and it is worrying that 
despite recruiting 40 controls only 12 of these appear to be reported in the final 
analysis. Despite these limitations they did find significantly higher factor VII levels in 
stroke subjects compared to TIAs and this information is, perhaps, more reliable. No 
demographic or clinical information is provided, however, regarding these two acute 
groups of admissions.
Antovic et al. reported factor VII activity in two publications In both these papers 
the same 30 subjects with ischaemic stroke were compared to controls recruited from 
the blood bank. Background information on neither the stroke cases nor the controls is 
provided in any useful depth. Different reporting and statistical analysis methods are 
used in the two papers. They found a significant reduction in factor VII activity in 
ischaemic stroke patients compared to controls; contradicting the results of the other 
three publications.
With regard to factor VII and stroke type Berge et al. have provided some useful 
information Their study measured factor VII antigen in 76 acute stroke patients. 
They found a trend towards lower factor VII antigen in “more severe strokes” (as 
assessed using the Oxfordshire Community Stroke Project Classification) and a 
significant reduction in factor VII antigen in embolic stroke (although these were not 
defined using rigid criteria).
Overall it seems that further work is required examining factor VII levels in acute 
ischaemic stroke, as results are contradictory. These problems may relate to different 
measurement techniques along with methodological issues in some studies.
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■ Tissue Factor/ Tissue Factor Pathway Inhibitor:
Tissue factor (TF) is central to the extrinsic coagulation pathway through its 
relationship with factor VII. Few studies have so far examined TF or tissue factor 
pathway inhibitor (TFPI)(which inhibits activated factor VII-TF complex). The 
available information is summarised below.
Kappelmayer et al. measured monocyte TF antigen expression in a small study of 
highly selected young patients and found elevated levels in cases compared to controls 
The laboratory analyses used appeared not to be practical tests which could be used 
in everyday clinical practice. He et al. measured TF antigen and activity in 71 cases of 
ischaemic stroke and found that both these markers were elevated by comparison with 
a control group They found that TFPI antigen and activity levels were lower in the 
stroke group, a finding replicated by Abumiya et al. In their study subjects were 
categorised into subgroups (atherothrombotic/ lacunar/ cardioembolic/ unclassified). 
Subjects with atherothrombotic and lacunar strokes had low TFPI activity levels, 
whereas those with cardioembolic strokes did not. Numbers in these subgroups were 
small, making it difficult to draw firm conclusions. Berge et al., however, found a non­
significant trend towards higher TFPI activity in non-embolic strokes raising the 
question that these levels may just reflect the underlying atherosclerotic process.
■ Factor VIII:
Factor VIII plays a key role in thrombin formation; it acts as a cofactor for the 
activation of factor X by factor IXa at the conclusion of the intrinsic coagulation 
pathway. Factor VIII complexes with von Willebrand factor (vWF), which will be 
discussed later. Landi et al. measured factor VIII coagulant activity in 70 consecutive 
subjects with acute stroke, recruited within 48 hours of onset of symptoms Primary 
intracerebral haemorrhage (PICK) subjects were not excluded and made up 
approximately 25% of strokes assessed. They found that factor VIII levels were 
elevated in acute stroke, even in multivariate analysis (including other 
haemorheological vaiiables). Factor VIII levels were also associated with death in the 
follow up period. This seems a well designed study and the results seem robust. Studies 
which examined stroke subjects less acutely drew similar conclusions
Confusingly, a more recent acute study by He et al. has produced some controversy 
with respect to factor VIII and stroke They found reduced factor VIIIc in subjects
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with acute ischaemic stroke recruited within 24 hours of onset. It is interesting that they 
also had an acute myocardial infarction group who had markedly raised factor VIIIc 
levels in the acute phase.
In view of the contiadictory results regarding factor VIII levels in acute ischaemic 
stroke, firm conclusions cannot be drawn.
■ Factor II (prothrombin) and Ha (thrombin):
The activation of factor II (prothrombin) to generate factor Ila (thrombin) is central to 
clot formation and is the common final result of the intrinsic and extrinsic coagulation 
pathways. Thrombin activates factor XIII and is also directly involved in the 
conversion of fibrinogen to soluble fibrin. Thrombin generation tends to be measured 
indirectly using circulating markers. These markers have been studied extensively in 
the acute stroke situation. Prothrombin fragments 1+2 (FI+2) are produced as part of 
the process of prothrombin activation to thrombin. Thrombin-anti thrombin complexes 
(TAT) are produced by inactivation of thr ombin by antithiombin and are, therefore, an 
indirect measure of thrombin generation.
Uchiyama et al. first studied F I+2 and TAT levels in subjects within 3 days of stroke 
Unfortunately some patients with myocardial infarction (n = 9) were included along 
with cerebral infarction subjects (n = 26) in data analysis, and so this paper is 
unhelpful. In 1992 Takano et al. published a paper examining haemostatic markers in 
subjects with ischaemic stroke TAT levels were measured within 48 hours of stroke 
onset in 54 subjects and compar ed to 20 controls. Exclusion criteria used included 
subjects who could not be classified to a stroke subtype and also anyone on antiplatelet 
agents prior to admission. The control group was, perhaps, not ideal (all male and 
younger than cases). TAT levels were found to be significantly higher in cardioembolic 
stroke than the control group. There was also a trend for higher TAT levels in non- 
embolic stroke, although the numbers studied were small.
In 1993 van Wersch et al. published a study on coagulation factors in 47 patients with 
cerebral infai'ction Blood samples were taken immediately after admission; 
however, an unspecified number of subjects took several days to present. Although 
reportedly matched on the basis of age, the controls (n = 135) proved to be ten years 
younger than stroke cases. They found that TAT levels were higher in cases than
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controls. The weaknesses of this study make drawing firm conclusions difficult. Altès 
et al. studied haemostatic function in 86 subjects with ischaemic stroke Blood 
sampling was within 24 hours of the ischaemic event. Unfortunately controls (healthy 
blood donors) were unmatched and proved to be younger than the cases. Parametric 
statistical tests were used without any transformation of variables; this seems likely to
■have been inappropriate. They found significantly higher TAT levels in cases 
compared to controls. Similar statistical anomalies occurred in the paper by Seki et al., 
who studied 28 patients acutely and reached identical conclusions
Catto et al. studied admission Fl+2 levels in 191 subjects with acute stroke (including 
16 cases of cerebral haemorrhage) and found that levels were significantly higher in 
cases than in controls (n = 33 volunteers) The control group was 7 years younger 
than the acute stroke group. In 1998 Giroud et al. published a paper describing 
measurement of a variety of coagulation markers in 54 subjects with ischaemic stroke, 
sampled within 24 hours of stroke onset The control group was poorly described 
and may, in fact, have been an age-adjusted normal laboratory reference range.
Subjects with possible cardioembolic stroke were excluded, as were subjects on 
antiplatelet medication prior to admission. Their conclusion was that Fl+2 levels were 
significantly higher in stroke cases than controls.
More recently additional papers by Kappelmayer Kataoka Soncini Toghi 
Topcuoglu and McConnell have been published; all examining Fl+2 and/ or TAT 
levels in subjects with acute stroke compared to controls. All of these studies have 
weaknesses which will be discussed later in this chapter. The general findings of these
i
studies, along with those mentioned earlier, aie summarised in table 2.2. From the 
large number of studies, of varying quality, it is probably reasonable to conclude that 
there is evidence of increased thrombin generation in acute ischaemic stroke.
Finally, a study published in 2002 reported factor II levels (rather than marker levels) 
in 71 subjects with acute ischaemic stroke They found significantly raised factor II 
activity in these stroke subjects compaied to 50 age-matched controls.
1  
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Several studies have reported markers of thrombin generation with respect to stroke 
subtype. Takano et al. found a trend towards elevated TAT levels in subjects with 
cardioembolic stroke compared to subjects with atherothrombotic or lacunar stroke
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Seki et al. divided subjects into those with cortical or lacunar stroke, but with no 
differentiation between embolic or non-embolic cause No differences in TAT levels 
between the two groups were found, however, only 28 subjects were included in this 
study.
Abumiya et al. classified 64 stroke patients as atherothrombotic, lacunai*,
cardioembolic or “unclassified” (n = 9) and compared TAT levels in these groups
Both atherothrombotic and cardioembolic stroke groups had higher TAT levels than
lacunai' stroke patients and there was a trend towards higher TAT levels in
cardioembolic, compared to atherothi'ombotic, stroke. Altès et al. used a similai' design
and reached similai- conclusions Similarly Kataoka et al. found that TAT levels
were significantly raised in subjects with cardioembolic infarct or atherothrombotic
infarct compared to lacunai- infaiction Parametric statistical techniques were used in
this study; this might, potentially, be inappropriate. Topcuoglu et al. measured Fl+2
and TAT levels in subjects with cortical strokes They found trends towards higher
levels of both these markers in subjects with cardioembolic, as opposed to
atherothrombotic, stroke. These results may not be generaliseable, as subjects were '
highly selected.
Finally, Berge et al. found no evidence of elevation of Fl+2 levels in subjects with 
presumed embolic infarction in their cohort of 76 acute stroke patients From the 
above studies it seems reasonable to conclude that markers of thrombin generation are J
elevated in cortical compared to lacunar stroke. This may relate to infarction size rather : J
than mechanism, although there is also some suggestion of greater thrombin generation 
in cardioembolic stroke when compai'ed to atherothrombotic cortical stroke.
Thrombin generation markers have also been studied with respect to prognosis. Here 
the evidence is somewhat patchy. A study by van Wersch et al, demonstrated a non­
significant trend towards increased numbers of stroke subjects with TAT levels 
“outside of the normal reference range” in those who had fatal outcome Soncini et ]
al. found higher TAT and Fl+2 levels acutely in subjects who died in the first six 
months after stroke Only non-cardioembolic stroke patients were included in this 
analysis. Berge et al. found that poor discharge outcome (defined as Rankin scale score 
>1) was associated with significantly higher acute Fl+2 levels No firm conclusions 
can be drawn from these limited data.
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■ Other coagulation factors:
Here the literature is limited with regai'd to the acute setting. Shinmyozo et al. found 
higher factor XII activity in stroke patients than controls Recruitment, 
unfortunately, was within 5 days (rather than 3 days) of stroke onset. With regard to 
factor XIII (involved in converting soluble fibrin to cross-linked fibrin), Kohler et al. 
found that the A sub-unit antigen was similar in patients with stroke compared to 
controls, but that low factor XIII A-sub-unit antigen (caused by increased thrombin 
generation) was strongly associated with post-stroke mortality Subjects in this 
study were recruited up to 10 days after admission. This is an area which may benefit 
from more research, as the evidence base is weak.
Fibrin Generation:
Under the influence of thrombin and activated factor XIII, fibrinogen is converted to 
soluble fibrin and then cross-linked fibrin. A measurable marker of the conversion of 
fibrinogen to fibrin is fibrinopeptide A (FpA).
Landi et al. found elevated levels of FpA in 70 acute stroke subjects in a study discussed 
earlier in this chapter RICH patients were included in the analysis. These findings were 
confirmed by D’Angelo et al., who examined 29 acute ischaemic stroke patients admitted 
within 48 hours of stroke onset and by Fisher et al. who examined 78 patients 
(approximately two thirds acute stroke and one third TIA) within 72 hours of onset A 
paper by Kataoka et al. similarly provides convincing evidence of elevated FpA levels in 
acute ischaemic stroke Ferlito et al. found no conclusive evidence of increased FpA 
levels in acute stroke, however, this is a poor study, as has been discussed earlier (in the 
coagulation factors section, chapter two)
Douglas et al. studied FpA levels in 100 acute stroke admissions to Glasgow Royal 
Infirmary during the mid 1980s Although admissions were “usually studied within 24 
hours of stroke onset” some may, presumably, have been recruited beyond 72 hours. Brain 
imaging was not carried out in all admissions, and so some patients with RICH and non­
stroke diagnosis will have been included. They found that FpA levels were significantly 
elevated in subjects who died within the 1 year follow up period. No significant difference
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was found in FpA levels between those survivors who were dependent or independent at 1 
year follow up.
There is evidence from these studies to conclude that FpA is elevated in acute stroke, 
suggesting increased fibrin generation. FpA may be a predictor of poor outcome.
Fibrin Turnover:
Once fibrinogen is converted to cross-linked fibrin network the fibrinolytic system acts, 
through plasmin, to degrade this network into fibrin degradation products (FDPs). Thus 
FDPs are a measure of thrombin activity and fibrin turnover. Fragment E and fibrin D- 
dimer, as individual FDPs, are markers of this process.
■ “Fibrin Degradation Products”:
Landi et al. found no significant elevation of FDP levels in subjects with acute stroke 
(including PICH patients) and no evidence of any association between these markers 
and outcome Takano et al. found evidence of raised FDPs in acute cerebral 
embolism but not cerebral thrombosis Douglas et al. found that subjects who died 
within the first year of acute stroke did not have significantly raised FDP levels 
compaied to survivors Measurement of total FDPs has been superceded by more 
modern methods.
■ Fragment E:
In 1982 de Boer et al. recruited 67 subjects, within 48 hours of stroke onset, as part of a 
heparin intervention study Subjects with suspected cardioembolic stroke were 
excluded. The control group was said to be “healthy” but no details of age or gender 
were supplied. They found that fragment E levels were significantly higher in the 
stroke patients than the control group. More recently Kataoka et al. showed elevated 
fragment E levels in acute ischaemic stroke Although the statistical methods 
employed may have been inappropriate, the magnitude of these differences seemed 
large. Fragment E levels were higher in atherothrombotic and cardioembolic stroke 
than lacunar stroke.
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Douglas et al. found raised fragment E levels in subjects with acute stroke who died 
within one year of onset compaied to those subjects who survived beyond this time
•  Fibrin D-dimer:
Fibrin D-dimer is of particular interest as a mai'ker of haemostatic activation, as many 
hospitals already have this analysis available for screening for other disorders, such as 
pulmonary embolism. D-dimer levels are resistant to ex-vivo activation, in the 
sampling tube, and have a long half-life in contrast to Fl+2 and TAT (meaning that the 
samples do not require to be spun and stored, or analysed, immediately). Numerous 
case control studies have been performed, examining alterations in D-dimer levels 
following acute ischaemic stroke. Some papers have already been mentioned above. 
Summai'ised below are those that have not. A summary of the results of all relevant 
papers is shown in table 2.3.
Fisher et al. examined D-dimer levels in acute stroke patients recruited within 72 hours 
of stroke onset Subjects were young (mean age 52 yrs old) and D-dimer levels were 
only reported for 66 out of the 85 recruited patients. D-dimer levels were found to be 
higher in acute stroke subjects than controls. Kappelmayer et al. examined D-dimer 
levels in 25 acute stroke patients This study recruited a young cohort (< 50 yrs old) 
and used multiple exclusion criteria. Statistical reporting was inconsistent. They found 
no significant evidence of elevated D-dimer levels in ischaemic stroke (301 ng/ml in 
the stroke group compared to 254 ng/ml in the control group). In a study published in 
2001 by Lip et al., 59 patients were recruited within 12 hours of stroke onset 
Subjects over the age of 75 were excluded. D-dimers levels were significantly raised in 
the stroke group compared to controls, a finding mirrored by Ageno et al. Toghi et
al, studied 116 stroke patients recruited within 24 hours of symptom onset Only
mild (National Institutes of Health Stroke Scale < 10), non-cardioembolic, strokes were 
included. They found that only subjects with C-reactive protein levels > 0.6mg/dl (30% 
of all admissions) had significantly raised D-dimer levels. Results for the entire stroke 
group were, unfortunately, not reported.
Results of studies, examining D-dimer levels, by Takano van Wersch Ferlito 
Altès Seki Antovic Giroud Kataoka and Li are also shown in table 
2.3. Weaknesses of these studies have been discussed earlier in this chapter. The
I
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overall picture does support the view that D-dimer levels are elevated in acute 
ischaemic stroke.
With regal'd to D-dimer and stroke subtype there is, again, some available evidence. 
Fisher et al. demonstrated elevated D-dimer levels in cortical stroke compaied to 
lacunar stroke a finding supported by Seki et al. although their results did not 
reach statistical significance. Papers by Abumiya and Altès found the highest D-dimer 
levels in cardioembolic stroke (with a tendency for patients with atherothrombotic 
stroke to have higher levels than lacunar strokes) Kataoka et al. performed one
of the few studies large enough to demonstrate that cardioembolic infarction patients 
have higher D-dimer levels than atherothrombotic infarction subjects, who, in turn, 
have higher D-dimer levels than lacunai' stroke patients Berge et al. found elevated 
D-dimer levels in cardioembolic stroke in comparison to atherothrombotic or lacunar 
stroke Both Takano and Ageno also found elevated D-dimer levels in 
cardioembolic stroke in comparison to atherothrombotic or lacunar stroke and 
produced sensitivities and specificities for diagnosis of cardioembolic stroke using the 
D-dimer assay
D-dimer may also have a role in predicting outcome. Several studies have
shown that D-dimer levels predict poor outcome in terms of dependency, death and 
further vascular events.
Fibrinolysis:
Fibrin is degraded to FDPs by the action of plasmin. Plasmin is produced through 
activation of plasminogen by tissue plasminogen activator (t-PA). t-PA circulates 
complexed with its inhibitor plasminogen activator inhibitor (PAI-1). Measurement of t- 
PA antigen, therefore, also reflects PAI-1 concentrations. Plasmin also degrades fibrinogen 
to its breakdown products, including 81-42 fragment, which can be measured as a marker 
of fibrinolysis (or, more accurately, “fibrinogenolysis”). Plasmin-a2 plasmin inhibitor 
complex (PIC) is produced by binding of free plasmin by its most important inhibitor a2 
plasmin inhibitor. This process is central to regulation of the fibrinolytic process.
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■ Plasminogen:
Papers by Takano and Altès have been mentioned earlier in this chapter. Takano 
et al. found no significant difference in plasminogen levels between stroke and control 
subjects. Altès et al. found a significant reduction in plasminogen levels in 
cardioembolic and atherothrombotic stroke, but not lacunai’ stroke. The statistical 
methods chosen for this study may have been inappropriate and also control subjects 
were importantly younger than stroke cases. Li et al. examined plasminogen activity in 
35 subjects with acute cerebral infarction using samples withdrawn within 24 hours of 
admission . The reporting of this study was poor, however, the authors concluded 
that plasminogen activity was lower in cases than controls. On the basis of these 
studies firm conclusions cannot be drawn, although there is some suggestion that 
plasminogen levels may be reduced in acute ischaemic stroke.
■ Tissue plasminogen activator (t-PA):
As mentioned previously, t-PA is involved in activation of plasminogen to plasmin. t- 
PA levels have been studied in acute ischaemic stroke. Shang et al. measured t-PA 
activity within 72 hours of stroke and found this activity reduced compaied to controls 
Ferlito et al. found no difference between t-PA levels in acute stroke patients and 
controls in their study (one which has several weaknesses) a conclusion also made 
by Topcuoglu et al. Altès et al. and Li et al. found increased t-PA levels in acute 
stroke . These conflicting results might reflect a number of issues including 
variation in study design and quality, differences in assays used, sampling timing issues 
and ex-vivo problems with samples. Three of these studies have gone on to examine 
stroke type and t-PA levels however, in view of their lack of reproducibility
with regar d to alterations of levels in acute stroke as a whole, their results are felt 
unlikely to be informative in subtype analyses.
■ Plasminogen activator inhibitor (PAI-1);
Studies have also examined levels of PAI-1 in acute stroke. Here results have been, 
perhaps, more consistent.
Fisher et al., Ferlito et al. and Topcuoglu et al. found no difference between PAI-1 
levels in acute stroke patients and controls subjects in studies discussed earlier in this 
chapter^®’ These studies have weaknesses and, in particular, Topcuoglu
separated strokes into a number of categories, hence limiting the statistical power of
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their study Altès et al., Lip et al. and Li et al. found significantly elevated PAI-1 
levels in acute stroke . Shang et al. also examined PAI-1 levels, within 3 days
of symptom onset, in acute cerebral infaiction patients and found raised levels 
compared to the control group Haapaniemi et al. studied 55 patients with ischaemic 
stroke and found elevated PAI-1 levels compared to the control group This was a 
small paper with limited descriptive information about the stroke or control cohorts. 
Patients unable to consent were excluded; presumably those with dysphasia or reduced 
conscious level. It is also possible that 20 out of the 55 cases were anticoagulated at the 
time of sampling Olah et al. also found elevated PAI-1 levels in stroke Their 
study results cannot be generalised for reasons discussed later in this chapter. The 
results of all of these studies ai'e summai'ised in table 2.4. Overall, the pattern here 
appears to be of elevated PAI-1 levels in acute ischaemic stroke.
With regal'd to stroke type Altès et al. found greater elevations of PAI-1 in 
cardioembolic strokes than thrombotic strokes. Small numbers may have been the 
reason for non-significant results Shang et al. found a trend towards higher PAI-1 
levels in cortical strokes compaied to lacunar sti’okes Because of the limitations of 
study design and stroke classification the study by Topcuoglu and colleaugues is 
unhelpful
In terms of prognosis, Lip et al. found that high PAI-1 levels were associated with 
reduced event-free survival following ischaemic stroke
■ Bl-42 fragment:
In 1990 Fisher et al. published a study examining haemostatic function in ischaemic 
stroke. 81-42 fragment levels (a marker of plasmin activity) were measured in 35 cases 
of acute stroke or transient ischaemic attack Unfortunately members of the control 
group used for this paiticular analysis were, on average, 13 years younger than the 
stroke group. 81-42 levels were found to be lower in acute stroke patients than control 
subjects. The methodology used in this study was not strong enough to draw clear 
conclusions. Fisher’s results are similar to those found by Feinberg et al. in a study 
which withdrew samples too late after stroke onset to be included in this review
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Douglas et al. found elevated B15-42 levels in subjects with acute stroke who died 
within the first year of onset These levels also appeared to be associated with 
functional outcome (defined simply as “dependent” or “independent”).
■ Plasmin-a2 plasmin inhibitor complex:
Plasmin-a2 plasmin inhibitor complex levels have been measured in several acute 
stroke studies. These studies, of varying methodological quality, have consistently 
demonstrated raised PIC levels in acute stroke Most studies examining
stroke subtypes have shown that cai'dioembolic strokes have higher PIC levels than 
atherothrombotic stroke although these results did not always reach statistical 
significance
Natural Anticoagulants/ Coagulation Inhibitors:
The three most studied natural anticoagulant proteins are antithrombin III (ATIII), protein 
C and protein S. As discussed eailier ATIII complexes with thrombin (and also inhibits 
factors XIa, IXa and Xa); thereby preventing the effect of thrombin in stimulating the 
formation of cross-linked fibrin. Protein C inactivates the coagulation cascade at the stage 
of both factor Villa and factor Va. Protein S is a cofactor in this inhibition process. Many 
of the papers studying natural anticoagulant levels in acute stroke have already been 
mentioned. Their results are summai'ised in table 2.5. Summarised below are those studies 
which have not previously been discussed.
Aral et al. measured antithiombin III activity in 57 subjects with acute ischaemic stroke. 
They found reduced ATIII activity in these stroke subjects compared to a control group 
The control group was, unfortunately, 30 years younger than the cases! By modern 
standards the reporting of this study was poor. A publication by Hossmann et al. had 
similai’ weaknesses and drew similar conclusions, although in this study there was not such 
an age difference D’Angelo et al. studied 37 consecutive acute stroke patients 
(including eight cases of PICH) and found no evidence of significant reduction of protein 
C levels in stroke Anzola et al. studied proteins C and S in 43 acute ischaemic stroke 
admissions The stroke subjects were relatively young (mean age 57 years), but the 
control subjects were 12 years younger. There did seem an excess of subjects with reduced
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protein C and S levels in the stroke group compared to the control group, however, the 
analysis and reporting methods were not ideal.
A study by Olah et al. concentrated on young stroke and transient ischaemic attack patients 
(age range 15 -  49) Results were compared to a “normal reference range”,supplied by 
the manufacturer. There was evidence of reduction of ATIII, protein C and protein S levels 
in a significant number of patients compared to the reference range. The majority of these 
abnormalities had resolved by 3 month follow up. The results of this study are not 
generaliseable, particularly in view of the young age group used. Further analysis of a 
group of 55 stroke patients by Haapaniemi et al. showed significantly reduced 
antithrombin levels following acute stroke, but elevated protein C levels This study had 
several flaws. Many cases appear to have been on anticoagulant therapy, and separate 
information was not supplied for the 35 subjects who were not. Some potentially important 
groups of patients were also excluded.
It can be seen from table 2.5 that, although the methodology used has not always been 
ideal, there is a fairly consistent pattern for reduced ATIII levels in early acute ischaemic 
stroke. Results for protein C and S are less convincing.
With regard to natural anticoagulants and stroke subtype several studies have pointed 
towai’ds reduced ATIII in cardioembolic stroke These studies have not
always been large enough, individually, to prove this statistically, however, this appears to 
be the overwhelming message. Y as aka et al. found reduced ATIII levels in subjects with 
acute cai'dioembolic stroke who had recurrent brain infarction within the first 2 weeks of 
stroke onset With regard to mortality Landi et al. found a trend towards lower ATIII 
levels in acute stroke subjects who died in the follow up period
von Willebrand factor:
von Willebrand factor (vWF) is released predominantly from endothelial cells and is said 
to be a marker of endothelial dysfunction. It has a major role in platelet aggregation, but 
also acts as a carrier protein for factor VIII, itself involved as a cofactor for activating 
factor X.
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A number of acute strokes studies have measured vWF levels. Studies by Landi, Bath, 
Blann, Lip, Kozuka and Reynolds have all shown evidence of elevated vWF levels in acute 
stroke In the paper by Bath et al. 163 acute ischaemic stroke subjects
were recruited within 48 hours of symptom onset and compared to 33 healthy age-matched 
controls. Concenti’ations of vWF were reported in only 117 of the cases and 25 of the 
controls. Within these groups vWF was significantly higher in stroke patients than the 
control group. Kozuka et al. recruited 52 consecutive acute stroke patients, within 48 hours 
of onset, and found significantly raised vWF levels compared to an age matched control 
group. A study by Seki at al. also showed non-significant trends towards increased vWF in 
acute stroke
Subjects with larger cortical infarcts may have higher vWF levels than lacunar stroke 
patients There is also evidence that vWF is associated with poor outcome in acute
stroke, in terms of death or institutionalisation
Fibrinogen:
As the precursor of fibrin, and also through its effects on platelet aggregation, fibrinogen is 
a critical haemostatic factor. It is also the major determinant of plasma viscosity. It is 
produced in the liver in response to IL-6 and is a well recognised acute-phase reactant. For 
these reasons it is hai'd to tease out the real meaning of altered fibrinogen levels in the 
situation of acute ischaemic stioke. There is a large amount of published work, which 
suggests that fibrinogen levels are elevated in samples withdrawn within 3 days of stroke 
onset There is some, not always statistically significant, evidence to also suggest that 
raised fibrinogen levels may be associated with poor outcome in acute stroke 
148,158,161, 162^ although a paper by Lip et al. did not support this finding As with CRP, 
these raised levels may reflect the acute-phase response to stroke and be associated with 
stroke severity; hence, the reasons for potential associations with poor outcome.
Concluding notes:
This review has attempted to be as comprehensive as possible. Small studies (less than 25 
patients) were excluded. These studies were felt likely to have been underpowered and 
were generally of poorer quality. Non-English language papers were also excluded. The
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number of these studies was relatively low, however, no resource was available to translate 
such papers into English. Studies including subjects with blood samples withdrawn more 
than 72 hours after symptom onset were also excluded. It seems likely that levels of 
haemostatic markers sampled beyond this time reflect medical complications of acute 
sti'oke as well as the stroke itself. This time window was chosen pragmatically. The next 
common cut-off used by studies, following this time, was one week.
The trials reported are of variable quality and the results should, therefore, be treated with 
caution. There does seem, however, clear evidence of alterations of some coagulation 
markers in acute ischaemic stroke. These alterations may be more marked in cardioembolic 
rather than atherothrombotic or lacunar stroke. How much these abnormalities reflect 
acute-phase response is uncertain, however, the changes do suggest a hypercoagulable 
state which is potentially open to modification. More evidence regarding the role of these 
markers in early prognosis of stroke is required.
69
I
I>
cr
1ftSm
S'2
Figure 2.1 : Stylised illustration of the coagulation system. This includes markers reported 
in this chapter and in the studies reported later in this thesis.
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Figure 2.2: Stylised illustration of the intrinsic and extrinsic coagulation cascades. This 
includes markers reported in this chapter and in the studies reported later in this thesis.
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1. Cerebrovascular Disorders/ or Amaurosis Fugax/ or Cerebrovascular Circulation/ or Retinal 
Vessels/ or Dementia, Multi-Infai'ct/ or Endarterectomy, Carotid/
2. (Cerebrovascular or Cerebral artery or Cerebral isch$ or Brain isch$ or Carotid$ 
or Strokes or Cerebral Hemorrhage! or Basal Ganglia Hemorrhage$ or Cerebral 
Haemorrhages or Basal Ganglia HaemorrhageS or TIA or CVA or Endarterectomy 
or Amaurosis or (Brain adj2 infarctS) or (Cerebral adj3 infarctS)).tw.
3. (Leukoaraiosis or Small vessel disease or White matter lesions).tw.
4. 1 or 2 or 3
5. PROTHROMBIN/ or THROMBIN/ or (factor V or factor VII or factor VIII or 
factor IX or factor X or factor XI or factor XII or factor XIII).tw.
6. (Fl+2 or Antithrombin$ or TAT).tw.
7. FIBRIN/ or fibrinopeptide a.tw.
8. (FDPS or XDPS or d dimer or fragment E).tw.
9. Tissue Plasminogen Activator/ or PLASMINOGEN/ or (t-PA or PAI-1 or PAI-2 
or PAI1 or PAI2 or plasminS or PIC).tw.
10. FIBRINOGEN/
11. ANTITHROMBINS/ or Antithiombin IE/ or (ATIII or Protein C or Protein 
S).tw.
12. (von Willebrand or vwf).tw.
13. HEMOSTASIS/ or Blood Viscosity/ or Erythrocyte Aggregation/ or 
RHEOLOGY/ or Blood Sedimentation/ or HEMATOCRIT/ or Platelet Function 
Tests/ or Blood Coagulation Tests/ or Blood Coagulation Disorders/ or Blood 
Coagulation Factor Inhibitors/ or Blood Coagulation Factors/ or Plasminogen 
Inactivators/ or Protein C/ or THROMBOMODULIN/
14. (Haemosta$ or HemostaS or Coagul$ or Viscosity or Fibrin$ or Platelet$ or 
(Erythrocytes adj3 rate) or Erytlirocyte$ aggregation or ESR or Rheolog$ or 
HemorheologS or HaemorheologS or Haematocrit or Hematocrit or Sedimentation 
or ThiombosS or ThrombomS or Thromboplastin or Sticky blood or Protein Z or 
beta-Thromboglobulin or beta-TBG or B-TBG).tw.
15. 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14
16. 4 and 15
17. limit 16 to (human and english language and y i-1980-2004)
Table 2.1: Ovid Medline search strategy for review of haemostatic function in acute stroke.
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Author Year Reference Subjects F I+2 TAT
Study
relevance
Control
group
Takano 1992 134 54 N/A t Acceptable Borderline
van Wersch 1993 135 47 N/A t Poor Poor
Altès 1995 136 86 N/A t Acceptable Acceptable
Catto 1995 137 191 t N/A Acceptable Borderline
Seki 1995 91 28 N/A Borderline Acceptable
Giroud 1998 138 54 t N/A Borderline Poor
Kappelmayer 1998 129 25 t Poor Acceptable
Kataoka 2000 97 137 N/A ♦ Acceptable Acceptable
Soncini 2000 139 40 t t Poor Acceptable
Toghi 2000 140 116 N/A t Poor Acceptable
Topcuoglu 2000 141 96 — t Borderline Acceptable
McConnell 2001 99 25 t t Acceptable Acceptable
,'4 :
Table 2.2: Review of haemostatic function in acute stroke; case control studies examining 
prothrombin fragments 1+2 (FI+2) and thrombin-antithiombin (TAT) levels in subjects 
with acute stroke recruited within 72 hours of admission. Decision on “study relevance” is 
a subjective judgement based on factors including the patient population chosen (can the 
results be generalised to other populations?), subject recruitment (were consecutive, 
unselected patients recruited?), statistical methods used and completeness of reporting. 
Decision on control group is a subjective judgement based on the appropriateness of the 
control group chosen (for instance were they age and sex matched to stroke cases?).
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Author Year Reference Subjects
D-dimer
levels
Study
relevance
Control
group
Fisher 1990 145 66 t Borderline Acceptable
Takano 1992 134 54 t Acceptable Borderline
van Wersch 1993 135 47 t Poor Poor
Ferlito 1994 90 45 t Poor Poor
Altès 1995 136 86 Acceptable Acceptable
Seki 1995 91 28 t Borderline Acceptable
Antovic 1998 93, 94 30 t Poor Poor
Giroud 1998 138 54 t Borderline Poor
Kappelmeyer 1998 129 25 Poor Acceptable
Kataoka 2000 97 137 t Acceptable Acceptable
Toghi 2000 140 116 t Poor Acceptable
Lip 2001 98 59 t Acceptable Acceptable
Ageno 2002 146 86 Acceptable Acceptable
Li 2003 147 35 t Poor Borderline
Table 2.3: Review of haemostatic function in acute stroke; case control studies examining 
fibrin D-dimer levels in subjects with acute stroke recruited within 72 hours of admission. 
Decision on “study relevance” is a subjective judgement based on factors including the 
patient population chosen (can the results be generalised to other populations?), subject 
recruitment (were consecutive, unselected patients recruited?), statistical methods used and 
completeness of reporting. Decision on control group is a subjective judgement based on 
the appropriateness of the control group chosen (for instance were they age and sex 
matched to stroke cases?).
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Author Year- Reference Subjects PALI
Study
relevance
Control
group
Fisher 1990 145 73 Borderline Acceptable
Ferlito 1994 90 45 Poor Poor
Altès 1995 136 86 Acceptable Acceptable
Shang 1995 150 62 t Borderline Acceptable
Haapaniemi 2000 151 55 Poor Borderline
Topcuoglu 2000 141 96 Borderline Acceptable
Lip 2001 98 86 t Acceptable Acceptable
Olah 2001 153 53 t Poor Poor
Li 2003 147 35 t Poor Borderline
Table 2.4: Review of haemostatic function in acute sti'oke; case control studies examining 
plasminogen activator inhibitor (PAI-l) levels in subjects with acute stroke recruited 
within 72 hours of admission. Decision on “study relevance” is a subjective judgement 
based on factors including the patient population chosen (can the results be generalised to 
other populations?), stibject recruitment (were consecutive, unselected patients recruited?), 
statistical methods used and completeness of reporting. Decision on control group is a 
subjective judgement based on the appropriateness of the control group chosen (for 
instance were they age and sex matched to stroke cases?).
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Author Year Reference n - ATIII PC PS
Study
relevance
Control
group
Arai 1983 135 57 * N/A N/A Poor Poor
Hossmann 1983 156 36 * N/A N/A Poor Acceptable
Landi 1987 82 70 — N/A N/A Borderline Acceptable
D’Angelo 1988 144 37 N/A — N/A Borderline Acceptable
Takano 1990 86 63 — N/A Acceptable Borderline
Takano 1992 134 54 N/A N/A Acceptable Borderline
Anzola 1993 157 43 N/A 4* 4k Borderline Borderline
Ferlito 1994 90 45 — — — Poor Poor
Altès 1995 136 86 — t Acceptable Acceptable
Seki 1995 91 28 4 N/A Borderline Borderline
Antovic 1998 93, 94 30 N/A N/A Poor Poor
Kataoka 2000 97 137 4 N/A N/A Acceptable Acceptable
Olah 2001 153 46 4k 4^ Poor Poor
Haapaniemi 2002 152 55 — Poor Borderline
He 2002 101 71 Acceptable Acceptable
Table 2.5: Review of haemostatic function in acute stroke; case control studies examining 
natural anticoagulant levels in subjects with acute stroke recruited within 72 hours of 
admission. Decision on “study relevance” is a subjective judgement based on factors 
including the patient population chosen (can the results be generalised to other 
populations?), subject recruitment (were consecutive, unselected patients recruited?), 
statistical methods used and completeness of reporting. Decision on control group is a 
subjective judgement based on the appropriateness of the control group chosen (for 
instance were they age and sex matched to stroke cases?). ATIII indicates antithrombin III; 
PC, Protein C; PS, Protein S
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Chapter 3
“Retrospective Assessment of Initial Levels of Neurological Impairment from Routine
Hospital Admission Records”
In the chapters examining the “PROCESS” database (chapters four, five and six), levels of 
initial neurological impairment were retrospectively assessed using information contained 
in routine hospital admission records (the details of this database are discussed in the 
methods section of chapter four). A tiained research nurse also made assessments face-to- 
face on day 3, allowing the diagnosis of progressing stroke to be made. In the main 
prospective observational acute study examining haemostatic function in progressing 
ischaemic stroke (chapter seven) assessments were made by a single observer (the author) 
as soon as practical following hospital admission. As delays of up to 16 hours may have 
occurred between hospital admission and this assessment, in some patients, it was felt that 
some retrospective information, taken from the admission clerk-ins, should be used to 
inform decisions on whether very early neurological deterioration had occurred. This 
approach has not been previously validated, although it is a method which has been used 
before
The severity of initial neurological impairment after stroke is known to have a significant 
impact on short-term and long-term outcome At the time of performing the
research contained in this thesis our unit did not routinely use standardised tools to record 
information on stroke neurological impairment. Even if such tools had been employed 
they may have been recorded with a low level of reliability unless all admitting staff were 
given detailed training in their use. For purposes of case-mix adjustment and audit it 
would be an advantage to know that admission neurological impairment scores can be 
reliably estimated retrospectively from routinely recorded data. This examination of 
reliability is also essential for the research contained herein.
The Scandinavian Stroke Scale (SSS) was first described in 1985 when it was used in 
assessing the acute prognosis and long-term outcome of ischaemic stroke in the 
Scandinavian Hemodilution Study It is a simple tool that can be used to monitor 
neurological progress'. It has good interobserver reliability when performed face-to-face
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Unlike the National Institutes of Health Stroke Scale (NIHSS) and Canadian 
Neurological Scale (CNS) there is little evidence for the reliability of retrospective 
assessment of initial stroke severity, from routinely recorded information in hospital 
admission records, using the SSS.
Aims:
To validate the use of retrospectively obtained information in estimating total SSS score 
and scores in various component parts of this total score. To demonstrate validity of the 
diagnosis of progressing stroke when this diagnosis is made using retrospective assessment 
of admission SSS.
Methods:
This was a prospective study using a convenience sample of acute stroke referrals to 
Glasgow Royal Infirmary. Admission documentation was in a standardised pro forma, 
which includes specific sections for coma scale recording, orientation, communication and 
standard neurological assessment (all as free text). This document was designed as a tool 
for use in general medical admissions with the specific aim of improving all areas of case 
record documentation. None of the admitting physicians were aware of this study; no extra 
care in documentation was, therefore, made. Basic demographic information was recorded 
for each admission, as was Oxfordshire Community Stroke Project (OCSP) classification 
(total anterior circulation syndrome (TACS), partial anterior circulation syndrome (PACS), 
lacunai' syndrome (LACS) or posterior circulation syndrome (POCS))
Assessment of neurological status was performed using the Scandinavian Stroke Scale (see 
appendix A). The SSS consists of 9 items (consciousness; eye movements; arm motor 
power; hand motor power; leg motor power; orientation; speech; facial palsy and gait) with 
between 2 and 5 possible grades of deficit ranked in decreasing order; that is, the lower the 
score, the worse the deficit. A single experienced examiner, blinded to case note 
information, assessed each patient within 4 hours of (but normally considerably closer to) 
the examination performed and documented by the admitting medical team. Assessment 
of gait was not made in the Accident and Emergency department. This meant that the 
maximum possible score on the face-to-face SSS was 46.
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Retrospective SSS score was estimated using information documented in the case sheet by 
the admitting medical team. A research nurse trained in the use of this measure performed 
the assessment blinded to the patients’ clinical condition. In circumstances where no case 
record documentation of examination in a particulai" domain was present, e.g. the presence 
or absence of gaze paresis, then this was assumed to imply that there was no abnormality 
found in this domain. A second independent examiner (the author) also estimated a 
retrospective SSS score from the medical documentation to allow analysis of inter-rater 
reliability of retrospective assessment.
The purpose of this validation exercise, as far as work contained within this thesis is 
concerned, was to examine whether the diagnosis of progressing stroke could be made if 
the first assessment of SSS score was made retrospectively from hospital admission 
records (and a formal day 3 assessment made face-to-face). To this end, agreement 
between progressing stroke diagnoses made by the face-to-face assessor and the author 
(observer 2) was examined. Progressing stroke diagnosis was based on the European 
Progressing Sti'oke Study (EPSS) group definition, over the period from admission to day 
3, without inclusion of the gaze component The reasons for choosing to exclude the gaze 
component of the EPSS progressing stroke definition are discussed in chapter six.
As documentation of limb weakness by medical staff is predominantly made using the 
Medical Research Council (MRC) scale within our unit, a simple algorithm was 
developed for conversion to SSS scores for limb power:
For upper limb power:
A MRC score of 0 or 1 became a SSS score of 0 (none);
A MRC score of 2 became a SSS score of 2 (not against gravity);
A MRC score of 3 became a SSS score of 4 (elbow flexion);
A MRC score of 4 became a SSS score of 5 (reduced);
A MRC score of 5 became a SSS score of 6 (normal).
For a score of 2 on the MRC scale the observer was allowed some discretion as to the SSS 
score allocated (depending on other information in the admission notes this could be 
converted to a SSS score of 4). A similai* process occurred for conversion of MRC leg 
power scores to SSS scores. The algorithm is demonstrated in graphic form in figure 3.1.
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Statistical Analyses
Agreement between domains of the face-to-face and retrospective SSS was performed 
using weighted kappa statistics An excel spreadsheet was developed to perform these 
calculations. This spreadsheet allowed, if necessary, for calculation of kappa values in non­
square tables; a function not available with weighted kappa in many statistical packages. 
Weighting of kappa occurred by giving weights to each cell of the table depending on the 
distance from the diagonal that indicates agreement. The weight is calculated as shown in 
the formula in figure 3.2a. An example of the weights, which would apply to a 5 x 5 table 
from this formula, is shown in figure 3.2b. This approach to weighting of kappa is common 
and does have the advantage of rewarding “near misses”. It has the weakness, however, of 
treating the SSS components as ordinal and treating the differences between the various 
components of the SSS as equal. It has become accepted that interpretation of agreement 
for different values of kappa statistic may be made as follows
Kappa Statistic Strength of 
agreement
<0.20 Poor
0.21-0 .40 Fair
0 .41-0 .60 Moderate
0 .61-0 .80 Good
0.81 -  1.00 Very Good
Agreement between composite scores was estimated using the method described by Bland 
and Altman The mean difference between face-to-face and retrospective SSS scores 
was calculated. A 95% confidence interval (based on 1.96 x the standard error of the 
mean) was then calculated to allow an estimate of the accuracy of use of retrospective SSS 
scores. A regression coefficient was calculated for the difference between the two 
measurement methods and the mean score to look for systematic differences in SSS 
recording between scores with higher, or lower, values.
f .
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Results:
Fifty patients were recruited to the study. The median age was 73 years (interquartile 
range 61,79) and the median composite SSS score on admission was 37.5 (interquartile 
range 24,43) out of a possible 46 points. Twenty three (46%) were left hemisphere events. 
Fifteen (30%) were TACS, 16 (32%) were PACS, 10 (20%) were LACS and 9 (18%) were 
POCS. Completion of documentation in the medical admissions’ pro forma was 
consistently high with the exception of eye movements and facial palsy. If a patient was 
admitted with a minor stroke medical staff tended not to specifically document “no gaze 
palsy” and the retrospective assessors assumed gaze palsy to be absent.
Figure 3.3 demonstrates an example of a cross tabulation for agreement between 
retrospective and face-to-face assessment of admission SSS leg motor score. Weighted 
kappa statistics for both observers for retrospective assessment of domains of the SSS are 
shown in table 3.1. Weighted kappa statistics (based on the agreement for both observers 
combined) between domains of the face-to-face and retrospective SSS were as follows: 
consciousness kappa 0.73, eye movements kappa 0.60, aim motor power kappa 0.83, hand 
motor power kappa 0.71, leg motor power kappa 0.81, orientation kappa 0.81, speech 
kappa 0.80, and facial palsy kappa 0.53.
The mean difference between composite SSS scores performed retrospectively and face-to- 
face was 0.78 (95% confidence interval -0.17, 1.73) points for observer 1 and 0.72 (95% 
confidence interval -0.30, 1.74) for observer 2 (the face-to-face score being higher in both 
instances). The regression coefficients for the difference between the two measurement 
methods and the mean score were 0.064 (95% confidence interval -0.005, 0.133) and 0.057 
(95% confidence interval -0.018, 0.131) for observers 1 and 2 respectively. There is, 
therefore, no demonstrated evidence of significant systematic differences in SSS recording 
between retrospective and face-to-face assessments across the total range of SSS scores. 
Bland Altman plots for the performance of observers 1 and 2 are shown in figures 3.4a and 
3.4b respectively.
Kappa statistics for interobserver reliability of the retrospective SSS are shown in table 3.2. 
Again agreement was good except for the gaze domain, where agreement was moderate 
(weighted kappa 0.58).
81
With regard to assessment of the EPSS definition of progressing stroke (as used in chapter 
seven), utilising retrospective case note information for the baseline assessment, agreement 
was excellent. Thirteen (26%) of the 50 patients assessed had progressing stroke as 
diagnosed by the face-to-face examiner. The kappa statistic for agreement between the 
face-to-face and retrospective assessment (observer 2, the author) was 0.88.
Discussion:
This exercise has demonstrated that admission neurological scores can be estimated 
reliably from routine hospital admission records. It has also shown that it is possible to 
accurately diagnose progressing stroke using retrospective assessment of initial 
neurological impairment along with face-to-face assessment on day 3.
Reliability of retrospective scoring of both the NIHSS and CNS have previously been 
shown to be high. Kasner et al. demonstrated good retrospective agreement for total 
NIHSS score in a selected group of ischaemic stroke patients admitted by neurologists 
as part of experimental clinical studies. Retrospective scoring was from clinical study 
forms, which might lead to higher quality documentation and, therefore, these results may 
not necessarily be generalised to community/ district hospitals. More recently scoring of 
retrospective NIHSS score using an algorithm has been shown to be reliable Again 
initial documentation was by neurologists (who may make more detailed records of 
neurological impairments than junior general physicians). Removing some unreliable and 
redundant items of the NIHSS may improve reliability for retrospective use In many 
countries only a minority of sti'oke patients are admitted to neurological centres and when 
retrospective scoring of NIHSS is extended to community hospitals without acute 
neurological consultation reliability falls A similar pattern is seen when retrospective 
scoring of the CNS is performed in district hospitals
Strengths of this study aie that it used an unselected population assessed prospectively.
The admitting teams involved were generalists with no specific stroke or neurology 
training; doctors early in their training performed most of the assessment and 
documentation. These results, therefore, may be applicable to many general hospital 
settings, pai'ticularly in the United Kingdom, Attempts were made to examine the 
paiticipants as closely as possible to the assessment made by the admitting team, however, 
clinical examinations may have occurred as much as two to three hours apart.
Anecdotally, some of the patients studied had fluctuating neurological signs. It is known
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that around a quarter of patients deteriorate neurologically within a few hours of stroke 
onset, using a definition based on the SSS A similar number may improve. This could 
mean, potentially, that the results presented here are an underestimate of the true 
agreement between retrospective and face-to-face assessments.
Documentation in the pro formas was not always complete for the eye movement and 
facial palsy domains. This may explain the low agreement between face-to-face and 
retrospective scores, although these domains are ones which generally have poor 
interobserver agreement even when performed face-to-face It could be ai’gued that, in 
the present study, the absence of documentation for these components of the SSS would 
lead to an overestimation of interobserver agreement for retrospectively assessed scores. 
Kappa values, however, were not higher for these domains than others. This study 
validated the reliability of retrospective assessment of the SSS using two observers. 
Interobserver agreement was only compared between these two observers. Ideally this 
validation study should be repeated using multiple observers (perhaps five, from a variety 
of disciplines, would suffice) to ensure that reliability is confirmed in a wider setting.
Use of the MRC scale by many of the admitting doctors aided conversion of limb 
components of the SSS. Undergraduate medical training includes teaching on the use of 
the MRC scale. This ensures that, although in medical units there is no prescriptive advice 
on the use of this scale, it is commonly recorded. Williams et al. have also included MRC 
scale conversion in an algorithm for reti'ospective assessment of NIHSS scores Units 
that do not record limb weakness using standardised measures, such as the MRC scale, 
may not obtain such reliable estimates of retrospective neurological impairment scale 
scores for limb weakness.
Gait assessment is an important component of the SSS. This was not assessed in the 
emergency department by the admitting staff and, therefore, agreement between 
documented clinical findings and those of the experienced examiner could not be 
estimated. Local policy is for suitably trained physiotherapy staff to assess gait after ward 
admission and before mobilisation is allowed; we would, therefore, not expect 
documentation of this SSS component by junior medical staff in the Accident and 
Emergency department. This is a limitation of this study. Despite this, the present analysis 
has demonstrated the reliability of retrospective estimation of all other individual 
components of the SSS. This study does mean that the prognostic score (made up of the
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consciousness, eye movement, aim and leg motor power components) can be reliably 
estimated, in full, retrospectively
In summary, this study has demonstrated that key components of the SSS can be reliably 
estimated reti'ospectively from routine hospital admission records in non-specialist centres, 
including our own. It has also shown that using retrospective information retrieved from 
hospital admission records can be reliably used to diagnose the EPSS definition of 
progressing stroke, provided that the day 3 assessments are performed face-to-face. This 
validation lends support to the methodology used for the observational study on 
haemostatic function and progressing ischaemic stroke reported in chapter seven.
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MRC SSS
grade score
Normal power
Active movement against gravity and 
resistance 
g Active movement against gravityI
i  Active movement, with gravity 
eliminated
Flicker or trace of contraction 
No contraction
Normal power
Active movement against gravity and 
resistance 
^ Active movement against gravityI
tiO Active movement, with gravity 
eliminated
Flicker or trace of contraction 
No contraction
Raises arm with normal 
strength
Raises arm with 
reduced strength 
Raises arm with flexion 
in elbow
Can move, but not 
against gravity 
Paralysis
Normal strength
Raises straight leg with 
reduced strength 
Raises leg with flexion 
of knee
Can move, but not 
against gravity 
Paralysis
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Figure 3.1 : Algorithm for converting MRC power scale to arm and leg SSS score using 
retrospective information from hospital admission records. MRC indicates Medical 
Research Council; SSS, Scandinavian Stroke Scale. Some discretion was allowed with an 
MRC scale score of 2, depending on other information recorded in the case sheet (for 
instance by a second examiner).
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Figure 3.2a: Formula for calculating weights for kappa statistics. This applies to a table 
with cells in rows i and columnsy. | i - j | is the distance in squares from agreement. The 
number of cells down the side of the grid is g.
1 0.75 0,5 0.25 0
0.75 1 0.75 0.5 0.25
0.75 1 0.75 0.5
0.25 0.5 0.75 1 0.75
0 0.25 0.5 0.75 1
Figure 3.2b: An example of the kappa weightings which would apply to a 5 x 5 table, 
calculated using the formula in figure 3.2a. For the shaded square the formula would be 
W = 1 - 2/(5-1).
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SSS leg motor power face to face
Not
against
gravity
Knee
None flexion Reduced Normal
None
Not
against
gravityIO Kneeflexion
Reduced
Normal
Figure 3.3: Example of agreement between retrospective (from hospital admission records) 
and face-to-face leg motor scores for observer 1. Weighted kappa value for this domain, as 
above, is 0.80. SSS indicates Scandinavian Stroke Scale.
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Figure 3.4a: Comparison of retrospective (observer 1) and face-to-face assessment of 
Scandinavian Stroke Scale (SSS) score presented as a Bland Altman plot. Regression line 
0.064 (95% confidence interval -0.005, 0.133)
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Figure 3.4b: Comparison of retrospective (observer 2) and face-to-face assessment of 
Scandinavian Stroke Scale (SSS) score presented as a Bland Altman plot. Regression line 
0.057 (95% confidence interval -0.018, 0.131)
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SSS item Kappa
Observer 1
95% confidence 
interval Kappa
Observer 2
95% confidence 
interval
Facial Palsy 0.49 0.25, 0.73 0,56 0.33,0.79
Consciousness 0.74 0.43,1 0.72 0.41,1
Eye Movements 0.46 0.05,0.86 0.71 0.44,0.98
Motor Power Ai'm 0.84 0.68,1 0.82 0.65,0.99
Hand 0.74 0.54, 0.94 0.68 0.46,0.90
Leg 0.80 0.63, 0.98 0.82 0.64,0.99
Orientation 0.80 0.62,0.99 0.82 0.65,1
Speech 0.80 0.61,0.99 0.80 0.62,0.99
Table 3.1 : Agreement between domains of the face-to-face and retrospective (hospital 
admission record) Scandinavian Stroke Scale (SSS). Analysis is by weighted kappa 
statistics except for the assessment of facial palsy (a binary outcome) where a simple kappa 
statistic is used.
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SSS item
Interobserver agreement
95% confidence 
Kappa interval
Facial Palsy 0.76 0.58,0.94
Consciousness 0.71 0.37,1
Eye Movements 0.58 0.23,0.93
Motor Power Arm 0.93 0.81,1
Hand 0.93 0.81,1
Leg 0.96 0.88,1
Orientation 0.86 0.70,1
Speech 0.94 0.83,1
Table 3.2: Interobserver agreement for two observers retrospectively scoring the 
Scandinavian Stroke Scale (SSS) from hospital admission records. Analysis is by weighted 
kappa statistics except for the assessment of facial palsy (a binary outcome) where a simple 
kappa statistic is used.
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Chapter 4
“Predictors of Early Progression after Acute Stroke”
Numerous explanations for progressing stroke have been postulated, including clot 
propagation, surrounding oedema, neurotoxic effects of associated medical complications, 
haemorrhagic tr ansformation or aitefact. Although it is unclear whether progressing stroke 
is an inevitable part of a natural disease process, it does appear to be associated with high 
morbidity and mortality as demonstrated in chapter one. The idea that progressing stroke 
may indicate specific avoidable phenomena is attractive, as this might potentially lead to 
the development of targeted interventions to prevent deterioration.
Previous studies examining predictors of progressing stroke have either ignored baseline 
imbalances or have relied on multivariate analysis to try and control for important baseline 
differences in variables, such as age and stroke type or severity. Results from these studies 
have often been contradictory, sometimes raising more questions than they try to answer.
A potential concern is that these studies may not have fully controlled for baseline 
imbalances, especially sti’oke severity (as measured using standardised stroke neurological 
impairment scales), which appears to be of major importance
This chapter reports the results of a case control study, controlling for age and stroke type, 
designed to investigate which factors are associated with progressing stroke. The purpose 
of the analysis was to examine potentially modifiable predictors of progressing stroke once 
unmodifiable predictors (age and stroke type) had been conti’olled for. Because of the size 
of the database it was hoped that this would provide useful information on which factors 
might need to be included as covariates in multivariate analysis for the observational 
haemostatic function in progressing ischaemic stroke study reported in chapter seven. In 
view of the sparcity of previous evidence this study was designed with the particular 
purpose of determining whether prior drug treatment (with anticoagulant or antiplatelet 
agents) or adverse physiological features (hypoxia, hyperglycaemia, pyrexia and 
dehydration) are associated with progressing stroke.
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Aims:
To determine whether prior drug treatment or early adverse physiological features are 
associated with progressing stroke.
Methods:
A case control analysis was conducted using a hospital-based research stroke register; the 
“PROCESS” database. This database was provided in a raw form, with much gathering of 
clinical, laboratory and follow up information still to be performed prior to data analysis. 
Consecutive patients admitted with acute stroke to Glasgow Royal Infirmary, over a 2 year 
period, were registered in this database. Throughout nineteen months of the study stroke 
patients were admitted to medical wards with early assessment and management by the 
stroke multi-disciplinary team. In the remaining 5 months a dedicated acute stroke ward 
was opened. Patients were excluded if there was a delay of more than 24 hours from stroke 
onset to admission All data were collected prospectively as part of a research
protocol.
Variables recorded from routine admission documentation included information on 
demography, presenting clinical features, routine biochemistry and haematology, and early 
clinical signs (including the conscious level, hand, arm, leg, speech, and facial components 
of the Scandinavian Stroke Scale (SSS)) Retrospective assessment of admission SSS 
from hospital records can be performed with a high level of accuracy as shown in chapter 
three Physiological variables (temperature, blood glucose, oxygen saturation, blood 
electrolytes and non-invasive blood pressure (using Propaq 104EL, Protocol Systems Inc.)) 
were routinely recorded in the 3 days following admission. Clinical outcome assessment 
[including the total SSS, Barthel index (appendix B) and the Rankin scale (appendix C)] 
was carried out at 3 days after admission, with a further follow up at 30 days post-stroke 
175,176 I'esearch nurse, who was unaware of the planned analysis, made all assessments.
At the time of performing this analysis there was uncertainty about which definition of 
progressing stroke would be most appropriately utilised. Validation work on retrospective 
assessment of SSS scores from admission notes (see chapter three) had not yet been 
completed. It seemed feasible to reliably extract information on limb weakness and 
dysphasia from admission records and, therefore, a modification of the Jprgensen 
definition for progressing stroke was chosen for this analysis Progressing stroke was
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defined as a drop in neurological score between admission and day 3 in any of the 
following components; drop in speech score by 3 or more points, drop in arm score by 2 or 
more points, drop in hand score by 2 or more points or drop in leg score by 2 or more 
points. Death within 3 days was also recorded as progressing stroke.
Mean arterial blood pressure (MABP) was calculated using the formula DBP + 1/3 (SEP- 
DBP) where DBP is diastolic blood pressure and SBP is systolic blood pressure. Pulse 
pressure was calculated as SBP -  DBP.
Matching was performed using a pivot table in the softwaie package SPSS for Windows 
version 9.0. Subjects were included, without outcome measure results being available, 
using their unique hospital identification number. Controls (non progressing strokes) were 
matched to cases of progressing stroke, using a 1:1 ratio, on the basis of Oxfordshire 
Community Stroke Project (OCSP) classification (total anterior circulation syndrome 
(TACS), paitial anterior circulation syndrome (PACS), lacunar syndrome (LACS) or 
posterior circulation syndrome (POCS)) age band (20-40, 40-60, 60-70, 70-80, 80-90, 
90-100years) and haemorrhage/ infarction status (based on reporting of CTs by hospital 
radiology staff, who were unaware of this analysis). Matching was performed on the basis 
of first available matching case within the database. Only once matching was completed 
were individual patient data included in the final database for outcome comparison 
analysis.
Statistical Analyses
The Pearson chi-square test was used for analysing dichotomous data. As subjects were 
individually matched, they were treated as paired data for the purpose of this analysis. 
Statistical tests used were chosen to reflect this pairing. For between group comparisons 
the paired t test was used for normally distributed data and the Wilcoxon signed ranks test 
for non-normal distributions. Variables that appeared important predictors of progressing 
stroke in univariate analysis were further assessed using a conditional logistic regression 
model, again allowing for the paired nature of the dataset. Variables were included in the 
model if p values were less than 0.10 in the univariate analysis.
Blood pressure was included in logistic regression in 10 mmHg increments. There is no 
single recognised method of reporting blood pressure in multivariate models. The 10 
mmHg increment does, however, seem one which is meaningful to clinicians. Alternatives,
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which might have been considered included: 1 mmHg increments -  producing a small odds 
ratio for each unit, 20 mmHg increments and an increment based on the blood pressure 
measurement divided by the standard deviation of the mean blood pressure. Each of these 
alternatives is equally valid, and the decision to choose lOmmHg increments was made on 
a pragmatic basis.
Throughout this chapter results are expressed as median unless stated otherwise. All 
analyses were performed using SPSS for Windows version 9.0.
Results:
Eight hundred and seventy three subjects were registered in the stroke database. Of these, 
complete data on progressing stroke was missing for two subjects (one was transferred to 
another hospital and one was lost to 3 day follow up). One hundred and thirty one subjects 
were excluded as they were admitted greater than 24 hours after symptom onset. Of the 
remaining 740 patients, 231 (31%) had progressing stroke. Thirteen cases of progressing 
stroke had no recorded OCSP classification meaning that 218 cases of progressing stroke 
were matched to 218 controls, giving a total group size for analysis of 436 patients.
Following this matching, progressing stroke subjects and controls (table 4.1) appeared well 
matched for OCSP classification, age, side of lesion, gender, pre-stroke modified Rankin 
score and baseline total white cell count (WCC). Groups were also well matched for time 
from symptom onset to admission (see figure 4.1 and table 4.1). More controls were on 
anticoagulant medication prior to admission; despite small numbers this reached borderline 
statistical significance (8% v. 3%, p=0.06).
The median time from admission to CT scan was 3 days in both the progressing stroke 
group and the .control group (see table 4.2). No appropriate visible infarction was seen on 
the CT scan in 10% of the progressing stroke group and 20% of the control group (p<0.01). 
Figure 4.2 shows the cumulative total of patients with appropriate visible lesions on CT 
scanning. The difference between the two groups became more apparent the longer the 
delay from admission to imaging.
Mean SBP on admission (table 4.2) was significantly higher in the progressing stroke 
group than the control group (171 v. 161 mmHg, p=0.003). There were no significant
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differences in mean admission DBP (92 v. 91 mmHg). Quartiles of admission pulse 
pressure were examined to assess associations of this pressure with the incidence of 
progressing stroke. As shown in figure 4.3 a positive relationship existed. The higher the 
pulse pressure the greater the risk of progressing stroke, p=0.001.
There was a trend towai'ds an increased chance of the patients in the progressing stroke 
group having a recorded pyrexia defined as temperature > 37°C in the first 72 hours (55% 
versus 46%, p = 0.08). There was, however, no statistically significant difference in the 
incidence of hyperglycaemia (sugar > lOmmol/1 in the first 72hours), dehydration 
(calculated osmolarity > 300mmol/i in the first 72 hours) or hypoxia (oxygen saturation < 
93% in the first 72 hours).
Multivai'iate analysis was performed using a conditional logistic regression model to 
examine independent predictors of progressing stroke. Results are shown in table 4.3. 
Variables were included in this analysis if recognised clinically important or statistically 
significant differences were noted between groups on univariate analysis. Independent 
associations of progressing stroke in this model were warfarin treatment prior to admission 
(odds ratio 0.17, p<0.01), visible lesion on CT scan (odds ratio 2.46, p=0.01), SBP on 
admission (odds ratio 1.08 for each 10 mmHg increase, p=0.04) and baseline stroke 
severity, as measured using the SSS (odds ratio 1.04 per point increase, p=0.02). Pyrexia 
was not significantly associated with progressing stroke in this model (odds ratio 1.31,
p = 0 . 26) .
Day 3 and 30 outcomes are shown in table 4.4. Outcomes were worse in the progressing 
stroke group.
Discussion:
This has been a carefully matched analysis, performed to try and avoid some of the 
potential limitations of previous studies. It has examined independent associations of 
progressing stroke. It has previously been suggested that progressing stroke is dependent 
on the initial stroke severity and in performing matching for age and stroke type it 
appears that a good match for baseline abbreviated SSS has been achieved. In fact, 
following matching, there was a trend for worse neurological impairment, as measured 
using the SSS, at baseline in the stable control group. This has been corrected for in
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logistic regression analysis. The matching process achieved a good match for WCC 
(another marker of baseline stroke severity and for time from symptoms to admission 
The findings confirm previous observations of longer hospital stays and poorer 
functional outcomes in subjects with progressing stroke (see chapter one).
An important finding is that progressing stroke is associated with the development of a 
visible abnormality on CT scan, giving some credence to the concept that progressing 
stroke is a real phenomenon rather than an artefact of the natural history of stroke. This is 
particularly interesting as there were no differences in stroke clinical classification at the 
time of admission. It has been shown that having a normal early CT scan (1-24 hours after 
ictus) is associated with higher neurological scores and early improvement 
Hypodensity, signs of an infarction or oedema on very early CT scan (within a few hours), 
is known to be associated with progressing stroke It is difficult, however, to interpret 
these early changes as CT scan features may take over 24 hours to fully develop. The 
presence of a persistent infarction on a later CT scan reflects a more severe stroke with 
more severe deficits and the likelihood of a poor outcome In the studied patient
group, given the timing of the CT scans (three quarters were done after 24 hours), the best 
explanation for the findings is that progressing stroke represents a true pathological process 
of developing stroke, which is reflected by sustained CT scan abnormalities. This is 
supported by a small study published after the completion of this project which found a 
link between progressing stroke and early ischaemic features (on diffusion weighted MRI 
imaging).
It is known that blood pressure is initially high and spontaneously falls after admission 
with acute stroke and that high blood pressure in the acute phase of stroke is
associated with poor long term outcome Previous papers relating progressing stroke
to blood pressure are, however, contradictory. One paper suggested that higher SBP was 
associated with increased risk of progressing stroke when corrected for initial stroke 
severity The numbers in this study were relatively small. A larger study, also coixected 
for baseline stroke severity, showed an association between progressing stroke and blood 
pressure; the higher the SBP, the lower the rate of progressing stroke The present study 
has shown that SBP on admission directly predicts progressing stroke, but with an odds 
ratio of only 1.08 for each 10 mmHg rise in SBP. Interestingly, there was a marked direct 
relationship between pulse pressure and progressing stroke. As demonstrated in figure 4.3 
there was no evidence of a j-shaped curve to this relationship. Recent work on the Glycine
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Antagonist in Neuroprotection (GAIN) study population (n=1455) has suggested that early 
pulse pressure is associated with poor 3 month outcome A theoretical link between 
these two factors might be elevated intracranial pressure.
Findings of an association between abnormal physiological variables and poor outcome 
have previously been reported . These features may also be associated with early 
neurological recovery . Treatment of all of these variables may be one of the
factors which make stroke units effective There is currently much interest in 
intensive monitoring stroke units The results of this study do not support
previous findings, in an analysis matched for baseline severity; no significant association 
was found between hypoxia, hyperglycaemia or dehydration and early neurological 
deterioration. Possible trends towards more subjects in the progressing stroke group 
developing pyrexia were not supported in multivariate analysis. It may be that the dataset 
did not have enough power to show a statistically significant difference. It is also possible 
that the abnormalities found in previous studies have represented worse stroke severity; 
achieving a good match for baseline stroke type / severity has potentially limited this 
association.
The study found that use of antithrombotic agents seemed to be related to progressing 
stroke. This is not an artifact relating to inclusion of subjects with haemorrhagic stroke. 
Prior full anticoagulation with warfarin predicted stable or improving neurology (odds 
ratio 0.17 for progressing stroke). In subjects with progressing ischaemic stroke there may 
be ongoing activation of the coagulation system. There is evidence of abnormalities of 
haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in acute 
stroke (see also chapter two). Some of these factors have been associated with
increased mortality Fibrinogen has been shown to be a predictor of progressing
stroke as have markers of activation of the coagulation system One explanation for 
the findings of the present study is that antithrombotics have some protective effect against 
this coagulation activation, perhaps through reducing the frequency of clot propagation. 
There were, however, baseline differences in the prevalence of atrial fibrillation (AF) 
between the two groups and this may explain differences in the numbers of subjects on 
warfarin. The finding of a trend towards more cases of AF in the control group is a little 
surprising. AF has been shown to be associated with poorer outcome after acute stroke 
and it has been suggested that AF may be a predictor of progressing stroke although this
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is controversial and perhaps related to differences in baseline stroke severity It is 
important to recognise that the study reported in this chapter was only exploratory.
It could be ai'gued that the ischaemic stroke subjects included in this study should have 
been matched to controls on the basis of a classification that refers to the 
pathophysiological mechanism of stroke such as the TOAST criteria Pathophysiological 
criteria rely on extensive investigation and a high autopsy rate. In published studies more 
than a third of subjects may be classified as “unknown aetiology” Patients who
do exhibit progressing stroke do have very poor outcomes and aie, therefore, less likely to 
undergo serial investigations such as carotid duplex scanning. In a relatively small study 
relying on careful matching of these chaiacteristics it was felt that that the use of 
pathophysiological criteria would allow too much uncertainty. The OCSP clinical 
classification was chosen as there is a literature suggesting that the OCSP classification is 
important in predicting an individual’s chance of progressing stroke There is also good 
evidence that the OCSP classification has a role in predicting the pathophysiological 
aetiology of stroke In a situation where extensive investigation was not always 
clinically appropriate, 93% of patients could be clinically classified into an OCSP group.
In summary, this exploratory, retrospective study has demonstrated, in a case control 
analysis (matched for baseline age, OCSP stroke type and infarction/ haemorrhage status), 
that visible abnormalities on CT scan are associated with eaiiy neurological deterioration 
after acute stroke. Lower systolic blood pressure on admission may predict stable/ 
improving neurological status. Anticoagulant use prior to admission to hospital could have 
had some protective effect against progressing ischaemic stroke. Although this final 
association may have occurred by chance alone it certainly supports the mounting of the 
study examining haemostatic function in subjects with progressing stroke reported in 
chapter seven.
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Figure 4.1: Case control analysis; cumulative totals of subjects in progressing stroke (n = 
218) and stable/ improving (n -  218) groups depending on time from symptoms to hospital 
admission.
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Figure 4.2: Case control analysis; cumulative total of subjects with positive results (visible, 
appropriate infai'ction) on computerised tomography (CT) in the progressing stroke and 
stable/ improving stroke groups.
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Figure 4.3: Case control analysis; the incidence of progressing stroke in relation to 
quartiles of admission pulse pressure. Chi-squared test p -  0.001.
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Variable Progressing Stroke 
n = 218
Controls 
n = 218
p value
Age (yrs) 72  ( 6 2 - 7 9 ) 71 ( 6 3 - 7 9 )
OCSP classification
TAGS 72  (33 %) 7 2  (33 %)
PACS 79 (36 %) 77(35 %)
LACS 57 (26 %) 59 (27 %)
POCS 10 (5 %) 10 (5 %)
Haemorrhagic stroke 22 (10 %) 22 (10 %)
Female gender 1 1 0 (5 0 % ) 1 1 4 (5 2 % ) 0.70
Time from symptoms to 2 ( 1 - 8 ) 2 ( 1 - 7 ) 0.87
admission - hours
Pre-stroke dependency (Rankin 44 (20 %) 45 (21 %) 0.90
3-5)
Left sided lesion 109 (50 %) 1 1 0 (5 0  %) 0.99
Previous hypertension 103 (48 %) 105 (49 %) 0.77
(n = 428)
Previous AF 19 (9 %) 28 (13 %) 0.15
(n = 422)
Known to be diabetic 43 (20 %) 31 (14 %) 0.13
(n = 433) 
Previous stroke 61 (28 %) 72 (34 %) 0.24
(n=429)
Antiplatelet medication 97 (45 %) 109 (51 %) 0.19
(n = 427)
Anticoagulant medication 7 ( 3  %) 17 (8 %) 0.06
Admission INR in those on 1.7 ( 1 .5 - 3 .0 ) 1 .8 ( 1 .2 5 - 2 .9 ) 0.80
warfarin
Abbreviated SSS on admission 20 (10 -  24) 20  (6 -  24) 0.08
Total white cell count on 9.3 ( 7 .6 - 1 1 .7 ) 9.4 ( 7 .2 - 1 2 .5 ) 0.76
admission (x10 /^L)
Table 4.1: Case control analysis; compaiison of baseline characteristics between subjects 
with progressing stroke and stable/ improving controls. OCSP indicates Oxford 
Community Stroke Project; ESfR, international normalised ratio; SSS, Scandinavian Stroke 
Scale. Abbreviated SSS is made up of aim + hand + leg + speech score (maximum possible 
28 points). Continuous data analysis is by the Wilcoxon signed ranks test and results are 
reported as median (interquartile range). Analysis of nominal data is by the Pearson chi- 
squared test and results reported as number (percentage). Where data are incomplete for 
any variable an appropriate “n” value is given for the number analysed.
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Variable Progressing Stroke 
n = 218
Controls 
n = 218
p value
CT abnormality
No appropriate lesion 21 43
Infarction 160 125 <0.01
Primary intracerebral haemorrhage 22 21
[n=392]
Time to CT scan -  days 
(median(interquarti!e range))
3 ( 1 - 6 ) 3 ( 1 - 5 ) 0 .625
(Wilcoxon
Signed
Ranks
test)
SBP on admission (mmHg) 171 (30) 161 (36) 0.003
DBP on admission (mmHg) 92 (18) 91 (22) 0.52
MABP on admission (mmHg) 1 1 8 (2 0 ) 1 1 5 (2 5 ) 0.06
Temp > 37°C on Days 0-3 1 1 8 (5 5 % ) 99 (46 %) 0.08
(n = 431)
Calculated Osmolarity >300 on Days 0-3 65 (34 %) 62  (32 %) 0.62
(n = 387)
Hyperglycaemia (>10mmol) Days 0-3 39 (20 %) 40  (20 %) 0.92
(n = 401)
Hypoxia (saturation < 93%) on Days 0-3 43 (20 %) 48 (23 %) 0.52
(n = 418)
Table 4.2; Case control analysis; comparison of early patient chaiacteristics (first 72 
hours) between progressing stroke subjects and stable/ improving controls. SBP indicates 
systolic blood pressure; DBP, diastolic blood pressure; MABP, mean arterial blood 
pressure. Continuous data analysis is by the paired sample t-test and results are reported as 
mean (standard deviation) unless otherwise stated. Analysis of categorical data is by the 
Pearson chi-squared test and results reported as number (percentage). Where data are 
incomplete for any vaiiable an appropriate “n” value is given for the number analysed.
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B(SE) R Odds
ratio
p value
Warfarin treatment prior to admission -1.75 (0.670) -0.14 0.17 <0.01
Abbreviated SSS on admission 0.040 (0.018) 0.12 1.04 0.02
Visible stroke lesion on CT scan 0.902 (0.357) 0.14 2.46 0.01
Temp > 37°C on Days 0-3 0.272 (0.240) 0.00 1.31 0.26
Systolic blood pressure on admission 
(per 10 mmHg increment)
0.080 (0.038) 0.10 1.08 0.04
Table 4.3: Case control analysis; conditional logistic regression model of independent 
factors associated with progressing stroke. Factors were included in this model if p < 0.1 in 
univariate analysis. SSS indicates the Scandinavian Stroke Scale. Abbreviated SSS is made 
up of arm + hand + leg + speech score (maximum possible 28 points). SE indicates 
standard error.
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Variable Progressing Stroke Controls p value
Modified Rankin scale day 3 
[n=212pairs]
Modified Barthel Index day 3 
[n=212pairs]
Modified Rankin scale day 30 
[n=218pairs]
4 ( 3 - 5 )
6 ( 1 - 1 1 )
4 ( 2 - 5 )
3 ( 2 - 4 )
11 (3 -1 8 )  
3 ( 2 - 4 )
< 0.001 
< 0.001 
< 0.001
Destination at day 30: 
private address 
still in hospital 
other (eg nursing home)
[n = l2 2  pairs]
53 (43 %) 
62 (51 %) 
7 (6 % )
87 (71 %) 
29 (24 %) 
6 ( 5  %)
< 0.001
Death by day 30 35 (16 %) 31(14% ) 0.689
Table 4.4: Case control analysis; patient outcomes up to day 30 in progressing stroke 
subjects and stable/ improving controls. Continuous data analysis is by the Wilcoxon 
signed ranks test and results aie reported as median (interquartile range). Analysis of 
categorical data is by the Pearson chi-squared test and results reported as number 
(percentage). Where data are incomplete for any variable an appropriate “n” value is given 
for the number of pairs analysed (total 218 pairs).
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Chapter 5
“Case Control Study of Prognosis in Primary Intracerebral Haemorrhage and
Cerebral Infarction?”
In European populations approximately 10% of stroke events are Primary Intracerebral 
Haemorrhages (PICH) It is well recognised that PICH patients suffer poor
outcomes and, as yet, no routine effective acute interventions have been
developed to treat this group. Over the last 10 yeai's there has been a significant expansion 
in the numbers of hospitals providing stroke care in specialist acute and rehabilitation 
stroke wai'ds. Evidence suggests that these units improve outcome after acute stroke 
and this is particularly likely to include benefits for those with PICH
From the perspective of this thesis it was not entirely clear how best to deal with the issue 
of PICH. Should these subjects be excluded from studies of progressing stroke? A number 
of papers examining progressing stroke have included subjects with PICH (for examples 
see Birschel et al., Britton et al. and Jprgensen et al. This approach does have
practical advantages, as it allows subjects who do not undergo brain imaging to be 
included; aiding recruitment. It seems likely, however, that reasons for neurological 
deterioration may be different in subjects with PICH as opposed to ischaemic stroke. Also, 
although haemostatic markers may be abnormal in PICH it is probable that these
alterations will have occurred through different mechanisms. This is somewhat worrying 
when designing an observational study, even though the numbers concerned may be 
relatively small. Finally, as discussed above, outcomes in PICH may be different to those 
in ischaemic stroke, adding unwanted heterogeneity to the results of any analysis. Indeed 
Birschel et al. found that haemorrhage/ infarct status, itself, was an independent predictor 
of progressing stroke. This chapter took the opportunity to examine differences in outcome 
between PICH and ischaemic stroke using an alternative approach to most of the previous 
literature.
Experience in Glasgow Royal Infirmary has been that although mortality seems high in 
patients admitted with PICH many do recover surprisingly well. This seems particularly 
true if compaiisons are made between subjects with similar severity of stroke at onset,
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especially if subjects avoid complications over the first few days. It has been suggested 
that PICH has no influence on mortality, once the effect of initial stroke severity has been 
taken into consideration Most analyses, however, have tended not to control for stroke 
severity when assessing outcomes in PICH and acute ischaemic stroke. It was decided to 
perform a nested case-control analysis to adjust for stroke severity so that outcomes in the 
two groups could be more reliably compared.
Aims:
To determine whether poor outcome in primary intracerebral haemorrhage is explained 
solely by stroke clinical severity.
Methods:
The initial part of this comparison was a univaiiate analysis, assessing outcomes in 
subjects with PICH (defined as spontaneous intracerebral haemorrhage not attributable to 
an underlying cause such as trauma, ruptured arteriovenous malformation etc.) and 
ischaemic stroke. Consecutive patients admitted with acute stroke to Glasgow Royal 
Infirmai'y, over a two year period, were registered in the “PROCESS” database. This 
database was provided in a raw form, with much gathering of clinical, laboratory and 
follow up information still to be performed prior to data analysis. All data were collected 
prospectively as part of a research protocol. A single experienced stroke radiologist, who 
had no access to patient outcome data, reviewed CT scans of all subjects with suspected 
PICH. Evidence of trauma or suspicion of haemorrhagic transformation of an ischaemic 
stroke on brain imaging led to exclusion. Subjects were excluded if they died or were 
transferred to a neurosurgical unit within 3 days, or if no Oxfordshire Community Stroke 
Project (OCSP) classification was available. Patients were also excluded if brain imaging 
was not performed.
Neurological impairment was measured using items of the Scandinavian Stroke Scale 
(SSS)  ^assessed at baseline and on day 3. Modified Rankin Scale (mRS) (see appendix 
C) scores were recorded on day 3 and day 30. A research nurse, who was unaware of the 
present analysis, caiTied out all assessments. Blood pressure was measured non-invasively 
on admission (Propaq 104EL, Protocol Systems Inc.). Mean arterial blood pressure
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(MABP) was calculated using the formula DBP +1/3 (SBP-DBP) where DBP is diastolic 
blood pressure and SBP is systolic blood pressure.
The second part of this investigation consisted of a nested case control analysis. Subjects 
with PICH were matched to ischaemic stroke controls using a 1:2 frequency matching 
technique. Matching was performed using a pivot table in the software package SPSS for 
Windows version 9.0. Subjects were included, without outcome results being available, 
using their unique hospital identification number. Cases were matched to controls on the 
basis of day 3 SSS (0-10,11-20, 21-30, 31-40,41-46), OCSP classification (total anterior 
circulation syndrome (TACS), paitial anteiior circulation syndrome (PACS), lacunar 
syndrome (LACS) or posterior circulation syndrome (POCS))’^^ , pre-stroke dependency 
(mRS band 0-2 or 3-5) and age band (20-40, 41-60, 61-70, 71-80, 81-90, 91-100 yrs) in 
that order. Matching was performed on the basis of first available matching case within 
the database. Only once matching was completed were individual patient data included in 
the final database for group comparison analysis.
Statistical Analyses
Comparison between the PICH and ischaemic stroke groups was performed using Mann- 
Whitney U and unpaired t tests, depending upon the normality of the distribution of the 
variable. All results are expressed as median (interquartile range) unless otherwise stated. 
As the cases were matched individually for important baseline differences further analysis 
of the nested cases and controls was by conditional logistic regression. This procedure 
allows for pairing of the cases and controls. All statistical analysis was earned out using 
SPSS for Windows version 9.0.
Results:
Eight hundred and seventy three subjects were initially available in the database. Brain 
imaging was performed before hospital discharge in 769 (88%) of these cases. Nine (1%) 
died or were transferred to a neurosurgical unit within 3 days and 81 (9%) had no OCSP 
classification. Following these exclusion criteria 679 cases remained in the dataset for this 
analysis. The median age was 70 (62-79) yrs and 49% were female. The median 
abbreviated SSS score (excluding the gaze, orientation and gait domains; maximum score 
36) on admission was 29 (20-32). With regard to clinical classification 24% were TACS,
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39% were PACS, 28% were LACS and 9% were POCS. The in-hospital mortality was 
fourteen percent.
Fifty three cases (8%) were classed as PICH after clinical and radiological review. The 
baseline characteristics of the PICH and infarction groups aie shown in tables 5.1 and 5.2. 
Important differences between the two groups included a longer delay to admission (4 v. 2 
hours, p < 0.05), less serious neurological impairment (abbreviated SSS score of 29 v. 23 
points, p < 0,001), fewer TACS (21% v. 55%, p < 0.001), a lower incidence of dysphagia 
(22% V. 53%, p < 0.001), lower admission MABP (114 v. 125mmHg, p < 0.001) and a 
more frequent past history of stroke (30% v. 17%, p < 0.05) in the cerebral infarction 
group. Outcomes for the PICH and ischaemic stroke groups are shown in table 5.3. These 
were worse in the PICH group with respect to mortality, length of stay and functional 
status (all p < 0.01). There was a non-significant trend towards increased need for 
institutional care in the PICH survivors (18% v. 12%, p = 0.29).
In the unmatched database a logistic regression analysis was performed examining 
independent predictors of poor outcome (mRS 3-5 or death). Independent variables 
included in the equation were age, OCSP classification (TACS or “other”), abbreviated 
SSS on admission, dysphagia after admission, MABP, pre-stroke dependency (mRS >3), 
history of diabetes and previous stioke. The enter logistic regression analysis results are 
shown in table 5.4. In forward stepwise logistic regression independent variables left in the 
model were age (odds ratio 1.03 for each year, p = 0.0001), OCSP classification; TACS or 
other (odds ratio 2.83, p < 0.01), abbreviated SSS on admission (odds ratio 0.91, p < 
0.0001), dysphagia after admission (odds ratio 2.12, p < 0.05) and pre-stroke dependency 
(mRS >3) (odds ratio 3.80, p < 0.0001). This supported the predefined matching criteria for 
the nested case control analysis.
Following matching for day 3 neurological impairment, OCSP clinical classification, pre­
stroke function and age, the only significant baseline imbalance between the PICH group 
and the infarction group was in admission MABP (125 v. 116 mmHg, p < 0.01)(see table 
5.2). Admission heart rates were similar (81 v. 84 beats per minute p = 0.96). Although 
there remained non-significant trends towards poorer outcome with respect to mortality 
and length of stay, the magnitude of these differences was greatly reduced when compared 
to the unmatched analysis (see table 5.3). Conditional logistic regression of the matched 
subjects, taking into account the pairing of the dataset, provided an odds ratio of 1.94 (95%
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confidence interval 0.67, 5.63, p = 0.22) for poor outcome in the PICH group. If MABP 
was then added to this model, PICH remained non-significantly associated with poor 
outcome, while MABP provided an odds ratio of 1.32 (95% confidence interval 1.09, 1,61, 
p < 0.01) for each 10 mmHg rise. The reasons for a decision to use a lOmmHg rise in 
blood pressure were discussed in chapter four.
Discussion:
This study has confirmed that, in an unselected consecutive series of acute stroke 
admissions to Glasgow Royal Infirmary, patients with PICH have higher mortality and 
worse functional outcomes than acute ischaemic stroke admissions. Outcome is very poor 
in this group with 47% of subjects dead or institutionalised compared to 23% of unselected 
ischaemic stroke admissions. Subjects with PICH suffer more severe strokes with a higher 
prevalence of TACS and worse neurological impairment as measured by the SSS. Once 
these factors, along with age, are controlled for in a nested analysis the differences between 
the groups appear much reduced, suggesting that clinical stroke severity is an important 
factor in poor outcome in PICH. There remains, however, a non-significant trend towards 
poor outcome in PICH even after matching.
Day 3 severity of neurological impairment was chosen as a matching variable to reduce the 
effects of very early death and deterioration in the PICH group. Prior to commencing the 
analysis it was decided to match the cases to controls on the basis of day 3 SSS score, 
OCSP classification, pre-stroke dependency and age. This was supported in multivariate 
analysis of the unmatched dataset. Matching using these variables has removed some, but 
not all, of the effect of PICH on poor outcome. The unadjusted odds ratio for poor 
outcome in the PICH group was 1.94 (95% confidence interval 0.67, 5.63) in the nested, 
matched dataset. Although this odds ratio is not statistically significant this may reflect the 
reduced sample size once matching has occurred. This compares to an odds ratio of 2.77 
(95% confidence interval 1.40, 5.47) in the unmatched database. Much of the “poor 
outcome” is accounted for by in-hospital deaths. In those who survived to discharge 
outcomes were similar in PICH and infarction groups in terms of mRS >3 at 30 days and 
need for institutionalisation.
Important independent predictors of 30 day mortality in PICH include initial level of 
consciousness and haematoma volume in performing this matching, a reasonable
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match for numbers of subjects with reduced consciousness on admission has been achieved 
(30% for PICH V. 25% for ischaemic stroke, p = 0.445). If CT scans had been performed 
at similar times then reporting infarct/ haemorrhage volume might have been useful in the 
analysis. CT scans were performed as part of routine clinical practice rather than in a 
formal research protocol and, therefore, there was a wide variation in delays to imaging 
(interquartile range 1-5 days). Because of this variation, patients’ infarctions and 
haemorrhages will have been at different stages of evolution, and measurement of size of 
lesion is unlikely to be informative. This is emphasized by the fact that many subjects in 
the cerebral infarction group (27% of the total infarct group, 19% of the matched infarct 
group) had no visible lesion when scanned. It is also not clear whether infarction volume 
equates to PICH volume on CT scan. Brain imaging was accordingly only used to classify 
subjects as haemorrhages or infarctions, particularly as the study was mainly interested in 
early clinical predictors.
Franke et al. found that pineal gland displacement on CT, admission blood glucose, 
Glasgow Coma Scale (GCS) eye and motor scores, and haematoma volume predicted two 
day mortality in a hospital cohort admitted during the late 1980s They performed a 
similai' nested case control analysis to the one presented here, on day two survivors; 
matched primarily on the basis of mRS and as near as possible to age and eye/ motor 
scores of the GCS. Unlike in the present study they found identical outcomes in the 
matched dataset without even trends towards poor outcome in the PICH group. This 
discrepancy may be due to the choice of the Rankin scale as the main matching variable.
Following completion of the study reported in this chapter a further publication by 
Paolucci et al. has been published In this Italian study subjects were recruited from 
stroke inpatient survivors admitted to a rehabilitation unit. PICH (n=135) patients were 
matched to ischaemic stroke patients (n = 135) on the basis of Canadian Neurological 
Scale score, Barthel Index at the time of transfer, age, gender and onset to admission 
interval. Subjects in the PICH group appeared, overall, to have better functional recovery 
during the rehabilitation process. This is, however, a selected group of survivors, matched 
at a later stage, and the results should, therefore, be treated with caution.
In the study presented in this chapter there was higher MABP in the PICH group. Blood 
pressure is normally initially elevated after acute stroke but falls over the next week in 
acute cerebral infarction and PICH High admission systolic blood pressure
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predicts early neurological deterioration after cerebral infarction and subsequent poor 
outcome PICH patients are known to have higher systolic and diastolic admission
blood pressures than ischaemic stroke patients These differences in blood
pressure remain significant once corrected for stroke severity; age, however, may be an 
important factor Even after matching there remained a non-significant, but
potentially important, difference in age between the groups. Carlberg et al. previously 
found that high blood pressure in PICH subjects was not predictive of death at 30 days 
(apart from in a subgroup with impaired consciousness) In the present study, within 
the unmatched dataset, no significant correlation was found between MABP and poor 
outcome once corrected for age, stroke severity and pre-morbid conditions in multivariate 
analysis. Even though MABP was found to be associated with poor outcome it seems 
unlikely that this alone is the cause of worse prognosis in the PICH group; it may reflect 
some other unrecognised process.
The 30 day case fatality rates tended to be lower for PICH and infarction (28% and 7% 
respectively) than in previous population studies The hospital based approach of
the study will mean that some subjects died prior to hospital admission and some subjects 
with milder strokes were managed as outpatients. Hospital based studies of PICH have 
shown similai' 30 day case fatality rates to those reported here Twelve percent of
cases in the study reported here had no brain imaging (or autopsy if they died before 
imaging). Case fatality at 30 days in this non-imaged group was 27%, which is again 
lower than in population-based studies. In some cases this lack of imaging may be because 
subjects had only minor symptoms and were discharged to outpatient follow up and 
investigation. Other subjects may have been so unwell or had such poor pre-morbid status 
that imaging was felt to be clinically inappropriate. It is not possible clinically to reliably 
diagnose PICH and it was, therefore, necessary to exclude these non-imaged subjects.
It is unlikely that this has significantly biased the results reported here. At thirty days the 
period of assessment was relatively short. This decision was taken, as it was believed that 
a longer time period might lead to incomplete follow up data. Time to discharge in the 
PICH group was longer (47 v. 24 days) and this may represent a delayed recovery in the 
PICH group, pai'ticularly as final discharge destinations were similar.
In summary this study has confirmed, in an unselected consecutive group of acute stroke 
admissions, that inpatient mortality after PICH is high and that survivors are more likely to 
be dependent. Mortality, however, is no longer statistically significantly different in the
112
- ;  ' : ' y
PICH group once matching for stroke severity, age and previous dependency has been 
performed. Dependency levels at day 30 and need for institutionalisation in those who 
survive to hospital discharge are similar in PICH and matched infarct groups.
The marked difference in uncorrected outcomes between PICH and ischaemic stroke 
confirmed the belief that PICH subjects should be excluded from the observational study 
on haemostatic function in progressing stroke reported in chapter seven. This should lead 
to more robust conclusions being drawn. This view is supported by evidence from Birschel 
at al. that PICH alters the likelihood of progressing stroke
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PICH
(n=53)
Cerebral
Infarction
(n=626)
Matched
Cerebral
Infarctions
(n=106)
Age (years) 74 (62-80) 70 (62-79) 71 (63-78)
Gender (percentage female) 45.3% 49.5% 41.5%
Delay to admission (hours) 2(1-6) 4(1-24) 2(1-13)
Baseline abbreviated SSS score 23 (10-30) 29(21-32) $ 20 (9-29)
Pre-stroke Rankin 3-5 7 (13.2%) 110(17.6%) 13 (12.3%)
Past history of diabetes 8(15.1%) 102(16.3%) 13 (12.3%)
Previous stroke 9 (17.0%) 190(30.4%) * 27 (25.5%)
Previous hypertension 19 (35.8%) 312 (49.8%) 50 (47.2%)
Table 5.1 : Case control study; comparison of baseline demographic data between primary 
intracerebral haemorrhage (PICH), total ischaemic stroke and matched ischaemic stroke 
groups. SSS indicates Scandinavian Stroke Scale. Abbreviated SSS is made up of all 
components except gaze, orientation and gait score (maximum possible 36 points). For 
continuous data results aie expressed as median (interquartile range) unless otherwise 
stated.
* p < 0.05 compaied to PICH
$ p < 0.001 compared to PICH
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PICH
(n=53)
Cerebral
Infarction
(n=626)
Matched
Cerebral
Infarctions
(n=106)
Day 3 total SSS score 28 (6-46) 45 (31-54) $ 30 (10-45)
Reduced conscious level 16 (30.2%) 55(8.8%) t 26 (24.5%)
OCSP classification 
TACS 
PACS 
LACS 
POCS
29 (54.7%) 
13 (24.5%) 
5 (9.4%) 
6(11.3%)
134(21.4%) t  
253 (40.4%) 
186 (29.7%) 
53 (8.5%)
56 (52.8%) 
28 (26.4%)
10 (9.4%) 
12(11.3%)
Dysphagia after admission 28 (52.8%) 137 (21.9%) $ 51 (48.1%)
Admission MABP mmHg 125(112-147) 114(100-128) $ 116(104-129) t
Incontinence day 3 37 (69.8%) 208 (33.2%) T 58 (54.7%)
Table 5.2; Case control study; comparison of baseline clinical data between primary 
intracerebral haemorrhage (PICH), total ischaemic stroke and matched ischaemic stroke 
groups. MABP indicates mean arterial blood pressure; SSS, Scandinavian Stroke Scale; 
OCSP, Oxfordshire Community Stroke Project classification (total anterior circulation 
syndrome (TACS), partial anterior circulation syndrome (PACS), lacunar syndrome 
(LACS) or posterior circulation syndrome (POCS)) For continuous data results are 
expressed as median (interquartile range) unless otherwise stated.
t  p < 0.01 compared to PICH
f p < 0.001 compared to PICH
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PICH
(n=53)
Cerebral
Infarction
(n=626)
Matched
Cerebral
Infarctions
(n=106)
Dead at 30 days 15 (28 %) 43(7%) $ 19(18%)
Death as discharge diagnosis 19 (36 %) 79(13% ) t 28 (26 %)
Poor outcome at 30 days (dead or 
modified Rankin scale 3 -5 )
42 (79 %) 363 (58 %) t 77 (73 %)
In survivors to discharge (n=34) (n=S47) (n=78)
30 day modified Rankin scale 3 - 5 23 (68 %) 282 (52 %) 49 (63 %)
30 day Barthel Index 8 (3-18) 16(10-19) $ 14(4-19)
Days to dischaige 47(11-101) 16(8-41) t 24 (12-65)
Institutional care 6 (18 %) 63 (11 %) 13 (17 %)
t  p < 0.01 compaied to PICH
$ p < 0.001 compaied to PICH
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Table 5.3: Case control study; outcome comparisons between primary intracerebral 
haemoiThage (PICH), total ischaemic stroke and matched ischaemic stroke groups. For 
continuous data results are expressed as median (interquartile range) unless otherwise 
stated.
#
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Vaiiable Odds ratio (95% Cl) p value
Age (yrs) 1.03(1.01, 1.05) 0.0001
OCSP classification (TACS or 2.99(1.50,5.95) <0.002
other)
Abbreviated SSS on admission 0.91 (0.88, 0.94) <0.0001
Dysphagia 2.03 (1.04, 3.99) <0.05
MABP (per lOmmHg) 0.93 (0.86, 1.02) 0.12
Pre-stroke dependency (mRS 3-5) 3.45 (1.91,6.22) <0.0001
History of diabetes 0.98 (0.79, 1.20) 0.82
History of stroke 1.25 (0.97, 1.61) 0.08
Table 5.4: Case control study; multivariate analysis examining independent predictors of 
poor outcome (mRS 3-5 or death) in the total stroke population. Analysis is by enter 
logistic regression. OCSP indicates Oxfordshire Community Stroke Project; TACS, total 
anterior circulation syndrome; SSS, Scandinavian Stroke Scale; MABP, mean arterial 
blood pressure; mRS, modified Rankin Scale; Cl, confidence interval.
I
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Chapter 6
“Validity of Different Definitions of Progressing Stroke”
Early clinical deterioration, after admission with acute stroke, is common. It occurs in 
between 12 and 42 % of admissions The reason for the importance of progressing stroke, 
as a diagnostic label, is that it is associated with increased mortality and dependency as 
demonstrated in chapter one This has led to the development of a large literature in the 
field, as efforts are made to identify potentially reversible risk factors for progressing 
stroke. There ai'e no widely agreed definitions for the diagnosis of progressing stroke and 
this has encouraged the development of a diverse group of criteria, based on several 
neurological impairment scales, with assessments being canied out at different time 
intervals. Such a variety of definitions is, perhaps, one of the reasons for the contradictory 
results between some studies.
Recently the European Progressing Stroke Study (EPSS) Group performed a validation 
exercise on a definition of progressing stroke agreed by an expert panel This work 
should be applauded and hopefully will lead to future standardisation of published 
research. Analysis was based on information collected from multiple centres and, 
therefore, by multiple investigators. Baseline neurological impairment was either assessed 
directly or taken from information documented in notes made by doctors in the Accident 
and Emergency department. Although there is no gold standard for the definition of 
progressing stroke the group decided to validate a number of definitions for their ability to 
predict poor outcome; their predictive validity. The results of this work needed to be 
confirmed using an independent cohort of stroke admissions. The assessment reported in 
this chapter only considers definitions of progressing stroke based on changes in individual 
neurological signs. Definitions based on changes in total stroke scale scores may be 
difficult to interpret
Aims:
To assess the predictive validity of three alternative definitions of progressing stroke.
a
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Methods;
All data were collected prospectively as pait of a reseai'ch protocol; the “PROCESS” 
database. Consecutive patients admitted with acute stroke (ischaemic stroke or primary 
intracerebral haemorrhage) to Glasgow Royal Infirmary, over a 2 year period, were 
registered in the database. Subjects were excluded if they were transferred to another 
hospital within 3 days of admission. They were also excluded if there was a delay of 
greater than 24 hours from stroke onset to hospital admission. Although death within 3 
days is often included as part of definitions of progressing stroke it was decided to exclude 
these cases, as the main outcome measure of “poor outcome” included death within 30 
days.
Neurological deficit (Scandinavian Stroke Scale (SSS) )^ was assessed on days 0 and 3. As 
with a proportion of patients in the Birschel paper the baseline SSS score was estimated 
retrospectively from hospital admission records. This can be done accurately as shown in 
chapter three. The day 3 assessments were performed face-to-face, by a single trained 
investigator. Subjects were classified clinically using the Oxfordshire Community Stroke 
Project (OCSP) classification (total anterior circulation syndrome (TACS), partial anterior 
circulation syndrome (PACS), lacunar syndrome (LACS) or posterior circulation syndrome 
(POCS)
Three different definitions of progressing stroke were assessed. These were the EPSS 
definition one based on the European Cooperative Acute Stroke Study (ECASS) 
definition  ^and one based on the Jprgensen definition each based on change from 
baseline to day 3 for the purposes of this analysis.
The EPSS definition is a reduction of 2 or more SSS points in conscious level, or eye 
movements, or leg or arm motor power between baseline and day 3 and/ or a reduction of 3 
or more SSS points in speech score. Progression is not said to have occurred if the 
conscious level improves significantly between the two assessments even if there has been 
a worsening of other domains. For the purposes of this analysis eye movement changes 
were excluded, as there is concern about reliability of this domain of the SSS for both face- 
to-face and retrospective assessment The ECASS definition refers to a reduction of 2 
or more SSS points in conscious level or arm, hand, or leg motor power and/ or a reduction 
of 3 or more SSS points in speech score. No specific recommendation is made for the 
group who show improvements in conscious level along with deterioration in other SSS
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components. The Jprgensen definition requires a reduction of 2 or more SSS points in arm 
or hand or leg motor power and/ or a reduction of 3 or more SSS points in speech between 
the baseline and follow up assessments. Conscious level is not included in this definition.
Functional outcomes and assessment of levels of dependency were assessed at day 30 
using the 20 point Barthel Index and modified Rankin scale A research nurse who
was unaware of the present analysis caiTied out all assessments.
Statistical Analyses
Multivariate analysis was performed using binary logistic regression models, designed to 
assess the independent predictive value of the three alternative definitions of progressing 
stroke. Covariates in these models included age, neurological impairment on admission 
and stroke type (haemorrhage or infarction). In addition to these covariates, as previously 
used by Birschel et al. OCSP clinical classification (dichotomised as TACS or “other”) 
and pre-stroke dependency (Rankin scale 3-5) were included.
Results:
After exclusion criteria were applied to the database of 873 patients 640 subjects were left. 
A further 63 cases were excluded because of incomplete OCSP classification and one 
subject had incomplete day 3 SSS data, leaving a total of 581 subjects for this analysis. The 
median age was 70 (62-79) years. Fifty one (9%) were primary intracerebral 
haemorrhages. One hundred and forty seven (25%) were TACS, 233 (40%) were PACS, 
158 (27%) were LACS and 43 (7%) were POCS. Ninety eight (17%) had a pre-stroke 
Rankin scale of three or greater.
Sensitivity and specificity of the three alternative definitions of progressing stroke with 
regal'd to poor outcome (death or Rankin scale 3-5 at day 30 and death or Barthel Index of 
<15 at day 30) are shown in table 6.1. Overall, the EPSS definition had the highest 
specificity and positive predictive value for the outcome measure of death or Rankin scale 
3-5 at day 30 (88% and 83% respectively) but with reduced sensitivity when compared to 
the other definitions. A similar pattern emerged with respect to the poor outcome measure 
of death or Barthel Index of <15 at day 30 (86% and 75% respectively).
Tables 6.2 and 6.3 show multivariate models investigating the independent prognostic 
value of the three definitions of progressing stroke with regard to 30 day poor outcome
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(death or Rankin scale 3-5 for table 6.2 and death or Barthel Index of <15 for table 6.3).
All definitions were strong independent predictors of poor outcome even when corrected 
for age, admission neurological impairment, haemorrhagic/ ischaemic stroke, pre-stroke 
Rankin scale and OCSP clinical classification. For death or Rankin scale of 3-5 the EPSS 
definition had a higher odds ratio as a predictor (3.47) compared to the ECASS and 
J0rgensen definitions (3.02 and 2.79 respectively)(all p<0.0001). For death or Barthel 
Index of <15 the odds ratios were 3.35 for both the EPSS definition and the ECASS 
definition and 3.10 for the Jprgensen definition. None of these odds ratios were, however, 
statistically significantly different from each other. This leads to the conclusion that the 
EPSS definition of progressing stroke appears to be as good as (and may be better than) the 
other two progressing stroke definitions with regard to predicting poor outcome.
Discussion:
This analysis has confirmed that these three definitions of progressing stroke, based on 
changes in individual neurological signs, are valid as independent predictors of poor 
outcome following acute stroke. Overall, the EPSS definition performed at least as well as 
the ECASS and Jprgensen definitions with respect to specificity and positive predictive 
value for poor outcome. When controlled for other important prognostic indicators all 
three definitions remained important predictors of poor outcome, with the EPSS definition 
having a trend for the highest odds ratio.
There is a need for standardisation in the diagnosis of progressing stroke. Previous studies 
examining predictors of progressing stroke, using different defining criteria, have produced 
contradictory results. Jprgensen et al. examined the role of admission systolic blood 
pressure on progressing stroke in 392 acute admissions The definition of progressing 
stroke used was based on changes in individual neurological signs (not including conscious 
level) as discussed above. Observations were made at baseline and 36 hours. They found 
that elevated systolic blood pressure was associated with a decreased risk of progressing 
stroke. Davalos et al. in a smaller study (n=152) found completely the opposite result, 
using a definition based on change in Canadian Neurological Scale (CNS) total score over 
48 hours A large study of 896 stroke admissions, using a definition based on change in 
total SSS score over 72 hours, found no relationship between admission systolic blood 
pressure and progressing stroke It seems likely that the differing criteria for progressing 
stroke in these studies has contributed to the heterogeneity of their results.
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The present validation exercise only assessed change in individual neurological signs 
rather than total stroke scale scores. Many stroke scales, including the SSS, give aibitrary 
weightings to the various components. A patient may deteriorate in one area and improve 
in another, and the balance of whether this defines progressing stroke or improvement 
depends on the weighting given to the relevant domains. Birschel et al. found that 
definitions based on changes in total SSS or CNS scores may perform less well than the 
EPSS definition with regard to sensitivity, specificity and positive predictive value for poor 
outcome. This may reflect the potential problems associated with the use of total scores
The present analysis has a number of strengths. The “PROCESS” cohort is a true 
consecutive unselected group of acute stroke admissions. All assessments were performed 
by a single observer, potentially reducing the effect of interobserver disagreement. Unlike 
the Birschel study the initial assessment of neurological impairment was always performed 
retrospectively from information documented by admitting medical staff. This has the 
benefit of avoiding delays to first assessment by the research team, during which time 
improvement or deterioration might occur. The study reported in chapter three 
demonstrated that retrospective assessment of this information from hospital admission 
records is valid with interobserver agreement similar to that obtained by two face-to- 
face investigators Retrospective assessment of gaze palsy is, however, less reliable 
(weighted kappa 0.6) and, for this reason, it was decided to exclude this domain from the 
EPSS definition of progressing stroke, for the purposes of this analysis. Removing the gaze 
palsy component of the EPSS definition does little to change its specificity or positive 
predictive value for poor outcome
This study excluded patients who died within 3 days of admission: a group who are often 
included in definitions of progressing stroke. The SSS was only documented at the time of 
admission and after 3 days and, therefore, did not objectively score a second SSS prior to 
death, to prove neurological deterioration in those who did die early.
The standardisation of the definition of progressing stroke now seems timely for further 
observational studies and trials. I would concur with Birschel et al. that the EPSS definition 
is an appropriate tool to use. When using retrospective assessment of baseline neurological 
impairment in observational studies it could be argued that the gaze component of the 
EPSS definition should be omitted; this is the methodology that was chosen for use in the 
prospective study reported in chapter seven. In the future further validation of the EPSS
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definition of progressing stroke should include compaiison with the National Institutes of 
Health Stroke Scale definition of progressing stroke.
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Total Poor Good Sensit­ Specif­ Predictive
outcome outcome ivity icity Value
Poor outcome 1:
Deterioration day 0-3 
EPSS definition 
(without gaze) of 
progressing stroke
159 132 27 37% 88% 83%
Deterioration day 0-3 
ECASS definition of 
progressing stroke
203 159 44 45% 81% 78%
Deterioration day 0-3 
J0rgensen definition of 
progressing stroke
183 140 43 40% 81% 77%
Poor outcome 2:
Deterioration day 0-3 
EPSS definition 
(without gaze) of 
progressing stroke
158 119 39 40% 86% 75%
Deterioration day 0-3 
ECASS definition of 
progressing stroke
201 143 58 48% 79% 71%
Deterioration day 0-3 
Jprgensen definition of 
progressing stroke
181 125 56 42% 80% 69%
Table 6.1: Predictive validity of progressing stroke definitions; comparison of the ability of 
alternative definitions of progressing stroke to predict poor outcome 1 (death or Rankin 
scale 3-5 at 30 days) or poor outcome 2 (death or Barthel Index of <15 at 30 days). EPSS 
indicates European Progressing Stroke study; ECASS, European Cooperative Acute Stroke 
Study.
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Variable Coefficient Odds
ratio
95% confidence interval 
Lower Upper p value
Age (yrs) 0.03 1.03 1.01 1.05 <0.001
Abbreviated SSS on admission -0.10 0.90 0.87 0.93 <0.0001
Haemorrhagic stroke vs. 
ischaemic stroke
0.32 1.38 0.59 3.23 ns
Pre-stroke dependency (Rankin 
scale 3-5)
1.54 4.65 2.35 9.21 <0.0001
OCSP classification (TACS or 
other)
0,98 2.66 1.27 5.60 <0.05
Deterioration day 0-3 EPSS 
definition of progressing stroke 
(without gaze)
1J4 3.47 2.09 5.77 <0.0001
Deterioration day 0-3 ECASS 
definition of progressing stroke
1.10 3.02 1.93 4.71 <0.0001
Deterioration day 0-3 J0rgensen 
definition of progressing stroke
1.03 2.79 1.78 4.39 <0.0001
Table 6.2: Predictive validity of progressing stroke definitions; logistic regression 
examining three different definitions of progressing stroke, each as independent predictors 
of poor outcome (death or Rankin 3-5) at 30 days. All definitions based on change from 
baseline to day 3 (ii"581). Abbreviated Scandinavian Stroke Scale (SSS) is composed of 
consciousness, arm, hand and leg motor power, speech and facial palsy. EPSS indicates 
European Progressing Stroke study; ECASS, European Cooperative Acute Stroke Study.
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Variable Coefficient Odds
ratio
95% confidence interval 
Lower Upper p value
Age (yrs) 0.03 1.03 1.01 1.05 <0.001
Abbreviated SSS on admission -0.11 0.90 0.87 0.93 <0.0001
Haemorrhagic stroke vs. 
ischaemic stroke
0.70 2.01 0.86 4.71 ns
Pre-stroke dependency (Rankin 
scale 3-5)
1.24 3.46 1.91 6.25 <0.0001
OCSP classification (TACS or 
other)
0.83 2.30 1.19 4.42 <0.05
Deterioration day 0-3 EPSS 
definition of progressing stroke 
(without gaze)
1.21 3.35 2.08 5.38 <0.0001
Deterioration day 0-3 ECASS 
definition of progressing stroke
1.21 3.35 2.18 5.18 <0.0001
Deterioration day 0-3 J0rgensen 
definition of progressing stroke
1.13 3.10 2.00 4.82 <0.0001
Table 6.3: Predictive validity of progressing stroke definitions; logistic regression 
examining three different definitions of progressing stroke, each as independent predictors 
of poor outcome (death or Barthel Index of <15/20) at 30 days. All definitions based on 
change from baseline to day 3 (n=578). Abbreviated Scandinavian Stroke Scale (SSS) is 
composed of consciousness, arm, hand and leg motor power, speech and facial palsy. 
EPSS indicates European Progressing Stroke study; ECASS, European Cooperative Acute 
Stroke Study.
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Chapter 7
“Haemostatic Function and Progressing Ischaemic Stroke”
Early clinical progression of ischaemic stroke is common, occurring in between one 
quar ter and one third of patients assessed within 24 hours of stroke onset Progressing 
ischaemic stroke is associated with poor prognosis with increased risk of death and long 
term dependency (see chapter one). Haemostatic activation may be an important cause or 
contributor to progressing ischaemic stroke. There is evidence of early activation of the 
coagulation system in acute stroke. This includes evidence of thrombin generation 
'T  fibrin turnover and altered fibrinolytic activity along with evidence
of disturbed endothelial function (see also chapter two for more details). There is, 
however, little evidence, to date, regarding alterations in haemostatic measures and 
progressing stroke. A small Japanese study found elevated thrombin-antithrombin complex 
(TAT) and fibrin D-dimer levels in patients with progressing stroke when samples were 
withdrawn within 7 days of onset De Boer et al., as part of a heparin intervention study, 
found a trend towards elevated admission serum fragment E (a fibrin degradation product) 
levels in patients who later developed motor progression Analysis of baseline variables 
in the NINDS rt-PA Stroke Trial demonstrated that fibrin degradation product levels were 
independently associated with late (within 7-10 days), but not early (within 24 hours), 
clinical deterioration
Trials of interventions (such as heparin) that potentially alter haemostatic function in 
ischaemic stroke have so far proved negative in terms of preventing neurological 
deterioration in the first days after stroke; perhaps partly because reduced thrombus 
formation may be balanced by an increased risk of intracranial and extracranial 
haemorrhage These studies, however, did not specifically target patients likely to
be at a high risk of progressing stroke.
From the background information provided above it was hypothesised that circulating 
haemostatic markers would predict progressing ischaemic stroke. The study described in 
this chapter aimed to characterise alterations in these markers in ischaemic stroke patients 
with progressing neurological signs, compared to patients without such progression. If
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measuring blood markers of haemostatic function could identify patients at high risk of 
progressing ischaemic stroke, this might allow more effective targeting of early 
antithrombotic therapy to prevent progressing stroke and improve clinical outcome.
Aims:
To characterise alterations in circulating haemostatic markers in patients with progressing 
ischaemic stroke. To then assess whether any alterations present are independently 
associated with progressing stroke. To examine whether the timing of blood measurement 
of haemostatic markers, in the acute phase of stroke, is important.
Methods:
Subjects were recruited from consecutive ischaemic stroke admissions to Glasgow Royal 
Infirmary between April 2002 and October 2003. Stroke was defined according to the 
World Health Organisation criteria with confirmation on CT scanning. All patients were 
treated on a standardised protocol for management of dehydration, hyperglycaemia, 
hypoxia and pyrexia (see figure 7.1) At the time of this study thrombolysis was not 
provided in the unit. No recruited patients were prescribed hepaiin in the first 72 hours 
after stroke onset. Following treatment in an acute stroke wai'd, patients were transferred to 
a stroke rehabilitation unit within 7 to 14 days where appropriate. Patients were excluded 
if any of the following criteria were met: a delay of greater than 24 hours from symptom 
recognition to admission, pregnancy, age less than 18 years, coma (only responding to pain 
on admission) or epileptic seizure activity. Patients anticoagulated prior to admission 
were also excluded, as were any patients who did not have ischaemic stroke confirmed on 
brain imaging or autopsy.
All patients were seen as soon as possible after admission by the author. Assessment 
included clinical classification (Oxfordshire Community Stroke Project (OCSP) 
classification ^^ )^, demographic variables and measurement of stroke severity using the 
Scandinavian Stroke Scale (SSS) Where necessary, information on severity of admission 
neurological impairment, as measured immediately the patient reached the emergency 
depaitment, was estimated retrospectively, which has been done with a high level of 
accuracy as described in chapter three Blood pressure was measured non-invasively 
using the Passport II® multiparameter monitoring system (Datascope Corporation, NJ,
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USA). Admission mean arterial blood pressure (MABP) was calculated using the formula 
DBP + 1/3 (SBP-DBP) where DBP is diastolic blood pressure and SBP is systolic blood 
pressure. Day 3 measurement of SSS was made, in all cases, by the author. Follow up was 
at 30 days using the Rankin scale and Barthel Index Length of hospital stay and
place of discharge were also recorded.
Progressing stroke was defined using a modification of the European Progressing Stroke 
Study (EPSS) criteria The EPSS definition of progressing stroke requires a reduction of 
2 or more SSS points in conscious level, or eye movements, or leg or arm motor power, 
between baseline and day 3 and/ or a reduction of 3 or more SSS points in speech score. 
Progression cannot be said to have occurred if the conscious level score improves 
significantly between the two assessments, even if there has been a worsening of other 
domains. For the purposes of this analysis the gaze component of the EPSS definition was 
excluded, as there is concern about reliability of this domain of the SSS for both face-to- 
face and retrospective assessment Removing the eye movement component of the 
EPSS definition does little to change its specificity or positive predictive value for poor 
outcome as shown by Birschel et al.
Blood samples were taken at one of two times (08:00-09:00hrs or 15:00-16:00hrs) to limit 
the effects of circadian variations in haemostatic factors and yet achieve sampling as soon 
as possible after admission. The blood samples were separated and plasma aliquots stored 
at -SO'^ C prior to analysis. Plasma viscosity was measured, at 37°C, using a semi­
automated capillary viscometer (Coulter Electronics, Luton, UK). Fibrinogen was 
measured by the Clauss method using a MDA180 coaguloraeter (Biomerieux, Basingstoke, 
UK) with reagents from the manufacturer. The calibrant used was the 8**^ British Standard 
(NIBSC). Plasma levels of fibrin D-dimer and tissue plasminogen activator (t-PA) antigen 
were measured with commercially available enzyme linked immunosorbent assays 
(ELISAs) from Biopool AB, Umea, Sweden. Plasma von Willebrand factor (vWF) antigen 
levels were measured using an ELISA, employing rabbit anti-human polyclonal antibodies 
obtained from DAKO pic. High Wycombe, UK. Highly sensitive C-reactive protein (CRP) 
was measured immunologically using the BN ProSpec nephelometer (Dade Behring, 
Milton Keynes, UK) using calibrants and reagents provided by the manufacturer. 
Prothrombin fragment 1+2 (FI+2) and TAT were measured using commercially available 
ELISAs from Dade Behring, Milton Keynes, UK. Activated partial thromboplastin time 
and coagulation factors FVIIc, VIIIc and IXc were measured by standard clotting assays on
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an automated coagulometer (MDA 180, Biomerieux, Basingstoke, UK) using calibrants 
and reagents provided by the manufacturer. Activated protein C (APC) resistance was 
measured on the MDA 180 using the Chromogenix Coatest kit from Quadratec, Epsom, 
UK.
A small validation project was also incorporated. It was recognised that if patients were 
admitted after 16;00hrs venepuncture was not performed until 08;00hrs the next morning. 
This raised the question as to whether this delay could lead to significant alterations in 
measured haemostatic maikers. Following discussion with the Local Research Ethics 
Committee it was agreed that the study protocol could be modified in a small group of
(between 15:00 and 16:00 hrs) and on the morning after admission (between 08:00 and 
09:00hrs). Changes to research governance meant that this modification only applied to
complex and D-dimer levels it was estimated that a total group size of 189 patients would 
be required. This calculation was based on the formula suggested by Campbell et al.
I
recruits to allow measurement of markers of circulating haemostatic factors (factors VIIc,
VIIIc and IXc, Fl+2, TAT, D-dimer, fibrinogen, t-PA and vWF) on the day of admission I
patients with the capacity to give informed consent personally. To apply the modification 
to all patients would have required full submission to the Multicentre Research Ethics
Committee; something which was not feasible within the time available.
Statistical Analyses
Power calculations were based on the findings of Uchiyama et al. and assumed a 25% 
rate of progressing stroke. They found that 52% of progressing stroke patients had TAT 
levels greater than 3.0 ng/ml compared to 22% in the stable group, and that 44% of 
progressing stroke patients had D-dimer levels greater than 150ng/mi compared to 19% of 
stable patients. For 90% power (p<0.05) to determine similar abnormalities in TAT
i
Results are expressed as median (interquartile range) throughout the text unless otherwise 
stated. For univariate comparison of categorical variables the Pearson chi-squared test is 
used. Normality was tested using the Kolmogorov-Smirnov statistic with a Lilliefors 
significance level. For non-normally distributed haemostatic variables transformations to 
normality were made where possible. These transformations were made using the 
lognormal transformation, except for vWF where a square root transformation was 
required. An example of the results of this kind of transformation is given in chapter nine. 
Univaiiate analysis of normally distributed and variables transformed to normality was by
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the unpaired t test. For other non-normally distributed continuous variables the Mann 
Whitney U test was used. ANOVA, with Bonferroni correction for post hoc analysis of 
multiple comparisons, was used for assessment of lognormal D-dimer levels between 
OCSP classification groups.
Multivariate analysis was by forward stepwise binary logistic regression. Variables were 
included in these analyses when significance levels in univariate analysis fell below 
p<0.10. The probability for stepwise entry was 0.05 and for stepwise removal was 0.10 in 
these regression models. SSS was dichotomised in this analysis around the median value. 
Scores of >35 (milder strokes) were labelled as 0 and scores of 35 or less (more severe 
strokes) were labelled as 1. OCSP classification was also included as a categorical variable 
in multivariate analysis; dichotomised as TACI or non-TACI. Blood pressure was included 
in logistic regression analysis in increments of lOmmHg. The reasons for choosing this 
increment were discussed in chapter four.
For analysis of the subgroup that had samples taken on admission and the next day (n=7) 
agreement between composite scores was estimated using the method described by Bland 
and Altman The mean difference between the first and second haemostatic factor 
measurement was calculated. A 95% confidence interval was then calculated to allow an 
estimate of the accuracy of use of the delayed sample. A regression coefficient was 
calculated for the difference between the first and second measurements and the mean 
reading, to look for systematic differences in haemostatic markers, at different 
concentrations, relating to sampling delay.
All analyses were carried out using SPSS for Windows version 9.0.
Results:
Of 474 admissions assessed, 280 patients were initially considered as potentially suitable 
for recruitment to the study. .Sixty one of these were subsequently excluded as they did not 
meet study inclusion criteria (these exclusions were completed blind to results of the blood 
analyses). A flow diagram of this recruitment strategy, explaining reasons for exclusion, is 
shown in figure 7.2. This left a database of 219 patients for further analysis; of whom 54 
(25%) met the criteria for progressing stroke.
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Important demographic differences between the progressing stroke patients and the stable/ 
improving patients are shown in table 7.1. Significant differences included older age (74 v. 
71 yrs, p=0.02) and a higher prevalence of female gender (67% v. 51%, p=0.04) in the 
progressing group. Clinical differences between the progressing stroke patients and the 
stable/ improving patients are also illustrated in table 7.1. Admission neurological deficit 
as measured by the SSS was more severe (30.5 v. 39 points, p<0.01) and there was a 
higher prevalence of OCSP classification total anterior circulation infarctions in the 
progressing group (46% v. 24%, p<0.01). There was a trend towards higher MABP (111 v. 
106 mmHg, p=0.099) and there was a higher prevalence of atrial fibrillation on admission 
ECG (22% V.  10%, p=0.03) in the progressing stroke group.
Patients with progressing stroke had significantly elevated levels of prothrombin fragments 
1+2 (1.28 V.  1.06 nmol/1, p=0.01), thrombin-antithrombin complexes (5.28 v. 4.07 pg/1, 
p=0.009), fibrin D-dimer (443 v. 194 ng/ml, p<0.001) and von Willebrand factor (216 v. 
198 iu/dl, p<0.05) compared to patients with no progression (see table 7.2). These 
differences are shown graphically in figures 7.3 and 7.4. Progressing stroke patients also 
had higher leukocyte counts (10.25 v. 9.30 xlO /^1, p=0.02) and CRP levels (8.66 v. 5.26 
mg/1, p<0.05) on univariate analysis. There were also trends towards higher factor IXc, 
plasma viscosity and fibrinogen levels in patients with progressing stroke. The results of 
forward stepwise binary logistic regression of predictors of progressing stroke are shown in 
table 7.3a. Of all demographic, clinical and haemostatic variables only mean arterial blood 
pressure (odds ratio 1.26 for each 10 mmHg rise) and D-dimer (odds ratio 1.88 for each 
natural log unit increase) were independently associated with progressing stroke. MABP 
was further examined in an attempt to exclude any evidence of a “U” shaped relationship 
between MABP and risk of clinical deterioration. The results are shown in figure 7.5 and 
do not support an association between low MABP and progressing stroke in this dataset.
A receiver operating chai acteristic (ROC) curve analysing the performance of D-dimer in 
predicting progressing stroke is shown in figure 7.6. The area under this curve is 0.678 
(95% confidence interval 0.600, 0.756). The performance of the D-dimer test in predicting 
progressing stroke at vaiious pragmatic cut-off levels is shown in table 7.4.
Outcome was poorer in the progressing stroke group (see table 7.5). Death was more 
common in the progressing stroke group at 30 days (33% v. 5 %, p<0.001) and there were 
also important differences with respect to outcomes in survivors as measured using the
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Rankin scale and 20-point Barthel Index. Length of hospital stay was significantly longer 
in surviving patients with progressing stroke (67 v. 13 days, p<0.001).
Haemostatic markers were then examined as predictors of poor outcome (defined as death 
or Rankin scale 3 - 5 at 30 days). Univariate comparisons of demographic, clinical and 
haemostatic markers between those with and without poor outcome are shown in tables 
7.6, 7.7 and 7.8. There were striking abnormalities of circulating haemostatic markers in 
patients who suffered poor outcome. In forward stepwise binary logistic regression (see 
table 7.3b) log D-dimer was a predictor of poor outcome, although this result was of 
borderline statistical significance (odds ratio 1.7, p=0.07). Other important predictors in 
this model were age (odds ratio 1.03 per year), prestioke dependency, OCSP classification, 
SSS score, CT abnormality and natural log CRP.
Haemostatic markers on the day of admission and the day after were examined in a small 
subgroup (n=7). Mean levels, differences, and regression coefficients for differences at 
various concentrations are shown in table 7.9. Significant differences between day 0 and 
day 1 were found for factors VIIc, VIIIc and IXc, however, the magnitude of these 
differences was small. An example of a Bland Altman plot for D-dimer (using a 
logarithmic scale) is shown in figure 7.7.
D-dimer levels were also examined by OCSP classification. Patients with clinically large 
total anterior circulation infarctions had the highest D-dimer levels (see figure 7.8). In view 
of the differences in the various OCSP groups between the progressing and stable/ 
improving groups it was decided to perform subgroup analysis of D-dimer levels by OCSP 
classification. This was an unplanned post-hoc analysis. In the TACI group D-dimer levels 
were higher in the progressing strokes compared to the non-progressing strokes [500 (224 - 
1138) V. 304 (170 - 814) respectively, p=0.085]. This was also true in the PACI group [387 
(152 -  788) V. 182 (85 -  549) respectively, p=0.04]. Within the LACP POCI group D- 
dimer levels were also higher in the progressing than the non-progressing stroke group 
[273 (113 -  1233) v. 109 (60-338) respectively, p=0.035].
Discussion:
This study has confirmed that progressing ischaemic stroke is a common problem, which is 
associated with high mortality, increased dependency and longer hospital stay. With regard
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to factors associated with progressing stroke, it has confirmed previous findings of 
associations, in univariate analysis, between early neurological deterioration and increasing 
age non-lacunar stroke severity of initial neurological impairment
and atrial fibrillation Important new findings are that a number of haemostatic variables 
aie higher in a large prospective study of patients admitted with ischaemic stroke who later 
deteriorate (confirming findings of previous, smaller studies and, in particular, that
once other potentially important factors are taken into consideration only D-dimer levels 
and MABP independently predict deterioration in this group. The study has then examined 
the sensitivity and specificity of D-dimer in predicting progressing stroke in the dataset, 
providing these results in a format that might guide future research. It has also confirmed 
that patients with larger cortical strokes have higher D-dimer levels than other groups, such 
as lacunar strokes
Further analysis of independent predictors of longer term poor outcome demonstrated that 
D-dimer predicts outcome at 30 days, although the results here were of borderline 
statistical significance. Confirmation of findings of previous studies of associations 
between age, OCSP classification, SSS score along with C-reactive protein and longer term 
outcome is reassuring.
Fl+2 and TAT aie markers of thrombin generation, while D-dimer, a fibrin degradation 
product, is a marker not only of thrombin generation, but also of cross-linked fibrin 
turnover. D-dimer is the most stable of these three measures Previous studies 
demonstrated evidence of early activation of the coagulation system in patients with acute 
sti'oke, when compaied to non-stroke controls (see chapter two). Measured markers 
included raised Fl+2, TAT and D-dimer levels Admission D-dimer may
also play a role in differentiating between stroke types In the study presented here these 
three markers of coagulation activation were each significantly raised in patients with 
progressing stroke. Only D-dimer levels, however, remained statistically significant after 
controlling for other factors in logistic regression.
There aie plausible mechanisms through which D-dimer levels could be closely related to 
progressing stroke. Increased D-dimer levels may reflect ongoing thrombus formation 
within cerebral vessels, or may be a marker of systemic hypercoagulability. A small study, 
of selected stroke patients, suggested that duration of arterial occlusion, as demonstrated on 
serial transcranial doppler (TCD), was significantly associated with neurological
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progression TCD evidence of middle cerebral artery asymmetry or “no-flow” within 6 
hours of stroke has predictive value for stroke progression/ improvement Recently 
Pedraza et al. suggested that middle cerebral artery occlusion (rather than perfusion/ 
diffusion mismatch) on MRI imaging is a strong predictor of progressing stroke
Some markers of haemostatic function are acute-phase reactants. D-dimer is one of these; 
hence, it is possible that elevated D-dimer levels in patients with progressing stroke are 
simply a marker of a more severe stroke, as part of a reactant inflammatory process. This 
study has minimised this possibility by withdrawing samples soon after admission, and 
also by including other recognised acute-phase reactants in the analysis (CRP, fibrinogen 
and leukocyte count). Adjustment of the association of D-dimer with progressing stroke for 
these inflammatory markers did not account for the association. There is, in fact, some 
evidence that fibrin degradation products, including D-dimer, may act to stimulate the 
inflammatory process and this might provide a further pathological mechanism 
through which D-dimer is linked to progressing stroke
The finding that MABP, on admission, independently predicts progressing stroke is 
interesting. This mirrors findings of the previous retrospective case control study reported 
in chapter four In that study systolic blood pressure was 10 mmHg higher in the 
progressing stroke patients, and this remained a significant, although weak, association 
after adjusting for other important factors. Previous studies have produced similar findings 
with regard to systolic blood pressure, although numbers have often been too small to 
allow realistic assessment of statistical significance A notable exception was the
study of Jprgensen et al., which found an inverse relationship between systolic blood 
pressure and incidence of deterioration The relevance of these findings is uncertain, as 
there is not enough evidence to support interventions for deliberately altering blood 
pressure in acute stroke
This study has a number of strengths. Patients were recruited from consecutive admissions 
to a general hospital, few exclusion criteria were used and a single observer made all 
assessments. Samples were obtained relatively early after admission and a validated 
definition of progressing stroke was utilised Interpretation of results may be more 
difficult in blood samples taken later than this. Medical complications of stroke such as 
deep venous thrombosis, urinary tract infection or chest infection all of which can
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modify circulating markers of haemostatic function, may occur, and act as confounders, in 
the first few days after admission.
The study has potential weaknesses. Blood samples were not taken at the time of 
admission, but instead were withdrawn as soon as practical (and always within 24 hours of 
symptom recognition). A number of different commercial D-dimer assays are available and 
so the results reported here, in terms of sensitivity and specificity of D-dimer in predicting 
progressing stroke, may not necessarily be generalised to all assays. Imaging was not 
performed as part of the study protocol, but as part of routine clinical practice. Thus, 
imaging was performed at a variety of time points after stroke onset, and so the study does 
not have reliable information on infarction volume. The analysis relied on a single 
measurement of admission mean arterial blood pressure, taken at a time of great stress.
This raises questions over the accuracy of a single measurement of blood pressure.
The analysis cannot exclude the possibility that elevated coagulation markers predated the 
acute event. These patients may have had widespread vascular disease prior to stroke onset 
and are, therefore, likely to have increased pre-event levels when compared to population 
controls. The measured levels in the present study, however, far exceed those recorded 
even in a population of patients with clinical atherosclerosis who later develop stroke 
Acute and convalescent samples suggest that D-dimer levels may fall over the months 
following acute stroke The difference in levels between those patients with progressing 
strokes and stable patients also suggest that D-dimer elevations are connected, in some 
way, to an acute process rather than to chronic inflammation and atherosclerosis.
There was an excess of TACI strokes in the deteriorating group. This is important as figure 
7.8 did demonsti'ate that these subjects do have higher D-dimer levels than other OCSP 
groups. It might be argued that elevated D-dimer levels are solely a reflection of larger 
TACI strokes. Although attempts were made to correct for this possibility, using logistic 
regression, it is not completely certain that this possibility has been entirely ruled out. The 
finding that D-dimer levels appear to be associated with progressing stroke even within 
OCSP groups goes some way to refute this possibility.
Small numbers limited the validation project designed to examine differences in samples 
taken soon after admission and then 16 hours later. Changes to research governance meant 
that it was only possible to recruit patients admitted during working hours and who were
136
capable of giving informed consent to having these additional samples taken. The two and 
a half months during which attempts were made to try and recruit these patients was 
particularly quiet for appropriate admissions, and it was only possible to recruit seven 
patients from fifty recruited to the progressing stroke study. The limited information 
obtained does not suggest major changes in haemostatic markers over this short period, but 
does point to a need for further work on the time-course of activation of haemostasis in 
acute stroke.
In summary, this study has shown that measurement of D-dimer independently predicts 
progressing stroke. This provides useful prognostic information, but may also be helpful in 
selecting patients who could benefit from interventions (such as newer anticoagulants) 
aimed at preventing early neurological deterioration after ischaemic stroke; in particular, 
those specifically targeted at manipulating the coagulation system.
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Routine Fluid Regime (unless contraindication)
Even if taking fluid orally:
■ 24 hrs - 0.9% NaCl IV (500ml in hrs 0-2, 500ml hrs 2-6, 
500ml per 6 hrs thereafter).
■ After 24 hrs - stop fluids if normal U&E’s AND normal oral 
intake AND no neurological deterioration.
■ If fluids should continue prescribe 6 hrly with 5% dextrose and 
0.9% saline 2:1 +/- KCl (depending on U&E’s).
Temperature
■ If temp >37°C prescribe paracetamol Igm qds (PO/PR).
" If temp >37.5°C take blood cultures and urine/sputum cultures if 
appropriate AND prescribe antibiotics.
■ In the absence of specific culture/ bacteriology 
recommendations commence blind therapy
- rV/PO Augmentin.
- Clarithi’omycin if penicillin allergic (with 
metronidazole if suspected aspiration).
Oxvgen
■ If 02  sats <95% prescribe 35% oxygen and check ABGs
Elevated Blood Glucose (whether or not known diabetic)
■ IV fluids use 0.9% NaCl. Suggested sliding scale:
BM Insulin/hr 
(1 unit/ml)
0 <  11 0
11 < 17 2
17 <25 3
>25 4
If BMs 4 - 8  mmol for > 6 hours on no treatment then stop 
monitoring BMs (otherwise BMs checked hourly).
If patients present with HONK / DKA the sliding scale and IV 
fluid therapy should be directed by clinical and laboratory 
findings.
Figure 7.1: Physiological component of the stroke protocol as used in the acute medical 
admissions unit.
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30 day follow up 
(n = 54)
30 day follow up 
(n=164)
Figure 7.2: Flow diagram of patient assessment, recruitment, analysis and follow up in the 
haemostasis in progressing ischaemic stroke study.
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Figure 7.3: Box and whisker plot of haemostatic variables in patients with progressing 
stroke and stable/ improving patients in the haemostasis in progressing ischaemic stroke 
study. Units used are nmol/1, pg/1, ng/ml and iu/dl for prothrombin Fl+2, thrombin- 
antithrombin (TAT) complexes, D-dimer and von Willebrand factor respectively.
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Figure 7.4: Dot plot of D-dimer measurements in patients with progressing stroke and 
those with stable/ improving stroke in the haemostasis in progressing ischaemic stroke 
study. D-dimer has undergone a natural log transformation and is, therefore, on a log 
normal ng/ml scale. Student t test p<0.001.
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Figure 7.5: Risk of progressing stroke by quartiles of mean arterial blood pressure in the 
haemostasis in progressing ischaemic stroke study.
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Figure 7.6: A receiver operating characteristic curve of the performance of D-dimer, 
measmed shortly after admission, in predicting progressing stroke in the haemostasis in 
progressing ischaemic stroke study. The area under this curve is 0.678.
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Figure 7.7: Comparison of admission day 0 and day 1 D-dimer measurements presented as 
a Bland Altman plot. A logarithmic scale is used on the X axis, but no transformation of D- 
dimer. Although a regression line is fitted this is non significant (regression coefficient -  
0.010, 95% confidence interval-0.130, 0.110).
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Figure 7.8: D-dimer level by OCSP classification in the haemostasis in progressing 
ischaemic stroke study. TACS represents total anterior circulation syndrome; FACS, 
partial anterior circulation syndrome; POCS, posterior circulation syndrome; LACS, 
lacunai' syndrome. D-dimer is shown in a natural log transformation. Statistical analysis is 
by ANOVA, with Bonferroni correction for post hoc analysis of multiple comparisons.
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Variable Progressing Stroke 
n = 54
No Progression 
n = 165
p value
Age (yrs) 74 (65 -  83) 71 (6 2 -7 8 ) 0.02
Female gender 36 (67%) 84 (51%) 0.04
Pre-stroke dependency 11 (20%) 28 (17%) 0.57
(Rankin 3-5)
Previous hypertension 31 (57%) 80 (48%) 0.26
Known diabetic 9 (17%) 24(15%) 0.70
Previous stroke 9 (17%) 39 (24%) 0.28
Antiplatelet medication 26 (48%) 76 (46%) 0.69
Current smoker 22(41%) 56 (34%) 0.41
Clinical Differences:
Admission delay (hrs) 5(2-13) 6(2-12) 0.76
Left hemisphere lesion 29 (54%) 89 (54%) 0.98
OCSP classification
TACI 25 (46%) 39 (24%) < 0.01
PACI 22 (41%) 71 (43%)
LACI 5(9%) 42 (25%)
POCI 2(4%) 13 (8%)
SSS score on admission 30.5 (20 -40 ) 3 9 (2 6 -4 2 ) < 0.01
(minus gait) (points)
Admission MABP (mmHg) 111(20) 106 (20) 0.10
Atrial fibrillation on ECG 12 (22%) 17 (10%) 0.03
Table 7.1: Demographic and clinical differences between patients with progressing stroke 
and those with stable or improving stroke in the haemostasis in progressing ischaemic 
stroke study. For categorical variables results are expressed as number (%) and the Pearson 
chi-squared test is used. For continuous variables results are expressed as median 
(interquartile range) and statistical analysis is by the Mann Whitney U test, except for 
blood pressure where results are expressed as mean (standard deviation) and analysis is by 
the unpaired t test.
146
Variable Progressing Stroke 
n = 54
No Progression 
n = 165
p value
T im e from sy m p to m s to  
a d m iss io n  (hrs) 5 (2-13) 6 (2-12) 0.76
T im e from a d m iss io n  to  
v en ep u n ctu re  (hrs)
1 1 ( 4 - 1 5 ) 8 ( 3 -  16) 0.541
Factor VIIc (iu/dl) 139 ( 1 1 1 - 1 7 1 ) 148 ( 1 2 7 - 1 6 5 )
Factor V ille  (iu/dl) 204 (166 -  240) 195 ( 1 6 2 - 2 3 5 ) 0.150
Factor IXc (iu/dl) 170 ( 1 4 8 -  188) 1 5 7 ( 1 4 2 - 1 8 4 ) 0.085
Prothrom bin F 1+2 (nm ol/l) 1.28 ( 0 .9 2 - 1 .7 4 ) 1.06 ( 0 .7 6 - 1 .4 8 ) 0.011
Throm bin-antithrom bin  
c o m p le x e s  (pg/l)
5.28 ( 3 .9 0 - 8 .4 6 ) 4.07 ( 3 .2 8 - 6 .2 5 ) 0.009
Fibrin D -dim er (ng/m l) 443 ( 1 6 4 - 1 0 9 1 ) 1 9 4 ( 9 2 - 4 8 1 ) <0.001
A PC  ratio (n = 1 6 4 ) 2 .7 3 (2 .4 4  -  3.07) 2.81 ( 2 .5 3 - 3 .1 2 ) 0.430
T issu e  p la sm in o g en  
activator a n tigen  (ng/m l)
12.7 ( 8 .9 - 1 8 .0 ) 11.0 ( 8 .2 - 1 5 .2 ) 0.102
von W illebrand Factor  
an tigen  (iu/dl)
216 ( 1 7 8 - 2 7 3 ) 1 9 8 ( 1 5 7 - 2 4 4 ) 0.045
P la sm a  v isco s ity  (m P a .s) 1 .32 (1 .21  -  1.38) 1 .2 6 ( 1 .2 0 - 1 .3 4 ) 0.066
H aem atocrit 0.40 ( 0 .3 7 - 0 .4 3 ) 0 .40  (0.36 -  0.43) 0.467
Fibrinogen (g/i) 3.97 ( 3 .5 0 - 5 .0 2 ) 3 .90 ( 3 .1 6 - 4 .5 4 ) 0.079
C -reactive protein (m g/l) 8.66 (3.69 -  30.45) 5 .2 6 ( 1 .6 4 - 1 8 .4 ) 0.049
L eu k ocyte cou n t (x10®/l) 10.25 (8.05 - 1 2 .7 8 ) 9.30 ( 7 .4 - 1 1 .5 ) 0.017
Table 7.2: Circulating haemostatic and haemorlieological variables in patients with 
progressing stroke and those with stable or improving stroke in the haemostasis in 
progressing ischaemic stroke study. Results are expressed as median (interquartile range). 
For time from admission to venepuncture, prothrombin fragments 1+2, thrombin- 
antithrombin complexes, plasma viscosity and haematocrit statistical analysis is by the 
Mann Whitney U test. For all other variables (after appropriate transformation if 
necessary) statistical analysis is by the unpaired t test. APC indicates activated protein C.
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B(SE) R Odds ratio p value
Constant -7.310(1.534)
MABP (per 10 mmHg) 0.231 (0.093) 0.138 1.26 0.01
Natural log D-dimer 0.633(0.156) 0.256 1.88 <0.0001
Table 7.3a: Stepwise logistic regression model of predictors of progressing stroke in the
haemostasis in progressing ischaemic stroke study. All variables with p value < 0.10 in
univariate analysis were included in this model. MABP indicates mean arterial blood
pressure; SE, standard error.
B (SE) R Odds Ratio p value
Constant -6.550(1.416)
Natural log D-dimer 0.337 (0.186) 0.068 1.40 0.07
Age 0.031 (0.016) 0.083 1.03 0.05
Scandinavian Stroke Scale 0.783 (0.397) 0.083 2.19 0.05
Visible infarction on CT 0.919 (0.376) 0.120 2.51 0.01
scan
Previously dependent 1.590 (0.626) 0.127 4.90 0.01
Natural log hs CRP 0.336 (0.121) 0.145 1.40 0.005
TACS / other 1.502 (0.525) 0.150 4.49 0.004
Table 7.3b: Stepwise logistic regression model of predictors of death or dependency 
(Rankin scale >2) at 30 days in the haemostasis in progressing ischaemic stroke study. All 
valuables with p value <0.10 in univariate analysis included in this model, hs CRP 
indicates highly sensitive C-reactive protein; TACS, total anterior circulation syndrome; 
SE, standai'd error. Scandinavian Stroke Scale was dichotomised around the median value. 
Adding in mean arterial blood pressure (p = 0.994 in univariate analysis) as a variable does 
not alter the results.
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D-dimer cut-off 
(ng/ml)
Number (%) of patients 
above this cut-off
Sensitivity Specificity
200 116(53%) 70% 52%
250 106 (48%) 67% 57%
300 94 (42%) 61% 63%
350 83 (38%0 59% 69%
400 77 (35%) 56% 71%
450 69(32%0 48% 74%
500 63 (29%) 46% 77%
600 53 (24%) 37% 80%
Table 7.4; Performance of the D-dimer test in predicting progressing stroke at various 
pragmatic cut-off levels in the haemostasis in progressing ischaemic stroke study
I
'-.1
Î
I
■f
149
Outcome Progressing Stroke 
n = 54
No Progression 
n = 165
p value
Day 3
Deceased 3(6% ) 0 (0%) 0.014
SSS total (survivors) 2 2 ( 6 - 3 2 ) 5 0 (4 0 -5 5 ) <0.001
Rankin >2 (survivors) 51 (100%) 92 (56%) <0.001
Barthel Index (survivors) 1 (0 - 5 ) 14 (7 -  17) <0.001
Day 30
Deceased 18(33% 0 8(5% ,) <0.001
Rankin >2 (survivors) 33 (92%) 70 (45%) <0.001
Barthel Index (survivors) 7 (3 - 12) 18 (1 3 -2 0 ) <0.001
Discharge destination
Did not survive to discharge 21 (39%) 16 (10%) <0.001
Private address 24 (44%) 141 (85%)
Institutional care 9 (17%) 8(5% 0
Length of stay in survivors 
(days)
67 (3 5 -  132) 1 3 (7 -2 8 ) <0.001
Table 7.5: Outcome assessment in patients with progressing stroke and those with stable or 
improving stroke in the haemostasis in progressing ischaemic stroke study. SSS indicates 
Scandinavian Stroke Scale (including gait component). For categorical variables results are 
expressed as number (%) and the Pearson chi-squared test is used. For continuous variables 
results are expressed as median (interquartile range) and statistical analysis is by the Mann 
Whitney U test.
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Dead or dependent at 
30 days (n = 129)
Alive and Independent at 
30 days (n = 90)
p value
Age (yrs) 74 (67 -  82) 66 (56 -  73) < 0.001
Female gender 76 (59%) 44 (49%) 0.142
Pre-stroke dependency 
(Rankin 3-5)
35 (27%) 4 (4%) <0.001
Previous hypertension 64 (50%) 47 (52%) 0.704
Known diabetic 20  (16%) 13(14% 0 0.829
Previous stroke 3O(23%0 18 (20% ) 0.576
Antiplatelet medication 66 (51%) 36 (40% ) 0.241
Current smoker 43 (35%) 35 (41% ) 0.424
Table 7.6: Demographic differences between patients who died or were dependent (Rankin 
3 - 5) at 30 days compared to those not, in the haemostasis in progressing ischaemic stroke 
study. For categorical variables the Pearson chi-squared test is used. For age results are 
expressed as median (interquartile range) and statistical analysis is by the Mann Whitney U 
test.
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Variable Dead or dependent at 
30 days (n = 129)
Alive and independent at 
30 days (n = 90)
p value
Admission delay -  hrs 6 (2 - 12) 5 (2 -12) 0.953
Left hemisphere lesion 65 (50%) 53(59% 0 0.214
OCSP classification
TACI 57 (44%) 7(8% 0 <0.001
PACI 47(36% 0 46(51% 0
LACI 20(16%) 27 (30% )
POCI 5(4% ) 10(11% )
SSS on admission 
(without gait component)
3 0 (1 4 -4 0 ) 41 (3 6 -4 2 ) <0.001
Atrial fibrillation 23(18% 0 6(7% 0 0.024
MABP (mmHg) 107 (20) 107 (20) 0.994
Temp > 37°C on Days 0-3 86(67% 0 42 (47%) 0.002
Hyperglycaemia (>10mmol) 
days 0-3
28 (22%) 14(17%) 0.374
Hypoxia (saturation<93%) 
days 0-3
25 (20%) 7(8 % ) 0.016
Visible abnormality on CT 
scan
87 (67%) 38 (42% ) <0.001
'S
Table 7.7: Clinical differences between patients who died or were dependent (Rankin 3 -5 )  
at 30 days compared to those not, in the haemostasis in progressing ischaemic stroke study. 
For categorical variables the Pearson chi-squared statistic is used. For continuous variables 
results are expressed as median (interquartile range) and statistical analysis is by the Mann 
Whitney U tests except for blood pressure where results are expressed as mean (standard 
deviation) and analysis is by the unpaired t test. SSS,represents Scandinavian Stroke Scale; 
MABP, mean arterial blood pressure.
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Variable Dead or dependent at 
30 days (n = 129)
Alive and independent at 
30 days (n = 90)
p value
Time from admission to 
venepuncture (hrs)
8 ( 3 -  15) 10(4 -1 6 ) 0.418
Factor VIIc (iu/dl) 141 (120- 166) 149 (129 -1 6 8 ) 0.040
Factor VIIIc (iu/dl) 209(182-253) 179 (144-216) <0.001
Factor IXc (iu/dl) 170(150- 191) 152 (136-171) <0.001
Prothrombin F I+2 (nmol/1) 1.16 (0 .93- 1.56) 0.97 (0 .68- 1.45) 0.001
Thrombin-antithrombin 
complexes (pg/1)
4.94 (3.70-8.40) 3.73 (2.89 -  5.64) <0.001
Fibrin D-dimer (ng/ml) 342(162-928) 128 (59-306) <0.001
APC ratio (n=164) 2.74 (2.46-3.11) 2.84 (2.60-3.16) 0.246
Tissue plasminogen activator 
antigen (ng/ml)
12.6 (9.3-17.4) 10.0 (7 .8-12.8) 0.003
von Willebrand factor 
antigen (iu/dl)
211 (180-269) 188 (142-216) <0.001
Plasma viscosity (mPa.s) 1.31 (1 .22- 1.37) 1.24(1.19-1.32) <0.001
Haematocrit 0 .40(0.36-0.42) 0.41 (0.39 -  0.44) 0.012
Fibrinogen (g/1) 4.08 (3.48-4.98) 3.58(3.01-4.30) <0.001
C-reactive protein (mg/1) 9.38 (4.96-28.88) 3.24(1.10-8.24) <0.001
Leukocyte count (x 10^ /1) 10.2 (7.8 -  12.5) 9.0 (7.4-10.9) 0.003
Table 7.8: Circulating haemostatic and haemorrheological variables in patients who died or 
were dependent (Rankin 3 - 5) at 30 days compared to those who were not, in the 
haemostasis in progressing ischaemic stroke study. Results are expressed as median 
(interquartile range). For time from admission to venepuncture, prothrombin fragments 
1+2, thrombin-antithrombin complexes, plasma viscosity and haematocrit statistical 
analysis is by the Mann Whitney U test. For all other variables (after appropriate 
transformation if necessary) statistical analysis is by the unpaired t test. APC is activated 
protein C.
SI
s
153
Haemostatic Factor Mean Mean
difference
95% Cl Regression
coefficient
95% Cl
Factor Vile (iu/dl) 156 10.6 1.1,20.0 0.132 -0.24, 0.50
Factor VIIIc (iu/dl) 179 27.9 6.8, 48.9 0.260 -0.23, 0.75
Factor IXc (iu/dl) 156 11.7 1.1,22.3 0.135 -0.52, 0.79
Prothrombin FI+2 (nmol/1) 1.26 0.18 -0.40, 0.76 -0.621 -1.45,0.20
Thrombin-antithrombin 
complexes (pg/1)
5.68 -0.07 -2.28, 2.14 -0.154 -0.51,0.21
Fibrin D-dimer (ng/ml) 692 53.6 -49.7, 156.8 -0.010 -0.13,0.11
Tissue plasminogen activator 
antigen (ng/ml)
11.7 -0.24 -2.21, 1.73 0.017 -0.68,0.71
von Willebrand factor 
antigen (iu/dl)
204 -3.00 -15.1,9.15 -0.135 -0.34, 0.70
Fibrinogen (g/1) 3.88 0.07 -0.05, 0.20 -0.122 -0.41,0.16
Table 7.9: Comparison of the values of a number of haemostatic factors on day 0 (15:00- 
16:00) and day 1 (08:00- 09:00)(n=7) in the haemostasis in progressing ischaemic stroke 
study. A positive mean difference suggests that first reading is higher than the second as 
this difference is calculated as day 0 -  day 1. Cl indicates confidence interval. The 
regression coefficient is for the difference between the two measurements (day 0 and dayl) 
at different mean concentrations.
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Chapter 8
“Validation of a Telephone Cognitive Test”
Chapter nine reports the results of a community survey examining dementia in atrial 
fibrillation (AF) and its relationship to haemostatic markers and to anticoagulation with 
warfarin. In performing this study within the limited time constraints allowed, an efficient 
method for diagnosing dementia had to be chosen. Detailed neuropsychological testing, 
perhaps the ideal, was not practical. This is not an approach that can be used without 
spending significant time reviewing each subject. The most realistic method of screening a 
large community cohort was by telephone or postal questionnaire. The idea of combining 
both these approaches was particularly appealing.
Previously published work has studied the combination of the Mini-Mental State 
Examination (MMSE) along with an informant questionnaire reporting cognitive 
decline (or improvement), the IQCODE to produce a more robust diagnosis of 
dementia This approach seemed relevant to the needs of the study reported in
chapter nine, as it combines a test of global cognitive function (the MMSE) with additional 
informant information on change over time (particularly in community subjects who would 
only be assessed on one occasion). It is not possible to complete the MMSE by telephone 
and so instead a modified version of the Telephone Interview for Cognitive Status (TICS), 
the TICSm, was chosen as a test of global cognitive function. More information is 
provided on the TICS and TICSm later in this chapter; however, it is of interest that 
Folstein, who earlier developed the MMSE, played a part in producing the TICS. This 
presumably explains the similarities between the two tests.
For the present validation project a group of post-stroke patients was chosen as a study 
sample. This decision was mainly for practical reasons; easy access was available to a 
steady supply of recruits through the cerebrovascular clinic and geriatric day hospital, and 
it would be considerably harder to recruit a similar number of stable AF subjects within the 
secondary cai'e setting. It also seemed likely that some of the expected cognitive problems 
found in subjects with AF were secondary to silent or clinical stroke, meaning that a stroke 
cohort was not an unreasonable choice for such a validation study.
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With regard to the chosen sample it is known that cognitive impairment and dementia are 
very common in the months and years following acute stroke, with a diagnosis of post- 
stroke dementia being made in between one quarter and one third of stroke survivors 
Older patients are at particular' risk Post-stroke dementia is likely to
contribute to increased levels of dependency and the need for institutionalisation. It also 
increases the risk of death, in the ten years following stroke, by between two and three 
times, after adjustment for age and stroke severity It would, therefore, seem appropriate 
that screening for cognitive impairment and dementia should be carried out routinely 
following stroke.
Assessment of cognitive function by telephone, for clinical follow up and longitudinal 
studies, is appealing. This method is potentially significantly cheaper than face-to-face 
contact and may be seen by patients as more acceptable; allowing repeated assessments. It 
might also be used for screening larger populations. In comparison to established tools 
used for dementia screening, a purely verbal test may be less influenced by post-stroke 
problems such as hemiparesis or visuospatial difficulties. Problems relating to aphasia, 
however, are not circumvented.
The TICS was initially developed and tested in elderly subjects with Alzheimer’s 
disease, with the intention of assessing subjects unwilling or unable to retui-n for follow up. 
It gathers information in the domains of orientation, concentration, short-term memory, 
mathematical skills, praxis and language. The TICS takes between five and ten minutes to 
perform, can be sensitive and specific, and has high test-retest reliability A previous 
study investigated its use in a sample of 36 subjects with a history of stroke, and found it to 
be sensitive for picking up cognitive difficulties The modified 13-item version of the 
TICS (TICSm) shares many questions with the original TICS. Delayed memory recall 
has been added and this means that a greater proportion of the overall score relates to 
short-term memory. The TICSm has not previously specifically been assessed in a stroke 
sample. The main purpose of this study was to further validate the TICSm and choose 
appropriate cut-off values for use in the atrial fibrillation and dementia study reported in 
chapter nine. As pai’t of the validation exercise the original TICS was examined and the 
results of this validation are also reported.
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Aims:
To test the validity of the modified TICSm in a cohort of post-stroke patients.
Methods:
Patients were a convenience sample of attendees at the cerebrovascular clinic and geriatric 
day hospital. Inclusion required that they had suffered an acute stroke, meeting the WHO 
definition within the past six months. Prior to inclusion a basic assessment of cognitive 
function was made using the abbreviated mental test (AMT) Subjects were excluded if 
they were unable to complete this test for reasons of dysphasia or deafness. Patients were 
also excluded if they refused to give written, informed consent to participation.
Once consent was obtained participants were assessed first using the TICS plus TICSm or 
R-CAMCOG (a modified version of the cognitive and self-contained part of the 
Cambridge Examination for Mental Disorders of the Elderly (CAMDEX), designed for use 
in stroke subjects). The R-CAMCOG can only be performed face-to-face. It examines 
several domains; orientation, remote memory, recent memory, recall, recognition, 
perception and abstraction. The R-CAMCOG was derived from the original CAMCOG 
with the aim of reducing the estimated administration time to 15 minutes or less and 
retaining, or perhaps even improving on, its diagnostic accuracy. Using a cut-off point of 
33 the R-CAMCOG has a sensitivity of 91 % and a specificity of 90% for screening for 
post-stroke dementia.
The TICS and R-CAMCOG were administered in random order. Randomisation (random 
permuted blocks of 4 derived from computer generated random numbers) was stratified for 
three different levels of cognitive impairment; AMT 9-10, AMT 6-8, AMT 0-5. This 
randomisation of test administration was performed with the aim of countering any order 
effect produced by consistently performing one or other test first. A secretary, on a site 
distant from patient recruitment, held the randomisation envelopes. Both the original TICS 
and the modified 13-item version TICSm were administered by telephone. The telephone 
contact occurred in a quiet room within the clinic or day hospital. The interviewer used a 
telephone in a separate room. The R-CAMCOG was performed face-to-face using enlarged 
images from the original CAMDEX to allow easier viewing. A single experienced stroke 
physician performed all assessments
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Basic demographic details were recorded for all subjects. Clinical classification of stroke 
subtype was performed using the Oxfordshire Community Stroke Project (OCSP) 
classification (total anterior circulation syndrome (TACS), partial anterior circulation 
syndrome (PACS), lacunar syndrome (LACS) or posterior circulation syndrome (POCS)) 
All subjects also had mood assessed using the 15-question version of the Geriatric 
Depression Scale (GDS) Disability was measured using the modified Rankin scale
Statistical Analyses
As the cognitive tests reported are not continuous variables, and are not all normally 
distributed, results are expressed as median (interquartile range, IQR) throughout the text. 
Normality of the distribution of the TICSm was examined using a frequency histogram, a 
normality plot and the Kolmogorov-Smirnov test. The TICSm followed an approximately 
normal distribution (see figure 8.1 and also De Jager et al. ^^ )^ and the scatter diagram 
plotted against the R-CAMCOG was roughly elliptical (see figure 8.2). In view of this, 
associations between the TICSm and R-CAMCOG scores were assessed using Pearson 
correlation coefficients rather than Spearman rank correlations. Receiver operating 
characteristic (ROC) curves were used to compare the performances of the TICS, TICSm 
and AMT in screening for dementia. This method is useful in comparing the balance of 
sensitivity and specificity for competing tests and for making the choice of the “best” cut­
off value. A perfect test would produce an area under the ROC curve of 1.
Results:
Seventy subjects were assessed for inclusion in the study. Three refused consent, a further 
two subjects were too dysphasic to complete the AMT and one subject was unable to use a 
telephone because of poor hearing. This left 64 patients who underwent the TICS/ TICSm 
and R-CAMCOG. Of these 30 (47%) were recruited from the cerebrovascular clinic and 34 
(53%) from the geriatric day hospital. The median age of the participants was 72 years 
(interquartile range 63-80) and the time from stroke onset to assessment 118 days 
(interquartile range 84-142). Three (5%) had been TACS, 28 (44%) were PACS, 24 (37%) 
were LACS and 9 (14%) were POCS. Thirty three (52%) had left hemisphere strokes.
Three subjects (5%) had a score of 0, ten (16%) had a score of 1, fifteen (23%) had a score 
of 2, twenty five (39%) had a score of 3, and eleven (17%) had a score of 4 on the 
modified Rankin scale.
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The median AMT score in the study group was 9 with 6 (9%) having an AMT between 0 
and 5, 22 (34%) having an AMT between 6 and 8, and 36 (56%) having an AMT of 9 or 
10. The median score on the GDS was 6 (interquaitiie range 3-8). Thirty two (50%) had 
the TICS/ TICSm performed first and 32 (50%) had the R-CAMCOG performed first. 
After exclusion criteria were applied, as above, all subjects were able to complete both the 
R-CAMCOG and the TICS.
The Kolmogorov-Smirnov statistic for the TICSm total was 0.073 with a p value of 0.200, 
suggesting that the distribution of the TICSm did not differ significantly from the normal 
distribution. A frequency histogram and normality plot for the TICSm are shown in figure 
8.1. The TICS, however, was not completely normally distributed (K-S statistic 0.111, p = 
0.047).
The median score on the R-CAMCOG was 35 (interquartile range 28-31) out of 49, on the 
TICS was 30 (interquartile range 26-33) out of 41, and on the TICSm was 21 (interquartile 
range 16-25) out of 39. The Pearson correlation coefficient between the TICS and the R- 
CAMCOG was 0.833 (95% confidence interval 0.74, 0.90, p<0.001)(see figure 8.2). The 
Pearson correlation coefficient between the TICSm and the R-CAMCOG was 0.855 (95% 
confidence interval 0.77, 0.91, p<0.001)(see figure 8.2).
Using a cut-off of 33 or less on the R-CAMCOG, 24 (38%) of the cohort met criteria for 
post-stroke dementia. The area under the ROC curve for this R-CAMCOG definition of 
dementia was 0.94 for the TICS. Using a cut-off of 28 or less on the TICS produced the 
best compromise between sensitivity and specificity with a sensitivity of 88% and a 
specificity of 85% for the diagnosis of post-stroke dementia. The area under the ROC 
curve for the R-CAMCOG definition of dementia was also 0.94 for the TICSm. On the 
TICSm a cut-off of 20 or lower produced a sensitivity of 92% and a specificity of 80% (a 
cut-off of 18 or lower did, overall, perform maiginally better than a cut-off of 20, but with 
the improvement in specificity to 95% balanced by a fall in sensitivity to only 80%).
Figure 8.3 illustrates the balance between sensitivity and specificity for the TICS and 
TICSm, against the R-CAMCOG diagnosis of dementia, at various cut-off levels.
The area under the ROC curve for the AMT for dementia diagnosis was 0.87. A cut-off of 
8 or less produced the best balance with a sensitivity of 76% and a specificity of 77%.
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Figure 8.4 shows ROC curves for the TICS, TICSm and AMT plotted against the R- 
CAMCOG definition of dementia.
There was a trend towai'ds better agreement between cognitive test scores in subjects with 
right hemisphere strokes. Peai'son correlation coefficients with the R-CAMCOG were
0.842 (95% confidence interval 0.75, 0.90) and 0.877 (95% confidence interval 0,80, 0.92) 
for the TICS and TICSm respectively in those with right hemisphere lesions and 0.806 
(95% confidence interval 0.70, 0.88) and 0.824 (95% confidence interval 0.72, 0.89) 
respectively in those with left hemisphere lesions. Using the cut-off scores of < 28 and <
20 for the TICS and TICSm respectively produced similar' sensitivities and specificities for 
dementia diagnosis in left and right hemisphere lesions.
Discussion:
This study has shown, in a sample of subjects with recent stroke, that the TICS and its 
modified version, the 13-item TICSm, correlate well with the gold standard (the R- 
CAMCOG). Both tests perform acceptably as screening tools for post-stroke dementia 
based on the R-CAMCOG diagnosis. The studied group of subjects had significant 
disability (56% with at least moderate handicap based on the Rankin scale) and might, in 
many circumstances, have been lost to routine follow up. The assessment was well 
tolerated and could be performed on all subjects without major verbal communication or 
hearing problems. Hemispheric latéralisation did not appear to have major impact on the 
validity of the telephone tests.
It has been suggested that the TICS has advantages over traditional dementia screening 
tools in subjects with major physical disabilities or visual deficits, and could be used face- 
to-face in this group By telephone, the reliability and validity of the TICS has 
previously been investigated in a study of 36 patients at an unspecified time after stroke 
In their sample only six (17%) were found to have dementia; making it a small study. The 
TICS had a sensitivity of 100% and a specificity of 83% using a cut-off score of less than 
25. Test-retest reliability was high. To the author’s knowledge the TICSm has not been 
investigated in a specific stroke group before. In non-sti'oke populations, when compared 
to other screening tools, including the CAMCOG, the TICSm has been shown to compare 
favourably with, and is felt to be less subject to the ceiling effect of, other tests
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One concern was that a prolonged battery of tests would be impractical in a frail 
population. The CAMCOG has been shown to be a useful tool for the assessment of 
cognitive problems after stroke Time taken to administer the examination is,
however, longer than many other screening tools for dementia. For this reason the R- 
CAMCOG was developed using a cohort of 284 subjects from the Rotterdam Stroke 
Databank The R-CAMCOG only takes around 10 minutes to complete and, in their 
study population, was as sensitive and specific as the CAMCOG. It has been suggested that 
visual acuity may have an effect on scoring in the CAMCOG Formal assessment of 
visual acuity was not performed in the present study. Images used in the R-CAMCOG 
were enlar ged to approximately twice their usual size and were printed on high quality 
paper to aid viewing. All assessments were carried out in a well lit room.
Overall the number of subjects who met R-CAMCOG criteria for post-stroke dementia was 
relatively high at 38%. In the stroke group used for the R-CAMCOG validation the 
dementia rate was around 20% One sixth of the subjects included in this databank were 
patients with TIAs who seemed less likely (non significantly) to develop dementia. 
Transient ischaemic attack subjects were excluded from the study reported here. Also, in 
selecting almost half of the subjects from the geriatric day hospital, a potentially frail, 
elderly group with a higher risk of cognitive impairment (median age in this group 78 
years (interquartile range 70-82) which is significantly higher than the median age of 66 
years (interquartile range 58-75) in the cerebrovascular clinic group, p<0.001) has been 
chosen.
Few patients with severe cognitive problems were recruited. This may be, in part, because 
many of these patients remain in hospital for prolonged periods or are discharged to 
institutional care following stroke. These patients may receive outreach team stroke follow 
up after discharge, but are less likely to return to the clinic or day hospital. This means that 
the associations between the TICS and R-CAMCOG in low scoring subjects have not been 
fully explored. It is likely that this group of very cognitively impaired subjects would 
screen positive for dementia on both tests and that their absence has led to an 
underestimate of the sensitivity and specificity of the TICS and TICSm in a complete 
follow up sample.
A single observer (the author) was used to perform all the patient assessments in this study. 
No information on interobserver variability is, therefore, available, and the results may not
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be generalisable to all clinical assessors. Use of the R-CAMCOG as the gold standard 
assessment for dementia may have lead to either an under- or over-estimation of the 
sensitivity and specificity of telephone examination. Detailed neuropsychological 
assessment is the optimal method of diagnosing dementia; however, even this can lead to 
wide variation in classification of subjects depending upon which diagnostic criteria for 
dementia are used Despite these limitations it can be concluded that both the TICS and 
the modified 13-item TICSm are practical and valid tools for telephone assessment of 
cognitive function in community outpatients following acute sti'oke.
When deciding upon which test to use in combination with the IQCODE for assessments in 
the community AF cohort reported in chapter nine, little was found to choose between the 
TICS and TICSm. Two reasons led to a decision to use the TICSm. Firstly, our unit has 
more experience of this test. Secondly, the TICSm appears overall to be less troubled by a 
ceiling effect, and is closer to being normally distributed for statistical analysis.
There was no scope within this project to validate the combination of the IQCODE and the 
TICSm (without any face-to-face contact). This would be a larger undertaking and is 
certainly a much needed project for the future. Similarities between the performances of 
the TICSm and MMSE go some way to reassuring the author that this is a reasonable 
approach.
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Figure 8.1: Frequency histogram (with normal distribution represented by broken line) and 
normality plot for the modified Telephone Interview for Cognitive Status.
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Figure 8.2: Correlation between the TICS, the modified 13-item TICS (TICSm) and the 
R-CAMCOG. TICS indicates Telephone Interview for Cognitive Status. The R-CAMCOG 
is a modified version of the cognitive and self-contained part of the Cambridge 
Examination for Mental Disorders of the Elderly.
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Figure 8.3: Sensitivity and specificity of the TICSm and TICS at various cut-off points for 
the diagnosis of post-stroke dementia. TICS indicates Telephone Interview for Cognitive 
Status.
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Figure 8,4: ROC (receiver operating characteristic) curves showing the performance of the 
TICSm, TICS and AMT against the gold standard diagnosis (R-CAMCOG) of dementia. 
TICS indicates Telephone Interview for Cognitive Status; AMT, abbreviated mental test; 
R-CAMCOG is a modified version of the cognitive and self-contained part of the 
Cambridge Examination for Mental Disorders of the Elderly.
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Chapter 9
“Atrial Fibrillation: issues of cognitive impairment, haemostasis 
and anticoagulation”
Atrial fibrillation (AF) affects 5% of women and 6% of men aged 65 or over AF is 
known to be an important causal factor for ischaemic stroke and may be found in as many 
as 20% of acute stroke admissions. An association has also been shown between AF and 
“silent” brain infarctions and with periventricular' white matter lesions on brain 
imaging. AF may also reduce cerebral blood flow There are, therefore, a number of 
plausible mechanisms by which AF may cause cognitive impairment and dementia.
Case-control studies have suggested that subjects with AF have poorer cognitive function 
(either dementia or cognitive impairment without dementia) compared to control subjects 
in normal sinus rhythm Cognitive impairment is thought to be present in 25% of
elderly, community dwelling subjects with AF
Information is lacking on whether anticoagulation is protective against cognitive decline in 
subjects with AF. A randomised intervention study is unlikely to take place, as there is 
already compelling evidence for the use of anticoagulants for the prevention of 
thromboembolic complications in this group This does not mean, however, that this is a 
question not worth addressing.
Recent research has suggested that markers of haemostatic function aie altered in atrial 
fibrillation Anticoagulation with warfarin can partly, or completely, reverse some of
these abnormalities It is possible that these markers may predict
cognitive deterioration in community subjects with AF. This chapter reports the results of a 
study that tries to answer two questions. Firstly, do markers of haemostatic activation 
predict cognitive decline whether subjects are anticoagulated or not? Secondly, is 
anticoagulation protective against cognitive impairment in AF?
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Aims:
To test the hypotheses that haemostatic function is altered in subjects with AF who develop 
dementia. To examine whether long-term warfarin anticoagulation is protective against the 
development of cognitive decline and dementia.
Methods:
Subjects were recruited from an observational cohort study of AF. The aim of this study 
was an assessment of the predictive value of clinical and laboratory risk markers for 
thromboembolic events (the Coagulation Activation and Risk of Stroke in Atrial 
Fibrillation Study; CARSAF Study) This was a non-interventional three year study of 
1055 patients with AF recruited from general practice and anticoagulant clinics. The 
present study commenced on completion of the three year follow up for the original study. 
Only those over the age of 55 were included in this cognitive part of the study. Subjects 
were excluded if prescribed antithrombotic therapy was altered during the course of the 
three year follow up: a change from antiplatelet to anticoagulant therapy or vice versa. 
During the CARSAF study careful follow up of incident vascular events, including stroke, 
was made using case note review and SMR information. An independent endpoints 
committee classified incident events.
All assessments were performed by telephone by a single trained researcher. This 
researcher was blind to the subjects’ clinical status and drug treatment. Written information 
about the study was sent by post to potentially eligible subjects. A two-stage telephone 
consent process was then employed; initial contact sought informed consent to take part in 
the study, and aiTanged a time for further telephone contact when consent was confirmed 
and the study assessments were performed. Subjects were selected in consecutive order of 
date of recruitment to the original cohort study. The initial plan was to recruit equal 
numbers of patients on and off warfarin, however as the study proceeded it became evident 
that an excess of patients on warfarin were being recruited. Frequency matching 
(performed by an independent observer) was then used to obtain a final sampling frame of 
2 patients warfarin anticoagulated to 1 not on warfarin (a similar ratio to that found, 
overall, in the CARSAF study). The telephone researcher remained blinded to patient 
anticoagulation status throughout the study.
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Direct patient assessments were by telephone contact. Evaluation of activities of daily 
living was performed using the OARS Multidimensional Functional Assessment 
Questionnaire (OMFAQ) Depression screening was performed using the five-item 
version of the Geriatric Depression Scale (GDS-5) Cognitive status was assessed using 
the modified 13-item version of the Telephone Interview for Cognitive Status (TICSm) 
an adaptation of the original TICS which adds emphasis to assessment of delayed 
memory recall. A cut-off of 20 or less on the TICSm was used to define significant 
cognitive difficulties (see chapter eight). The short form of the Informant 
Questionnaire on Cognitive Decline in the Elderly (IQCODE) was then mailed to a 
nominated relative/friend/carer for completion. A cut-off of 3.12 / 3.19 on the IQCODE 
was used to define deterioration; this has been shown to have a sensitivity of 85% and a 
specificity of 63% for diagnosing dementia or delirium Dementia was defined using the 
“and” rule Using this rule subjects can only be defined as having dementia if they score 
positive on both tests i.e. they show evidence of impaired cognition on the TICSm and this 
is supported by evidence of cognitive decline on the IQCODE.
A second mailing was performed if no response to the IQCODE was received within 4 
weeks. If, when the researcher contacted a carer or relative initially, they were told that the 
subject was too confused to cooperate with the assessment this was taken to reflect 
cognitive impairment and decline (as all subjects were capable of giving informed consent 
at the time of recruitment to the original CARSAF study).
Basic demographic variables and markers of haemostatic function were measured at the 
time of recruitment to the CARSAF study. The blood samples were separated and plasma 
aliquots stored at -80°C prior to analysis. Fibrinogen was measured by the Clauss method 
using an MDA180 coagulometer (Biomerieux, Basingstoke, UK) with reagents from the 
manufacturer. The calibrant used was the 8* British Standard (NIBSC). Plasma levels of 
tissue plasminogen activator (t-PA) antigen were measured with a commercially available 
enzyme linked immunosorbent assay (ELISA) from Biopool AB, Umea, Sweden. Plasma 
von Willebrand factor (vWF) antigen levels were measured using an ELISA, employing 
rabbit anti-human polyclonal antibodies obtained from DAKO pic, High Wycombe, UK. 
The measurement of plasma fibrin D-dimer was carried out using an ELISA kit from 
Biopool AB, Umea, Sweden. C-reactive protein (CRP) was measured immunologically 
using the BN ProSpec nephelometer (Dade Behring, Milton Keynes, UK) using calibrants 
and reagents provided by the manufacturer. Prothrombin fragment 1+2 (FI+2) and
169
«1
thrombin-antithrombin complex (TAT) were measured using commercially available 
ELISAs from Dade Behring, Milton Keynes, UK.
Ethical approval for this study was obtained from the Primaiy Care Local Research Ethics 
Committee.
Statistics and power calculations
The CARSAF study recruited 1055 subjects, of whom two thirds were receiving warfarin. 
Seven hundred and twelve survivors, who had not had their prescribed antithrombotic 
therapy changed during the study, remained at the time of completion of follow up. 
Approximately 65% of these were on anticoagulant therapy with warfarin. The study 
initially aimed to recruit equal numbers of subjects on anticoagulants and antiplatelet 
agents and predicted that to show a difference in cognitive impairment between the 
warfarin group and the non-anticoagulated group of 50% (15% cognitive impairment in 
one group and 30% respectively) 121 subjects would be required in each group for 80% 
power, p < 0.05. Revised power calculations for 2:1 recruitment of patients on warfarin 
compared to no warfarin indicated 185 and 93 patients respectively would be required to 
retain the same statistical power.
Normality was tested using the Kolmogorov-Smirnov statistic with a Lilliefors significance 
level. For laboratory variables natural log transformations were made, where necessary, to 
produce an approximation of the normal distribution and, therefore, to allow the use of 
unpaired t tests. An example of the effects of transformation on normality is shown in 
figures 9.1 (untransformed CRP) and 9.2 (natural log CRP). TAT levels could not be 
transformed to a normal distribution and statistical analysis, therefore, used the Mann 
Whitney U test. Univariate comparison of frequency of cognitive impairment between the 
warfarin and non-anticoagulant groups was made using the Pearson chi-squared statistic. 
Multivariate analyses were performed using binary logistic regression. Transformed 
haemostatic variables were used in these analyses. TAT levels were converted to a binary 
measure for multivariate analysis; divided into levels above and below the sample median. 
All analyses were carried out using SPSS for Windows version 9.0.
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Results:
From the CARSAF database attempts were made to contact 473 subjects; 108 could not be 
contacted, 18 were deceased and 89 were unable to perform assessments or declined (see 
figure 9.3). The remaining 258 subjects underwent telephone assessment and had IQCODE 
forms dispatched where a nominated informant was available. Of this group 166 (64%) had 
been on warfarin throughout the study period. The median duration of warfarin use was 6.5 
years (interquartile range 4, 9). Of the 92 not taking warfarin 68 (74%) were taking aspirin.
Baseline information for the 258 studied subjects, divided into those on and not on 
warfarin, at time of entering the CARSAF study is shown in table 9.1. Those taking 
warfarin were younger (70 v. 74 yrs, p=0.001), were less likely to have paroxysmal AF 
(13% V. 35%, p<0.001), were more likely to have structural heart disease, and were also 
more likely to have had a previous stroke (20% v. 8%, p<0.01). Ninety seven (38%) of the 
258 subjects contacted scored 20 or less on the TICSm, including 16 who were too 
confused to complete the assessment. Differences in haemostatic variables between those 
meeting TICSm criteria for dementia and those not meeting TICSm criteria for dementia 
are shown in table 9.2.
Response to the IQCODE was received from 218 (84%) informants. Combining 
information from the TICSm and IQCODE using the “and” rule it was possible to separate 
the AF subjects into two groups: those with (n = 49, 22%) and without (n=169, 78%) 
dementia. Important differences in baseline variables in these two groups, including 
haemostatic markers, are shown in table 9.3. There was evidence of prior haemostatic 
activation in subjects in the demented group compared to the non-demented group. D- 
dimer and F I+2 levels were higher in AF subjects with dementia compared to those 
without (geometric means 97.1 v. 62.0 ng/ml, p = 0.008 and 0.74 v. 0.53 nmol/1, p = 0.006 
respectively). TAT levels were also higher in AF subjects with dementia (median 1.78 v. 
1.44 pg/1, p -  0.003). Box-and-whisker diagrams for differences in TAT, F I+2 and D- 
dimer levels, between demented and non-demented subjects, are shown in figure 9.4.
These differences remained significant even if only non-anticoagulated subjects were 
considered (table 9.4). No significant associations with dementia were observed for 
fibrinogen, vWF, t-PA or CRP (table 9.3 and 9.4).
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Forward stepwise binary logistic regression was employed to examine independent 
relationships with dementia. Included in these models were INR and history of diabetes 
and then F I+2, TAT (as a binary variable) and D-dimer individually. In each model, each 
of these haemostatic vai'iables had an independent relationship with dementia; F I+2 odds 
ratio 1.82 (95% confidence interval 1.17, 2.83), p<0.01, TAT odds ratio 2.19 (95% 
confidence interval 1.13, 4.27), p=0.02 and D-dimer odds ratio 1.57 (95% confidence 
interval 1.14, 2.15), p<0.01. If age was added to the models, however, F I+2 and D-dimer 
were no longer independently associated with dementia; while TAT did reach borderline 
statistical significance (p=0.07).
There were no significant differences in GDS-5 scores between those with dementia and 
those without (p=0.41), however, subjects meeting TICSm criteria for dementia had lower 
functional scores on the OMFAQ; median scores 13 (interquartile range 9, 14) v. 14 
(interquartile range 11,14), p~0.022. Compliance with this pait of the assessment by the 
demented group was poor (67%) compared to the non-demented group (100%).
Assessment was made of the risk of dementia in those prescribed and not prescribed 
waifarin. Using TICSm /IQCODE criteria, dementia was less common in those treated 
with warfarin; 18% (n = 26) v. 32% (n = 23), p=0.023. Binai'y logistic regression 
(including waifaiin use, age and history of stroke, hypertension or diabetes) showed a 
trend towards warfarin use being independently associated with reduced prevalence of 
dementia [odds ratio 0.52 (95% confidence interval 0.26, 1.07, P=0.08)].
Discussion:
This study has shown that there is evidence of elevated circulating markers of haemostatic 
activation (FI+2, TAT and D-dimer) in community dwelling subjects with atrial 
fibrillation who aie later diagnosed as having dementia. This is independent of the effects 
of warfarin but is confounded by the effect of age. Cognitive impairment was less common 
in those subjects taking warfai'in. This remained the case even when other potentially 
confounding factors were taken into consideration, although the statistical significance 
became borderline. These findings are consistent with the hypothesis that warfarin has a 
protective role against the development of dementia in subjects with AF. Although the 
95% confidence intervals include the possibility of no effect, the estimated effect of 
warfai'in might be to reduce the dementia risk by half.
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There is limited prospective data available suggesting that measures of blood theology may 
be associated with future cognitive impairment in the general population (the majority of 
whom will be in sinus rhythm) Wilson et al. found, in a community sample of older 
people, that D-dimer was predictive of cognitive deterioration In the Rotterdam study,
Bots et al. found that TAT, D-dimer and t-PA activity were associated with an increased 
risk of dementia The authors, therefore, suggested that increased thrombin generation 
might be an important factor in the pathogenesis of cognitive decline.
There is a larger literature examining the association between atrial fibrillation and a 
prothrombotic state. Studies have suggested that D-dimer, F 1+2, TAT, vWF, factor VIIIc, 
fibrinogen, t-PA and plasminogen activator inhibitor-1 (PAI-1) levels are higher in subjects 
with AF than healthy controls Results from some of the smaller studies may have 
been biased by other characteristics known to modify haemostatic function such as age, 
gender and previous cardiovascular disease. In larger population studies Conway et al. 
demonstrated a linear relationship between vWF and the presence of AF in older subjects 
In the Framingham Offspring Study an association was found between AF and t-PA
antigen levels (but not fibrinogen, vWF, or PAI-1 after matching for age, sex and other risk
ed s
elevated t-PA antigen and factor VIII activity
factors) In a large Chinese population-bas tudy, AF was found to be associated with
Mai'kers of haemostatic function in subjects with AF may potentially identify subjects at 
high risk of cardioembolic complications In large cohorts of subjects with AF, D-dimer 
in the CARSAF study  ^and vWF were associated with risk of stroke and other vascular 
events; no independent association, however, was found between F I+2 or fibrinogen and 
prediction of future stroke
Warfaiin anticoagulation is widely used to reduce the risk of embolic complications in 
high-risk subjects with AF. In AF warfarin reduces F I+2 levels and D-dimer
levels Full anticoagulation with warfarin is more efficacious than the use of
low-dose warfarin, antiplatelet agents, or placebo for preventing embolic complications. 
For this reason any study examining cognitive change in AF, which randomised high risk 
subjects to receive warfarin or no warfarin, could be deemed unethical. The study reported 
here has attempted, using observational methodology, to circumvent the issue of 
randomising subjects to inferior treatment.
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The enforced study design is a weakness, and it is not possible to rule out selection bias in 
decisions as to whether subjects were anticoagulated or not. Some subjects may, indeed, 
have had a subtle degree of cognitive impairment leading to a decision by their physician 
not to use waifarin. High-risk subjects (those, for instance, with structural heart disease or 
previous stroke) are over represented in the warfarin group and this is a group who may be 
at higher risk of stroke or cognitive decline. These forms of bias could have lead to either 
an over- or under-estimation of the inverse association between warfarin use and dementia 
prevalence. Survival bias, in common with other cross-sectional studies, is a potentially 
important factor. This might lead to an underestimate of the risk of dementia, as subjects 
who do not develop dementia may be more likely to survive long enough to have cognitive 
testing performed. In the study recruiting subjects who had crossed over antithrombotic 
treatments during the investigation period was actively avoided. There are valid reasons for 
doing this, however, it could potentially lead to an underestimate of dementia prevalence 
as some subjects who develop dementia may have been taken off their warfarin 
prescription. This issue might, in addition, lead to an overestimate of the protective effect 
of warfarin. The numbers who changed antithrombotic therapy during the CARSAF study 
were relatively small (n = 70, 7%). Unfortunately the reasons for these changes were not 
systematically recorded.
Another potential limitation of the study is that it has examined subjects at a single time 
point. It has, therefore, not measured cognitive deterioration directly. In using the TICSm it 
has been possible to obtain an accurate assessment of present cognitive function. The 
informant completed IQCODE has allowed information to be obtained on cognitive 
deterioration over the previous five years. There is evidence to suggest that the IQCODE is 
a valid way of assessing cognitive decline when assessment can only be made at one time 
point There is good evidence to support combining the results of the IQCODE with
direct cognitive testing to increase accuracy in screening for dementia As yet there
is no validated weighted sum score for the TICSm/ IQCODE combination and so the “and” 
rule was chosen for the present study. The estimate of 22% of AF subjects having dementia 
is consistent with evidence from other community studies
It could be argued that the cognitive impairment found in this studied population is 
secondary to incident clinical stroke. It is also known that D-dimer predicts clinical stroke 
in AF  ^and this could explain the excess of discovered haemostatic abnormalities in the
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dementia group. It should be noted, however, that there was extensive follow up of 
subjects in the CARSAF study to monitor for incident vascular events. This follow up 
finished just as the cognitive study began, and so only events that occurred in the six 
months during which the cognitive assessments were performed were not sought. Prior to 
this there had only been 2 incident clinical strokes in the dementia group and 4 in the non­
dementia group.
Finally, there were differences in age between those with dementia and those without, 
which is perhaps not unexpected. Age is, itself, a significant risk factor for cognitive 
decline, and so the group classed as demented was likely to be older. Multivariate analysis 
suggested that age might be responsible for some of the demonstrated differences in 
haemostatic markers between demented and non-demented groups. TAT, however, an 
indirect marker of thrombin generation, retained an association with dementia of borderline 
statistical significance, independent of age. Age may be an important factor in the 
differing results in the two groups as the measured haemostatic mai'kers have been shown 
to alter with increasing age in cross-sectional studies Nevertheless, it is possible that
age-related alterations in haemostatic function are one explanation for the increased 
prevalence of cognitive impairment in older subjects.
In conclusion, the study presented in this chapter suggests that there is altered haemostatic 
function in subjects with AF who develop dementia, compared to those who do not. It has 
also provided modest evidence that warfarin therapy is associated with a reduced risk of 
dementia in subjects with AF. This effect could be mediated through reduced coagulation 
activation.
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CRP histogram
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Figure 9.1 : Histogram and normality plot for untransformed C-reactive protein in the 
haemostatic function and dementia in atrial fibrillation community study, Kolmogorov- 
Smirnov statistic 0.204, P<0.001.
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Natural log transformed CRP histogram
Normal Q-Q Plot of natural log CRP
tj
O bserved Value
Figure 9.2: Histogram and normality plot for natural log transformed C-reactive protein in 
the haemostatic function and dementia in atrial fibrillation community study, Kolmogorov- 
Smirnov statistic 0.053, P=0.076.
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Available CARSAF subjects (n = 712)
Not available CARSAF subjects;
Deceased (n = 197)
Antithrombotics changed during follow up (n = 70)
General practitioner requested contact not be made (n = 57) 
Moved awav from area (n = 19)
Attempted recruitment (n = 473) 
No attempt to recruit (n = 239)
Î
Telephone Assessment with TICSm (n = 258)
TICSm not performed;
Uncontactable (n = 108)
Deceased when contact made (n =18)
Too deaf to undergo assessment (n =17)
Unaware of taking part in the CARSAF study (n = 13) 
Declined consent (n = 30)
“Too unwell” (n = 24)
Too dysphasic to undergo assessment (n = 5)
Î Analysed (n = 218)Excluded from analysis;No appropriate informant or no response to IQCODE (n = 40)
Figure 9.3; Flow diagram of recruitment and subject analysis in the haemostatic function 
and dementia in atrial fibrillation community study. CARSAF indicates the Coagulation 
Activation and Risk of Stroke in Atrial Fibrillation study.
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p < 0 . 0 1
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Dem ented Not dem ented 
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D-D im er
Figure 9.4; Box-and-whisker diagrams for thrombin-antithrombin complexes (TAT, pg/i), 
prothrombin fragments 14-2 (FI+2, nmol/1) and fibrin D-dimer (ng/ml) in the haemostatic 
function and dementia in atrial fibrillation community study. Blood samples were taken at 
the time of recruitment to the CARSAF (Coagulation Activation and Risk of Stroke in 
Atrial Fibrillation) study. Cognitive testing was performed at the end of the follow up 
period.
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All Subjects 
n -  258
Prescribed warfarin 
n = 166
Not prescribed 
warfarin 
n = 92
Mean age (yrs) 72 (8.5) 70 (8.0) 74 (8.9) t
Gender (female, %) 139 (54%) 91(55%0 48 (52%)
Duration of AF (yrs) 4.0 (2, 8.5) 4.0 (2, 9.5) 4.5 (2, 8)
Paroxysmal AF 54 (21%) 22(13%0 32(35%0$
Valvular heart disease 82 (32%) 62(37%0 20 (22%) *
Prosthetic valve 35 (14%) 32(19%0 3(3% )$
LY dysfunction 90(35%0 66 (40%) 24 (26%) *
Ischaemic heart disease 113 (44%) 81 (49%) 32(35%0*
Previous stroke 41 (16%) 34(2O%0 7(8% )f
Hypertension 111 (43%) 70 (42%) 41 (45%)
Diabetes 36(14%) 22 (13%) 14 (15%)
Smoker 47 (18%) 32(19%0 15(16%0
F I+2 (nmol/1) 0.59 0.38 1.27$
TAT ( M g / 1 ) 1.52 (1.23, 2.01) 1.33(1.17, 1.61) 1.94(1.58, 2.50) $
Fibrin D-dimer (ng/ml) 71 51 127$
Fibrinogen (g/1) 3.56 3.64 3JW§
vWF antigen (iu/dl) 176 (46) 184 (46) 161 (43) $
t-PA antigen (ng/ml) 11.0 11.0 11.0
hs CRP (mg/1) 3.13 3.34 2J7
Table 9.1: Baseline characteristics (at the time of recruitment to the CARSAF study) in 
those subjects assessed by telephone in the haemostatic function and dementia in atrial 
fibrillation community study. For continuous variables results are expressed as geometric 
mean except for age and von Willebrand factor, which are expressed as mean (standard 
deviation) and duration of AF and TAT, which aie expressed as median (interquartile 
range). Statistics aie by the unpaired t test or the Mann Whitney U test as appropriate. 
Statistics for dichotomous variables are by the Pearson chi-squared statistic. F I+2 
represents prothrombin fragment 1+2, TAT represents thrombin- anti thrombin complexes, 
vWF represents von Willebrand factor, t-PA represents tissue plasminogen activator, and 
hs CRP represents highly sensitive C-reactive protein assay.
* p < 0.05 compai'ed to anticoagulated subjects
t  p < 0.01 compai'ed to anticoagulated subjects
$ p < 0.001 compared to anticoagulated subjects
§ p = 0.053 compai'ed to anticoagulated subjects
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Dementia 
n = 97
No Dementia 
n = 161
Age (yrs) 78 (8.0) $ 73 (8.5)
Gender (female, %) 54 (56%) 85 (53%)
Duration of AF 8 (6, 12) 7 (5, 12)
Previous stroke 21(22%0 27 (17%)
Hypertension 50 (52%) * 61 (38%)
History of diabetes 20 (21%)* 16 (10%)
Smoker 21 (22%) 26 (16%)
F1+2 (nmol/1) 0.70 t 0.53
TAT (pg/1) 1.61 (1.25, 2.34) 1.47(1.22, 1.90)
Fibrin D-dimer (ng/ml) 8T a§ 63.8
Fibrinogen (g/1) 3.62 3.53
vWF antigen (iu/dl) 179 (49) 174 (45)
t-PA antigen (ng/ml) 11.2 10.8
hs CRP (mg/1) 3.19 3.09
Table 9.2: Chai'acteristics at the time of telephone assessment and baseline haemostatic 
markers in all subjects defined by TICSm criteria for dementia (n = 258) in the haemostatic 
function and dementia in atrial fibrillation community study. For continuous variables 
results ai'e expressed as geometric mean except for age and von Willebrand factor, which 
are expressed as mean (standar d deviation) and duration of AF and TAT, which are 
expressed as median (interquartile range). Statistics are by the unpaired t test or the Mann 
Whitney U test as appropriate. Statistics for dichotomous variables are by the Pearson chi- 
squared statistic, F 1+2 represents prothrombin fragment 1+2, TAT represents thrombin- 
antithrombin complexes, vWF represents von Willebrand factor, t-PA represents tissue 
plasminogen activator, and hs CRP represents highly sensitive C-reactive protein assay.
p < 0.05 compared to subjects not meeting dementia criteria 
t  p < 0.01 compared to subjects not meeting dementia criteria 
$ p < 0.001 compar ed to subjects not meeting dementia criteria 
§ p = 0.074 compared to subjects not meeting dementia criteria
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Dementia 
n = 49
No Dementia 
n = 169
Age (yrs) 79 (7.3) $ 74 (8.3)
Gender (female, %) 29 (59%) 92 (54%)
Duration of AF (yrs) 8 (6-12) 7 (5-12)
Previous stroke 12 (24%) 27 (16%)
Hypertension 23 (47%) 67 (40%)
History of diabetes 11 (22%) * 19(11%)
Smoker 9 (18%) 30(18%)
F 1+2 (nmol/1) 0.74 t 0.53
TAT (pg/1) 1.78 (1.32-2.54) t 1.44(1.20-1.82)
Fibrin D-dimer (ng/ml) 97.11 62.0
Fibrinogen (g/1) 3.58 3.51
vWF antigen (iu/dl) 175.6 (43.6) 175.3 (47.7)
t-PA antigen (ng/ml) 11.3 10.7
hs CRP (mg/1) 3.15 2.97
Table 9.3: Characteristics at the time of telephone assessment and baseline haemostatic 
markers in subjects defined by TICSm/ IQCODE criteria for dementia (n = 218) in the 
haemostatic function and dementia in atrial fibrillation community study. For continuous 
variables results ai-e expressed as geometric mean except for age and von Willebrand 
factor, which are expressed as mean (standard deviation) and duration of AF and TAT, 
which are expressed as median (interquartile range). Statistics are by the unpaired t-test or 
the Mann Whitney U test as appropriate. Statistics for dichotomous variables are by the 
Pearson chi-squared statistic. F 1+2 represents prothrombin fragment 1+2, TAT represents 
thrombin-antithrombin complexes, vWF represents von Willebrand factor, t-PA rpresents 
tissue plasminogen activator, and hs CRP represents highly sensitive C-reactive protein 
assay
* p < 0.05 compared to subjects not meeting dementia criteria 
t  p < 0.01 compared to subjects not meeting dementia criteria 
$ p < 0.001 compared to subjects not meeting dementia criteria
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Dementia 
n = 23
No Dementia 
n = 50
F 1+2 (nmol/1) 1.39 1.20
TAT (pg/I) 2.37 (1.80-3.28) * 1.78 (1.54-2.35)
Fibrin D-dimer (ng/ml) 165.5 * 104.4
Fibrinogen (g/1) 3.36 3.40
vWF antigen (iu/dl) 159.1 (33.9) 161.4 (48.5)
t-PA antigen (ng/ml) 10.6 10.9
hs CRP (mg/1) 2.87 2.48
Table 9.4: Characteristics at the time of telephone assessment and baseline haemostatic 
markers in subjects defined by TICSm/ IQCODE criteria for dementia in the haemostatic 
function and dementia in atrial fibrillation community study. Only those not taking 
waifarin shown (n = 73). For continuous variables results aie expressed as geometric mean 
except for age and von Willebrand factor, which are expressed as mean (standard 
deviation) and duration of AF and TAT, which aie expressed as median (interquartile 
range). Statistics are by the unpaired t test or the Mann Whitney U test as appropriate.
F I+2 represents prothrombin fragment 1+2, TAT represents thrombin-antithrombin 
complexes, vWF represents von Willebrand factor, t-PA represents tissue plasminogen 
activator, and hs CRP represents highly sensitive C-reactive protein assay
* p < 0.05 compared to subjects not meeting dementia criteria
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Conclusions and Future Directions
This thesis has encompassed a substantial body of work, which has thrown light on the 
answers to some research questions, but has also opened up many new directions for future 
study.
1. Haemostasis in Progressing Ischaemic Stroke:
Chapter three demonstrated that Scandinavian Stroke Scale (SSS) scores can be 
estimated retrospectively from hospital admission records; a crucial piece of validation 
information for the Haemostasis in Progressing Ischaemic Stroke study reported in 
chapter seven. There is, however, a need to further assess the interobserver reliability 
of this procedure. This could be achieved using a relatively small group of patients, and 
perhaps five or six observers from a variety of disciplines. If, as suspected, the 
National Institutes of Health Stroke Scale (NIHSS) develops to become a more 
commonly used tool for defining progressing stroke (and takes over from the SSS and 
Canadian Neurological Scale (CNS)) then it will be necessar y to perform further 
assessment of the best definitions of progressing stroke based on NIHSS change. What 
is the best cut-off level, in terms of change in total NIHSS score, for defining 
progressing stroke? Would change in key components of the NIHSS, as with the SSS, 
be a better, and more credible, way of defining progressing stroke?
The Haemostasis in Progressing Ischaemic Stroke study concluded that D-dimer levels 
(measured on samples taken soon after admission) independently predict progressing 
stroke. This information adds a potentially useful prognostic marker to the available 
battery, and might pave the way towards new, targeted, interventions to prevent 
progressing ischaemic stroke.
One important question is whether the results would be reproducible using different D- 
dimer assays? The results of the Haemostasis in Progressing Ischaemic Stroke study 
should be confirmed using other commercially available assays. The assay utilised in 
this study was very sensitive at lower D-dimer levels, as it is predominantly used in 
studies examining stable cohorts. Discussions are presently underway regarding the
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possibility of running stored samples through a VIDAS D-dimer assay and an IL- 
Futura assay, to assess whether the results are reproducible in assays used by many 
hospital laboratories. These assays are designed to be most sensitive at high levels of 
D-dimer; for instance in excluding deep venous thrombosis or pulmonary 
thromboembolism. It is expected that these analyses will be performed in Spring or 
Summer 2004. A further priority is for the results to be confirmed in an independent 
cohort.
The main reason for mounting this study was to identify factors associated with early 
clinical deterioration after acute stroke. Progressing stroke has a poor prognosis and, as 
yet, few interventions have proved effective in preventing this occurence. It was hoped 
that identifying associated factors might lead to interventions directly aimed at 
reducing the incidence of progressing stroke. The findings of high D-dimer levels in 
those who have clinical deterioration raises the possibility of targeted interventions to 
prophylactically treat this high-risk group. This targeting might be directed by selecting 
a D-dimer level above which treatment would be considered. Interventions aimed at 
modifying haemostatic abnormalities after acute stroke, in an attempt to prevent 
progressing stroke, have generally been unsuccessful. Any potential benefits have, 
probably, been balanced by intracranial and extracranial bleeding complications. The 
finding of high levels of D-dimer in subjects who later deteriorate raises the possibility 
of targeted ti eatment, but also points at possible pathological mechanisms through 
which deterioration may have occurred.
There ai'e possible avenues down which pilot work might proceed. One option is to 
approach this problem in a retrospective manner. There have been a number of studies 
which have intervened, using heparin, in acute stroke. Some of these studies have 
measured progressing stroke. Some have stored blood samples for future analysis. It 
may be feasible to examine the risk/ benefit ratio of treatment in subjects recruited to 
these studies who had elevated D-dimer levels at baseline. Contact has been made with 
lead investigators from the 1ST, TAIST and HAEST studies to see whether 
collaborative analyses can be performed. None of the samples from these studies will 
be directly able to answer the research question (does very early heparin use prevent 
early progressing str oke in acute ischaemic stroke patients with elevated D-dimer 
levels?). An analysis of previous trials, however, could provide useful preliminary data.
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More work will be possible using data from the patients assessed in the Haemostasis in 
Progressing Ischaemic Stroke study. One area of particular interest is around 
associations of interleukins and progressing stroke. As discussed in chapter 1 there is 
some evidence that IL-6 concentrations are associated with early neurological 
deterioration in acute stroke and that there is an inverse relationship between IL-10 and 
progressing stroke A study performed on a different cohort, however, did not 
confirm these findings Stored samples are available from the Haemostasis in 
Progressing Ischaemic Stroke study on which these analyses should be performed in 
the near future.
Another area of interest is in the role of troponin I in acute stroke. Creatinine kinase- 
MB activity has been shown to increase in certain patients with ischaemic stroke, 
subarachnoid haemorrhage and head trauma in the absence of any other evidence of an 
acute coronary syndrome. Recently a small study has reported that troponin T, a more 
specific biochemical marker of myocardial injury, does not increase after stroke while 
CK-MB does (total 32 patients with large hemispheric infarction) James et al., 
however, demonstrated that troponin T was elevated in 17% of subjects admitted with 
acute ischaemic stroke (n=181) and was a powerful predictor of mortality Although 
not reported in this thesis, samples have been collected and analysed for troponin I and 
catecholamine levels (adrenaline and noradrenaline) from the 280 subjects initially 
recruited to the Haemostasis in Progressing Ischaemic Stroke study. Provisional 
analysis has shown that 42 (19%) of the 219 subjects included in the haemostasis in 
progressing ischaemic stroke study have troponin I levels of greater than 0.2. Those 
with positive troponin I results were much more likely to be dead at 30 days (31% v. 
7%, p<0.001). Adrenaline levels were significantly higher in subjects with positive 
troponin results (p=0.001). Ischaemic-like ECG changes and/or QT prolongation occur 
in up to 90% of patients during the acute phase of stroke and so admission 
electrocardiograms were also collected and have been reported according to the 
Minnesota coding system Further analysis of the coded ECGs has yet to take place,
A further option is to run a small pilot study of intervention with therapy that alters 
haemostatic function, in subjects with high D-dimer levels. Available possible 
interventions include unfractionated or low molecular weight heparin, direct tlirombin 
inhibitors (such as melagatran or ximelegatran) or specific factor Xa inhibitors (such as 
fondiparinux). Initially this study could be powered to look for changes in haemostatic
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mai'kers. Protln’ombin fragments 1+2 or thrombin-antithrombin complexes would be 
potential markers, as D-dimer has a long half-life and levels are, therefore, relatively 
resistant to acute interventions.
In the future, provided pilot work is satisfactory, a larger scale intervention study 
would be necessaiy, powered to examine the endpoints of progressing stroke and 
mortality/ functional outcomes.
2. Haemostatic Function and Dementia in Atrial Fibrillation Community Study:
Chapter eight showed that both the Telephone Interview for Cognitive Status (TICS) 
and a modified version (the TICSm) are practical and valid tools for diagnosing 
dementia in post-stroke subjects. The TICSm was used in combination with the 
Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) in the 
Haemostatic Function and Dementia in Atrial Fibrillation Community study reported in 
chapter nine. Although this combination seemed a reasonable choice further research is 
required. It is important to know whether using the “and”, “or” or “weighted sum of 
scores” rules to combine results of the two procedures is most sensitive and specific. 
This form of validation has been performed for the MMSE/ IQCODE combination 
but, to the author’s knowledge, no work has been performed on a weighted sum of 
scores for the TICSm/ IQCODE combination. This research question could be 
answered fairly easily using local resources, and is important as the TICSm has 
advantages over the MMSE for distant assessment of subjects.
From the Haemostatic Function and Dementia in Atrial Fibrillation Community study 
reported in chapter nine it was concluded that there was some evidence of increased 
thrombin generation and fibrin turnover in subjects with atrial fibrillation (AF) and 
dementia compared to those without dementia. The data also gave some support to the 
concept that long-term waifarin might protect against development of dementia in 
patients with AF. As discussed, this study has a number of unavoidable weaknesses, 
particularly relating to the issue of selection bias, and it is, therefore, important not to 
draw overly firm conclusions from the results. This was more of a hypothesis 
generating exercise, and from that point of view it was successful.
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Of course, it is unlikely that a placebo controlled trial of anticoagulation will occur in 
high-risk subjects for ethical reasons; there is no doubt that selected high risk subjects 
should receive anticoagulation for prophylaxis of embolic complications in AF.
Another option would be to consider TICSm/ IQCODE follow up of subjects recruited 
to one of the original warfarin randomised controlled trials in AF. Disadvantages of 
this approach, at this late stage, are the problems of attrition bias (demented subjects 
may be more likely to die) and crossover between treatment groups.
Modern alternatives to waifarin such as ximelegatran are being studied in subjects with 
AF They have theoretical advantages over warfarin and may not suffer the peaks 
and troughs of anticoagulation produced by warfarin. This might avoid 
thromboembolic complications during the warfarin “trough” phase. Those who ai'e 
studying the benefits of these newer drugs over warfarin have the opportunity to 
examine whether they have advantages over warfarin as cognitive protectors. This 
would be an interesting piece of research.
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Appendix A
Scandinavian Stroke Scale
Function Score Prognostic
Score Long Term  Score
Consciousness:
-fully conscious
-somnolent, can be awakened to full 
consciousness
-reacts to verbal command, but is not fully 
conscious
-unconscious 
Eye movement;
-no gaze palsy 
-gaze palsy present 
-conjugate eye deviation
Arm, motor power *:
-raises arm with normal strength 
-raises arm with reduced strength 
-raises arm with flexion in elbow 
-can move, but not against gravity 
-paralysis 
Hand, motor power *:
-normal strength
-reduced strength in full range
-some movement, fingertips do not reach palm
-paralysis
Leg, motor power *:
-normal strength
-raises straight leg with reduced strength 
-raises leg with flexion of knee 
-can move, but not against gravity 
-paralysis 
Orientation:
-correct for time, place and person 
-two of these 
-one of these 
-completely disorientated
«
I
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Speech:
-no aphasia
-limited vocabulary or incoherent speech 
-more than yes/no, but not longer sentences 
-only yes/no or less 
Facial palsy:
-none/dubious
-present
Gait:
10
6
3
0
2
0
*  Motor power is assessed only on the affected side.
Î
-walks 5 m without aids 12 Î
-walks with aids
-walks with help of another person
9
6 ;
-sits w ithout support 3 1
-bedridden/wheelchair 0
Maximal Score 58 22 48 ■■
cl:
IÏ
4I
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Appendix B
Modified Barthel Index
Feeding:
0 = unab le
1 = needs he lp c u ttin g , sp read ing  b u tte r, e tc ., o r requ ires m od ifie d  d ie t
2 = independen t
Bathing:
0 = dependent
1 = Independent (o r  in show er)
Grooming:
0 =  needs to  he lp  w ith  personal care
1 =  in de pen de n t fa c e /h a lr /te e th /s h a v ln g  (im p le m e n ts  p rov ided )
Dressing:
0 = dependent
1 =  needs help b u t can do a b ou t h a lf unaided
2 = in dependen t (in c lud in g  b u tto ns , zips, laces, e tc .)
Bowels:
0 = in co n tin e n t (o r  needs to  be g iven  enem as)
1 =  occasional acc iden t
2 = c o n tin e n t
Bladder:
0 = in con tinen t, o r  ca the te rised  and unab le to  m anage alone
1 = occasional acc iden t
2 = c o n tin e n t
Toilet Use:
0 =  dependent
1 =  needs som e he lp , bu t can do som e th ing  alone
2 = in dependen t (on and o ff, d ress ing , w ip ing )
Transfers (bed to chair, and back):
0 = unab le, no s itt in g  balance
1 =  m a jo r help (one o r  tw o  peop le, phys ica l), can s it
2 =  m in o r help (ve rb a l o r  phys ica l)
3 =  independen t
Mobility (on level su rfaces):
0 = im m o b ile  o r < 50 yards
1 = w h ee lcha ir independen t, inc lud ing  corners, > 50 yards
2 = wa lks w ith  help o f one person (ve rba l o r physica l) >  50 yards
3 = in de pen de n t (b u t m ay use any a id ; fo r  exam ple , s tic k ) >  50 yards
Stairs:
0 = unable
1 = needs help (ve rb a l, phys ica l, ca rry ing  a id )
2 = independent
Maximum = 20
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Appendix C
S e v e r e  d isability; b ed r id d e n ,  in co n t in en t  an d  requiring c o n s t a n t  
nursing  ca re  an d  a t te n t io n
D ead
..
193
! W;-.- '
Modified Rankin Scale
:
'■f
'sSCORE DESCRIPTION
0  No s y m p t o m s  a t  all
1 No s ign if ican t  d isab ility  d e s p i t e  s y m p t o m s ;  a b le  to  carry o u t  all 
u sual d u t ie s  and  a c t iv it ie s
2  S ligh t  d isability ;  u n a b le  to  carry o u t  all p r e v io u s  a c t iv i t ie s ,  b u t  a b le  
to  look a fter  o w n  affa irs  w ith o u t  a s s i s t a n c e
3 M od erate  d isability; requiring s o m e  he lp , b u t  a b le  to  w a lk  w ith o u t  
a s s i s t a n c e
I
?
M od erate ly  s e v e r e  d isability;  u n a b le  to  w alk  w ith o u t  a s s i s t a n c e  and  
u n a b le  to  a t t e n d  to  o w n  bodily  n e e d s  w ith o u t  a s s i s t a n c e
Appendix D
Telephone Interview for Cognitive Status (TICS)
:
1) P lease  tell m e your full nam e (Ip t. for first name, Ipt. for last name) /2
2) W hat is today's date?
DAY /  DATE /  MONTH /  YEAR /  SEASON /5
3) W hat is your hom e address? (W here are you right now )
NUMBER /  STREET /  CITY /  COUNTY /  POSTCODE
/5
4 ) P lease count backw ards from 20 to 1 No m istakes 
Second Try
/2/ I
5) I'm going to  read you a list o f 10 w ords.
P lease  listen  carefully and try to  rem em ber  
them . When I am  done, te ll m e a s  m any  
w ords a s  you can, in any order. Ready?
Now tell m e all th e  w ords you can rem em ber
CABIN
PIPE
ELEPHANT
CHEST
SILK
THEATRE
WATCH
WHIP
PILLOW
GIANT
/I/I/I/I/I/I/ I/ I/ I/ I
6) P lease take 7 aw ay from 100
Now continue to  take 7 aw ay from w hat you  
have left over until I ask  you to  stop
(up to 5 subtractions)
7) W hat do p eop le usually u se  to  cut paper? Scissors/Shears
How m any th in gs are in a dozen  
W hat is th e  prickly green  plant found in th e  desert?
W hat anim al d o es w ool com e from?
/I/I/I/I/I
/I/I/I/I
Î
8)
9)
10)
11)
Say th is  "no ifs, ands or buts"
P lease say  th is, 'M ethodist Episcopal'
Who is th e  prime m inister now?
Who is th e  Chancellor o f th e  Exchequer?
W hat is th e  op p osite  of W est?
W hat is th e  op p osite  of generous?
(selfish, greedy, stingy, tight, cheap, m ean, meagre, skimpy or other)
194
/I/I
/I/I
With your finger, tap  5 tim es  on th e  part o f th e  phone you sp eak  into /2
(Ipt. if 5 taps heard; Ipt. if subject taps more or less than 5 tim es)
/I/I
. 'I
Appendix E
1)
2)
3)
4 )
5)
6)
7)
Modified 13-item Telephone Interview for Cognitive Status (TICSm)
W hat is today's date?
DAY /  DATE /  MONTH /  YEAR /  SEASON
W hat is your age?
W hat is your phone num ber including national dialling code?
I'm going to  read you a list o f 10 w ords. 
P lease listen  carefully and try to  rem em ber  
them . W hen I am d on e, tell m e a s m any  
w ords a s  you can, in any order. Ready?
Now tell m e all th e w ords you can rem em ber
P lease take 7 aw ay from 100
Now continue to  tak e 7 aw ay from w h at you
have left over until I ask  you to  stop
(5 subtractions)
P lease  count backw ards from 20  to  1
W hat do p eop le  usually u se  to  cut paper?
CABIN
PIPE
ELEPHANT
CHEST
SILK
THEATRE
WATCH
WHIP
PILLOW
GIANT
No m istakes
Scissors/Shears
8) W hat is th e  prickly green  plant found in th e desert?
9 ) Who is th e  reigning m onarch now ?
10) Who is th e  prime m inister now?
11) W hat is th e  op p osite  of east?
12) P lease  say  th is, 'M ethodist Episcopal'
13) P lease  repeat the list o f 10 w ords I read earlier CABIN
PIPE
ELEPHANT
CHEST
SILK
THEATRE
WATCH
WHIP
PILLOW
GIANT
/5
/I
/I
/I/I
/I/ I/ I/ I/ I/ I/ I
/ I
/I/ I/I/I/I
/I
/I
/I
/I
/I
/I
/I
/I
/I
/ I
/ I/I
/I/I/I/I/ I
:1
:
fI
i
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Appendix F
R-CAMCOG
(Nam ing pictures: Shoe Typewriter Scales Suitcase Barometer Lamp)
Orientation
What day of the w eek is it?
What is the date today? Date Month Year 
Can you tell me where we are now?
For instance, in what county are we in? 
What is the name of this city?
What floor of the building are we on? 
What is the name of this place?
n
/3
nnn
/I
R em ote m em ory
Can you tell me when the First World War began?
Can you tell me when the Second World War began?
Who was the leader of the Russians in the Second World War (ST)? 
What was Mae West fam ous for?
Who was the famous flyer whose son was kidnapped (CL)?
/ I/I/I/I/I
R ecent m em ory
What is the name of the present Queen?
Who will follow her?
What is the name of the prime minister?
What has been in the new s in the past w eek or two?
/I/I/I
Recall
Can you tell me what were the objects in the colored pictures I showed 
you a little while ago? (Shoe Typewriter Scales Suitcase Barometer Lamp) /6
R ecognition
Which of th ese  did I show you before?
Shoe Typewriter Scales Suitcase Barometer Lamp /6
(W riting an address
Write this name and address on the envelope: Mr. John Brown 42 West Street Bedford)
Perception
I am going to place a coin into your hand and I want you to tell me what 
It is without looking at it. Pound /  50 pence /2
These are pictures of objects taken from unusual angles.
Can you tell me what they are?
Spectacles Shoe Purse/Suitcase Cup and Saucer Telephone Pipe /6
Abstraction
In what way are an apple and a banana alike? 
In what way are a shirt and a dress alike?
In what way are a table and a chair aiike?
In what way are a plant and an animal alike?
12121212
Recall address
What was the name and address you wrote on the envelope a 
short time ago?
Mr. John Brown 42 West Street Bedford /5
Maximum score: 49
196
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Appendix G
Abbreviated Mental Test (AMT)
Age / ITime (nearest hour) / IYear / IName of place / I42 West Street (for repetition later) / IDate of birth / IStart of WWl / IName of present monarch / IRecognition of 2 persons / ICount from 20 to 1 (backwards) / I
Maximum Score: 10
200
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Appendix H
15-question Geriatric Depression Scale (GDS-15)
Choose the best answer for how you have felt over the past week;
1. Are you basically satisfied with your life? Yes /  NO
2. Have you dropped many of your activities and interests? YES /  No
3. Do you feei that your life is empty? YES /  No
4. Do you often get bored? YES /  No
5. Are you In good spirits m ost of the time? Yes /  NO
6. Are you afraid that something bad Is going to happen to you? YES /  No
7. Do you feel happy most of the time? Yes /  NO
8. Do you often feel helpless? YES /  No
9. Do you prefer to stay at home, rather than going out and doing new things? YES /  No
10. Do you feel you have more problems with memory than most? YES /  No
11. Do you think it is wonderful to be alive now? Yes /  NO
12. Do you feel pretty worthless the way you are now? YES /  No
13. Do you feel full of energy? Yes /  NO
14. Do you feei that your situation is hopeless? YES /  No
15. Do you think that m ost people are better off than you are? YES /  No
Answers in BOLD CAPITALISATION indicate depression 
Maximum Score: 15
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Appendix I
OARS Multidimensional Functional Assessment Questionnaire (OMFAQ)
Can you u se  th e  telephone?:
Without assistance 2
With assistance 1
Unable 0
Can you g e t  to  p laces out o f w alking distance?:
Without assistance 2
With assistance 1
Unable 0
Can you go  shopping (g ro cer ies /c lo th es)? :
Without assistance 2
With assistance 1
Unable 0
Can you prepare you ow n m eals?:
Without assistance 2
With assistance 1
Unable 0
Can you do your own housew ork?:
Without assistance 2
With assistance 1
Unable 0
Can you take your ow n m edicine?:
Without assistance 2
With assistance 1
Unable 0
Can you handle your ow n m oney?:
Without assistance 2
With assistance 1
Unable 0
Maximum Score: 14
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Appendix J
5-question Geriatric Depression Scale (GDS-5)
(1 )  Are y o u  b asica lly  s a t is f ie d  w ith  y o u r  life?
( 2 )  Do y o u  o ften  g e t  b ored ?
Do y o u  o ften  fee l  h e lp le s s ?(3)
(4) Do y o u  prefer  to  s t a y  a t  h o m e  rather  th a n  g o in g  
o u t  and  do in g  n e w  th in g s?
Y es  /  NO 
YES /  No 
YES /  No  
YES /  No
( 5 )  Do y o u  fee l  p re tty  w o r th le s s  th e  w a y  yo u  a r e  n o w ?  YES /  No
P osit ive  a n s w e r s  for  d e p r e s s io n  sc r e e n in g  are  y e s  to  parts  2 , 3 , 4  and 5 an d  no  
to  part 1
Maximum Score: 5
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Addendum
The viva examination for this thesis took place on 14^ '' July 2004. On the panel were Prof. 
J.H. McKillop (Convener), Prof. K.R. Lees (Internal Examiner), Prof. L. Kalra (External 
Examiner) and Prof. D.J. Stott. The limitations of the studies presented in the thesis were 
discussed in detail, and can be summai'ized as follows:
At the time of the reseai'ch the clinical service in which the work was carried out had 
limited acute access to radiological imaging. All acute stroke imaging was performed 
using computed tomography (CT), with only occasional access to magnetic resonance 
imaging (MRI). There were often delays from stroke onset to obtaining this acute imaging 
(median 3 days in those recruited to the main study in chapter seven). In many cases this 
meant that neurological deterioration had occurred before imaging was performed, and in 
these circumstances usual care included a single CT brain scan (rather than two scans -  
one before and one after progression of stroke). Decisions on whether patients underwent 
carotid doppler imaging and echocardiography were based on perceived clinical need/ 
benefit rather than using a blanket policy of performing these imaging modalities in all 
patients.
In a fully resourced clinical service the progressing stroke studies would have been 
strengthened by having more information on infarct volume/ ischaemic penumbral area 
and vessel patency; both acutely at the time of arrival in hospital and after a few days 
(following any progression of stroke neurological signs). Currently the best methods for 
doing this include MR techniques (perfusion/ diffusion imaging and angiography). During 
the design of the studies consideration was made to attempting to obtain access to both MR 
imaging and transcranial doppler for a subset of patients recruited; however, the funding 
for these investigations could not be obtained. This is a limitation of the main study 
described in the thesis (chapter seven).
With regard to stroke categorisation a clinical classification (Oxfordshire Community 
Stroke Project, OCSP) was used. It is recognised that a more aetiologically based 
classification, such as the TOAST (Trial of Org 10172 in Acute Stroke Treatment) one, 
could have had advantages, especially in a study examining the role of thrombosis in 
progressing stroke. As discussed in chapter four these classifications do rely on a high 
level of radiological investigation and a high autopsy rate in those who die. A clinical
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classification was chosen as, without a blanket policy of carotid and cardiac imaging and 
with a low autopsy rate, the patients who could be accurately aetiologically classified may 
not have been a representative sample from the entire cohort. Again, with greater resources 
the study could have been strengthened in this respect.
Future studies of progressing stroke are likely to involve greater use of neuroimaging 
techniques and to require aetiological classification of ischaemic strokes. It is hoped that 
this will help further define the pathogenesis of progressing ischaemic stroke and enable 
effective prophylactic measures to be taken.
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